



UMediC Group Berhad
(Registration No. 202101015347 (1415647-D))



Bring **Excellence** In **Healthcare**

ANNUAL REPORT 2025



CONTENTS

02	Corporate Information
03	Corporate Structure
04	Media Highlights
08	Financial Highlights
09	Chairman's Statement
11	Management Discussion & Analysis
24	Board of Directors
25	Profile of Directors
34	Profile of Key Senior Management
36	Corporate Governance Overview Statement
43	Sustainability Report
76	Statement on Risk Management and Internal Control
80	Audit and Risk Management Committee Report
82	Nomination Committee Statement
83	Directors' Responsibility Statement
84	Additional Compliance Information
86	Financial Statements
140	List of Properties
141	Analysis of Shareholdings
143	Notice of Fifth Annual General Meeting ("5 th AGM")
146	Statement Accompanying Notice of 5 th AGM
147	Proxy Form
149	Administrative Guide



VISION

To provide an integrated healthcare supply chain with advanced technology, which ultimately improves the quality of human life.



MISSION

To be the trusted and preferred partner for all our stakeholders, which include our investors, suppliers, customers, employees and the communities.



CORE VALUES



Unity



Motivation



Commitment

CORPORATE INFORMATION

BOARD OF DIRECTORS

Dato' Seri Ng Chai Eng

Non-Independent Non-Executive Chairman

Lim Taw Seong

Executive Director/Chief Executive Officer

Dr. Pakirisamy Baskaran A/L P Thangavelu

Independent Non-Executive Director

Tan Chye Suan

Independent Non-Executive Director

Lee Yee Wooi

Independent Non-Executive Director

Dato' Dr. Teh Keng Hwang

Independent Non-Executive Director

Ng Sze Hui

Alternate Director to Dato' Seri Ng Chai Eng

AUDIT AND RISK MANAGEMENT COMMITTEE

Chairman

Lee Yee Wooi

Members

Dr. Pakirisamy Baskaran A/L P Thangavelu

Tan Chye Suan

REMUNERATION COMMITTEE

Chairman

Tan Chye Suan

Members

Dr. Pakirisamy Baskaran A/L P Thangavelu

Lee Yee Wooi

NOMINATION COMMITTEE

Chairman

Dr. Pakirisamy Baskaran A/L P Thangavelu

Members

Tan Chye Suan

Lee Yee Wooi

COMPANY SECRETARY

Ooi Yoong Yoong

MAICSA No.: 7020753

SSM PC. No.: 202008002042

AUDITORS

BDO PLT (LLP0018825-LCA) & AF 0206

Chartered Accountants

51-21-F, Menara BHL

Jalan Sultan Ahmad Shah

10050 Pulau Pinang

Tel: (604) 222 0288

Fax: (604) 222 0299

REGISTERED OFFICE

39 Irving Road

10400 George Town

Pulau Pinang

Tel: (604) 210 9828

Fax: (604) 210 9827

E-mail: cosec@adconsultpg.com.my

HEAD OFFICE/ PRINCIPAL PLACE OF BUSINESS

PMT 790, Jalan Cassia Selatan 5/2

Taman Perindustrian Batu Kawan

14110 Bandar Cassia

Pulau Pinang

Tel: (604) 589 9676

Fax: (604) 589 9677

Website: www.umedic.com.my

E-mail: ir@umedic.com.my

SHARE REGISTRAR

Boardroom Share Registrars Sdn Bhd

11th Floor, Menara Symphony

No. 5, Jalan Prof. Khoo Kay Kim

Seksyen 13

46200 Petaling Jaya

Selangor Darul Ehsan

Tel: (603) 7890 4700

PRINCIPAL BANKER

Hong Leong Bank Berhad

No.1823-G1, Jalan Perusahaan Auto-City

North-South Highway Juru Interchange

13600 Prai, Pulau Pinang

Tel: (604) 502 1488

STOCK EXCHANGE LISTING

Main Market of Bursa Malaysia Securities Berhad

Stock Name: UMC

Stock Code: 0256


Sector: Health Care

Subsector: Health Care Equipment & Services

CORPORATE STRUCTURE



UMeDiC Group Berhad
(Registration No. 202101015347) (1415647-D)



Company	Date of Incorporation	Ownership Interest	Principal Activities
UMeDiC Group Berhad ("UMC")	22 April 2021		Investment holding
Evo Medik Sdn Bhd ("Evo Medik")	13 August 2007	100%	Marketing and distribution of medical devices as well as the provision of after-sales service, healthcare and other related services. To operate nursing homes and healthcare centres as well as the provision of other related services
UMeDiC Healthcare Sdn Bhd ("UMeDiC")	8 November 2002	100%	Marketing and distribution of medical devices as well as the provision of after-sales service, training, healthcare and other related services
UWHC Sdn Bhd ("UWHC")	31 July 2018	100%	Holding of intellectual property rights
UWHM Sdn Bhd ("UWHM")	28 September 2011	100%	Developing, manufacturing and marketing of medical devices
Patho Solutions (M) Sdn Bhd ("Patho")	9 July 2019	70%	Marketing and distribution of laboratory equipment and consumables
Akiteck (Malaysia) Sdn Bhd ("Akiteck")	20 May 2024	70%	Design, assembly and distribution of medical mounting solution products and related parts
Ateria Medika Sdn Bhd ("Ateria")	30 July 2024	90%	Import, export, marketing and distribution of medical devices as well as the provision of after-sales service
Rescue Medic Sdn Bhd ("Rescue Medic")	11 March 2025	85%	Marketing and distribution of medical devices as well as the provision of after-sales service, healthcare and other related services

MEDIA HIGHLIGHTS

HLIB Downgrades UMediC After Results Fell Short

By Business Today Editorial


June 6, 2025

Share

Facebook

Twitter

LinkedIn



Hong Leong Investment Bank Bhd (HLIB) downgraded UMediC Group Bhd to HOLD from BUY, adjusting its target price to RM0.43 from RM0.69, citing ongoing earnings underperformance and weaker-than-expected revenue in the Distribution division. The house projected a modest capital upside of 7.5% and expect the total return to align accordingly, reflecting cautious sentiment amid persistent challenges.

UMediC reported a 3QFY25 core PATMI of RM1.8 million, down 15.1% quarter-on-quarter and 12.2% year-on-year, bringing the 9MFY25 core earnings to RM5.4 million, a 19.6% decline from the previous year. These results fell short of both HLIB's and consensus full-year forecasts, achieving only 68% and 71% of estimates, respectively.

The shortfall was primarily attributed to subdued revenue from the Distribution division, which suffered from a dampened demand for medical devices and consumables. In contrast, the Manufacturing division rebounded strongly with a 78.6% quarter-on-quarter increase in revenue, largely driven by recovering demand for respiratory products.

Despite a slight year-on-year revenue growth of 6.9% in the Distribution division, the Manufacturing segment's revenue fell 10.5%, impacted by a stronger Ringgit against the US dollar, which appreciated by approximately 7.3%, and softer demand for respiratory-related products.

The profitability in the Manufacturing division also weakened significantly, with the profit before tax margin declining from 46% to 31%, affected by unfavourable forex movements. Similarly, the Distribution division's PBT margin shrank to 13% from 19%, likely due to operating leverage pressures.

Year-to-date, UMediC's revenue contracted by 8.6%, with both divisions recording declines—3.1% in Distribution and a steeper 18.5% in Manufacturing. The core PATMI dropped sharply by 19.6%, primarily due to the margin erosion in the Manufacturing segment, where the PBT margin fell to 26% from 38%, again attributed to adverse currency effects.

Looking ahead, HLIB remains cautiously optimistic about the Manufacturing division's respiratory products, buoyed by global healthcare megatrends such as the ageing population. However, ongoing uncertainty persists in the Distribution division dampening overall outlook. In response to these factors and the profit misses over three consecutive quarters, HLIB trimmed its profit forecasts for FY25 to FY27 by 10% to 12%.

The downgrade to HOLD is accompanied by a lower valuation multiple, with HLIB reducing its price-to-earnings ratio target to 19 times, two standard deviations below the stock's three-year average, down from a previous valuation of 45.5 times. This adjustment reflects a more cautious stance following a series of earnings disappointments and a tempered view on future growth prospects.

UMediC continues to focus on marketing and distributing branded medical devices and consumables while developing its own medical consumables brand. Despite near-term hurdles, the company's positioning in healthcare remains relevant, though recovery depends heavily on improving sales dynamics in the Distribution division.

【行家论股】UMediC集团 业绩逊色财测下调

财经评论员 叶国良

2025年6月6日

UMediC集团

12/03/2025



分析：丰隆投行研究
目标价：0.43

最新资讯：
UMediC集团（0216，创业板）最近营收表现逊于市场预期，在2025财测年度（截至12月31日）净利润则调降23.7%，至1832万令。
同时，UMediC次季营收也同比萎缩14.9%，至1158万令。



行家观点：
UMediC集团2025财年上半年核心净利润预计达360万令，低于我们此前市场的预期，分析过去半年期间的14%和13%。主要受医疗设备收入下降影响，上半年营收收入累计下降12%，主要受医疗设备降价和供应链成本上升影响。
展望未来，我们预计，下半年及之后医疗设备降价和供应链成本上升，这将受到全球医疗设备行业长期趋势的支持，特别是老龄化人口的需求，预计将保持增长。
鉴于医疗设备行业趋势，我们预计，其未来三年内平均每年增长率为12%（CAGR）保持稳定，主要受公共与私人领域对医疗设备或医疗设备及耗材的需求驱动。
得益于设备降价，我们将2025财年的盈利预测，分别下调20%、19%和17%，以反映较低的利润率预期。
同时，我们预计未来半年内，下半年营收，将受医疗设备降价及公共与私人领域大幅萎缩19%，我们预计为医疗设备降价及公共与私人领域，进而维持“买入”评级。

UMediC集团 股价走势



UMediC集团业绩预测			
截至7月底财年	2025	2026	2027
营业额 (令吉)	5600万	6200万	6990万
净利 (令吉)	790万	910万	1050万
每股净利 (仙)	2.1	2.4	2.8
市盈率 (倍)	22.1	19.3	16.8
股价对账面价值 (倍)	2.2	2.0	1.8

12/03/2025 估值

现价：45.5 仙

起落：-1.5 仙

最高：45.5 仙

最低：45 仙

成交量：17万 800 股

52周最高：76.5 仙

52周最低：45 仙

资料来源：丰隆投行研究

dollar generates with respect to its shareholder investments.

AI is about to change healthcare. These 20 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under \$10bn in marketcap - there is still time to get in early.

How Do You Calculate Return On Equity?

The formula for ROE is:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

So, based on the above formula, the ROE for UMediC Group Berhad is:

11% = RM8.8m ÷ RM79m (Based on the trailing twelve months to April 2025).

The 'return' is the yearly profit. That means that for every MYR1 worth of shareholders' equity, the company generated MYR0.11 in profit.

See our latest analysis for UMediC Group Berhad

What Is The Relationship Between ROE And Earnings Growth?

We have already established that ROE serves as an efficient profit-generating gauge for a company's future earnings. Depending on how much of these profits the company reinvests or "retains", and how effectively it does so, we are then able to assess a company's earnings growth potential. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

UMediC Group Berhad's Earnings Growth And 11% ROE


When you first look at it, UMediC Group Berhad's ROE doesn't look that attractive. Yet, a closer study shows that the company's ROE is similar to the industry average of 10%. Having said that, UMediC Group Berhad has shown a modest net income growth of 18% over the past five years. Considering the moderately low ROE, it is quite possible that there might be some other aspects that are positively influencing the company's earnings growth. For example, it is possible that the company's management has made some good strategic decisions, or that the company has a low payout ratio.

Next, on comparing UMediC Group Berhad's net income growth with the industry, we found that the company's reported growth is similar to the industry average growth rate of 15% over the last few years.

MEDIA HIGHLIGHTS (CONT'D)

Is UMediC Group Berhad's (KLSE:UMC) Recent Stock Performance Influenced By Its Fundamentals In Any Way?

Simply Wall St
August 05, 2025



UMediC Group Berhad (KLSE:UMC) has had a great run on the share market with its stock up by a significant 13% over the last week. As most would know, fundamentals are what usually guide market price movements over the long-term, so we decided to look at the company's key financial indicators today to determine if they have any role to play in the recent price movement. In this article, we decided to focus on **UMediC Group Berhad's ROE**.

Return on equity or ROE is a key measure used to assess how efficiently a company's management is utilizing the company's capital. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.

About KLSE:UMC

UMediC Group Berhad
An investment holding company, develops, manufactures, markets, and distributes medical devices and consumables in Malaysia, the Asia Pacific, the Americas, Europe, the Middle East, Africa, and Oceania.



Flawless balance sheet and slightly overvalued.

[See The Free Research Report](#)



The company said it remains confident of its growth trajectory.

PETALING JAYA: **UMediC Group Bhd** believes the local medical device industry is poised for growth and development, bolstered by a conducive environment for manufacturing and a mature healthcare system that is globally recognised.

Barring unforeseen circumstances, the company said it remains confident of its growth trajectory, it said in a Bursa Malaysia filing.

For the fourth quarter ended July 31, 2024, UMediC's net profit dipped to RM3.04mil compared with RM3.37mil in the previous corresponding period, while revenue grew to RM14.88mil from RM12.02mil a year earlier.

UMediC said the increase in revenue was contributed by both the marketing and distribution and manufacturing segments. For the financial year ended July 31, 2024, UMediC's net profit dropped to RM8.99mil from RM10.32mil while revenue grew to RM54.57mil from RM45.43mil a year earlier.

医用加湿器需求旺 UMedic集团扩充产能拼成长

umedic集团

25
次转发

f 24

X

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

+

(吉隆坡4日讯) 分析员认为UMedic集团 (UMC, 0256, 创业板) 医疗产品制造业务在完成扩张后, 产能将扩大一倍, 并预计该业务未来数年的销售将增长33%至143%。

艾芬黄氏投行分析员预计, UMedic集团即将公布的2023财政年末季业绩(截至7月31日止), 将比上季更好, 第3季的销售因工厂保养工作和客户要求延迟交货而受影响。

与此同时, 分析员估计末季盈利将达250万令吉, 高于第3季的200万令吉, 全年盈利将提高至950万令吉。

他说, UMedic集团的医用加湿器 (prefilled humidifiers) 产能扩张和需求持续增长, 估计公司制造部门未来数年销售将取得33%至143%成长率。

此外, 分析员提到, 扩建后的工厂将有空间进一步增加生产能力, 从而在2023年底推动盈利增长。

“我们预测, UMedic集团2023年底的制造产能将提高一倍。”

分析员补充, UMedic集团的核心产品HydroX预填充加湿器, 目前的需求远大于其现有的生产量。

虽然该公司当前面临产能瓶颈, 不过分析员认为, 这主要是公司打算逐步增加产量, 以确保生产线顺利运作及顺利交货。

“与欧洲业者相比, UMedic集团拥有更好的成本优势, 因欧洲制造商面临更高的成本压力。”

另外, 由于UMedic集团的现有产能比全球市场的业者相对小, 因此获得一项合约将为其盈利增长带来巨大的上升空间。

鉴于医用加湿器需求前景乐观, 分析员相信制造业务将成为UMedic集团未来的“盈利增长引擎”。

分析员估计2024和2025财政年的盈利增长。将分别达到39%和22%。

艾芬黄氏投行重申UMedic集团的“买入”投资评级, 按照2024财政年的26倍预估计本益比计算, 其目标价是1令吉, 比当前的股价69.5仙, 仍有43.9%的上涨空间。

UMedic Group Berhad Announces Dissolution of Subsidiaries

Date: 19 May 2025

UMedic Group Berhad (UMC) has officially announced the dissolution of its subsidiary companies, Actimed Healthcare Sdn. Bhd. and U Medihealth Sdn. Bhd. This decision follows the final meetings convened by the Liquidator on 16 May 2025. The Return by Liquidator relating to the final meeting was lodged with the Companies Commission of Malaysia and the Official Receiver on 19 May 2025.

The companies will be dissolved three months after the Lodgement Date, marking the end of operations for these subsidiaries. This strategic move is part of UMedic Group's efforts to streamline its operations and focus on its core business areas.

Investors and stakeholders are encouraged to take note of this development, as it may impact the company's future direction. UMedic Group remains committed to transparency and will continue to provide updates on any significant changes within the organization.

Company Name	Actimed Healthcare Sdn. Bhd.	U Medihealth Sdn. Bhd.
Final Meeting Date	16 May 2025	16 May 2025
Lodgement Date	19 May 2025	19 May 2025
Dissolution Date	19 August 2025	19 August 2025

Related Stocks

Chart	Stock	Last	Change	Volume
	UMC	0.40	+0.04 (11.11%)	786,400

MEDIA HIGHLIGHTS (CONT'D)

星洲人 | VIP文

发布: 8:20am 26/05/2025 1278点阅

UMedC 投资问诊 医疗产品供应商

投资问诊 | UMedC前景向好 人口老龄化医疗需求大

投資問診文 / 陳艷芳

任何投資問題，歡迎問診把脈。
電郵: business@sinc Chew.com.my

问:

怡保读者张女士问，请问UMedC集团 (UMC,0256,主板医疗保健组) 这只股现在可以投资吗? 谢谢。

答:

医疗产品供应商UMedC集团主要业务是行销和分销知名品牌医用和消耗品产品器材，以及开发、制造和销售自身品牌的医用消耗产品，在私人领域强劲需求带动，加上股价在2月显著调整下，以风险回报评估，目前的投资前景相当受看好。

该公司3月公布截至2025年1月1日止第二季的净利下跌23.75%至189万1000令吉，半年净利降14.49%至373万6000令吉；第二季和半年营收也各下跌14%和12%，主要由于政府和私立医院，及医疗服务供应商对医疗器材的需求下降，冲击行销及分销和制造业务的表现。

不过，根据该公司管理层表示，公司的前景预计将在2025年7月杪的下半年后有所改善，主要是制造部门呼吸产品销售复苏。另外，该公司预计复苏将受到整体医疗保健趋势的支持，特别是世界各地人口老化，将继续推动需求。

丰隆研究也表示，该公司的行销和分销部门预计将实现稳步增长，3年复合年增长率为8%，得益于政府和私人机构增加医疗或实验室设备和耗材上的支出。该公司进军医疗保健服务也突显其多元化战略。

该公司也鉴于大马政府致力于提高国家医疗保健标准，对未来增长表示乐观，相信医疗设施升级、医疗旅游及解决医疗设施过度拥挤下，需求会继续增加。

大马政府在2025年财政预算案中宣布为卫生部拨款453亿令吉，比2024年增加10%，证明政府强调必须提供优质医疗服务，此外，政府还拨出13亿5000万令吉来升级医疗设施和维修，这预料将促进医疗保健业的增长，因此也对UMedC集团业务前景有利。

丰隆近期和该公司管理层会谈后，对该公司的制造业务维持不变看法，看好行销和分销业务成长，新成立的医疗保健中心业务暂时贡献不大，但前景相当看好。

Next, on comparing UMediC Group Berhad's net income growth with the industry, we found that the company's reported growth is similar to the industry average growth rate of 15% over the last few years.



KLSE:UMC Past Earnings Growth August 5th 2025

Earnings growth is a huge factor in stock valuation. It's important for an investor to know whether the market has priced in the company's expected earnings growth (or decline). Doing so will help them establish if the stock's future looks promising or ominous. If you're wondering about UMediC Group Berhad's valuation, check out [this gauge of its price-to-earnings ratio](#), as compared to its industry.

Is UMediC Group Berhad Efficiently Re-investing Its Profits?

UMedC Group Berhad doesn't pay any regular dividends currently which essentially means that it has been reinvesting all of its profits into the business. This definitely contributes to the decent earnings growth number that we discussed above.

Conclusion

Overall, we feel that UMediC Group Berhad certainly does have some positive factors to consider. Despite its low rate of return, the fact that the company reinvests a very high portion of its profits into its business, no doubt contributed to its high earnings growth. That being so, a study of the latest analyst forecasts show that the company is expected to see a slowdown in its future earnings growth. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? [Click here to be taken to our analyst's forecasts page for the company.](#)

财经 | 焦点财经

发布: 8:44am 11/03/2025 652点阅

UMedC集团

医疗器材需求下降 UMediC集团次季少赚23.8%

(吉隆坡11日讯) 由于医疗器材需求下降，拖累UMedC集团 (UMC,0256,主板医疗保健组) 截至2025年1月1日止第二季，净利报189万1000令吉，跌23.75%，前期为248万令吉。

该公司今日向大马股票交易所报备，首半年营业额也跌14.49%至373万6000令吉，前期为436万9000令吉。

根据文告，该公司次季营业额也跌14.10%至1157万9000万令吉；首六个月营业额也下滑12.03%至2463万4000令吉。

UMedC集团指出，由于公共和私立医院，及医疗服务供应商对医疗器材的需求下降，冲击营销及分销和制造业务的表现。

鉴于大马政府致力于提高国家医疗保健标准，该公司对未来的增长仍乐观，相信医疗设施升级、医疗旅游及为了解决医疗设施过度拥挤，需求会不断增加。

该公司指出，政府在2025年财政预算案中，宣布为卫生部拨款453亿令吉，比2024年的412亿令吉增加10%。也是第二大的预算案拨款，证明政府强调必须提供优质医疗服务，而且公共和私人医疗保健领域也日益重要。

此外，政府还拨出13亿5000万令吉来升级医疗设施和维修，料促进医疗保健行业的增长，这对UMedC集团未来的财务前景有利。

56,086,500 Ordinary Shares of UMediC Group Berhad are subject to a Lock-Up Agreement Ending on 26-JUL-2025.

Published on 07/25/2025 at 08:21 pm EDT
S&P Capital IQ

Share

UMEDIC GROUP +0.33%

56,086,500 Ordinary Shares of UMediC Group Berhad are subject to a Lock-Up Agreement Ending on 26-JUL-2025. These Ordinary Shares will be under lockup for 1104 days starting from 18-JUL-2022 to 26-JUL-2025.

Details:

The moratorium applies to the entire shareholdings of the Promoters for a period of six (6) months from the date of the Admission (?First Six (6)-Month Moratorium?) upon the expiry of the First Six (6)-Month Moratorium, the Company must ensure that the Promoters? aggregate shareholdings amounting to at least 45% of the total number of issued Shares (adjusted for any bonus issue or subdivision of Shares) remain under moratorium for another period of six (6) months (?Second Six (6)-Month Moratorium?), and upon the expiry of the Second Six (6)-Month Moratorium, subject to the Listing Requirements, the Promoters may sell, transfer or assign up to a maximum of 1/3 per annum (on a straight line basis) of their Shares held under moratorium.

光明日報
Guang Ming Daily

【一户一急救员课程】最年长74岁 最小11岁 127老小认真学急救

2025-07-09



嘉宾与筹委于开幕仪式上合影；右起陈思晴，沉珺羽，黄伟良，苏伟婷，陈润辉，曾靖娘，伍俊炫，陈明忠，纪少奇，Rescue Medic Sdn Bhd 代表。



参与急救课程的民众将所学知识学以致用，前右起沈琰羽、曾靖娘、陈明忠、黄伟良、苏伟婷、陈润辉、伍俊炫、纪少奇、巴欣蓓。

（大山脚8日讯）“一户一急救员课程”周日（6日）在武拉必中学举行，吸引127名年龄介于11岁至74岁，来自各领域涵盖家庭主妇和学生学员，参与学习急救知识。

此活动由红新月会威中县成人组第四分队、甘榜勿刺乡管会、该校家协协办。

会上，马来西亚红新月会威中县分会后助与采购委员会兼杭州后助与采购主席陈明忠分享急救须知事项，包括如何包扎患处、伤口处理、处理烧伤伤口等。

此外，红新月会威中县分会主席纪少奇，则分享应对中毒、骨折及搬运伤者所需的知识，而红新月会培训委员会副主席兼杭州州训与教育委员会主席伍俊炫，则分享心肺复苏术（CPR），教导民众正确使用心脏体外除颤器（AED）。

主讲者透过幽默、活泼的方式与民众互动，分享真实个案，让学员们容易吸收知识。

会上，民众皆认为急救知识可运用到生活中，74岁的黄来福就认为，“活到老，学到老”，每个人都应学习急救知识。至于喜爱登山运动的谢伟铭，则将学到的知识运用在登山时，如遇有人骨折、心脏骤停，可派上用场。

武拉必区州议员王丽丽的代表威中县市议员黄伟良说，每户人家如掌握急救知识，将能及时对突发状况伸出援手，每个人所学习知识，或就是生命的一线希望。

出席者包括工委会主席苏伟婷、大山脚国会议员沈志强的代表威中县市议员陈润辉、甘榜勿刺乡管会主席曾靖娘、红新月会威中县分会救护服务主管巴欣蓓、武拉必中学家协副主席沈琰羽、红新月会威中县成人组第四分队指挥官陈思晴。

■黄来福（右）认真学习心肺复苏术，左为陈明忠。

一户一急救员课程

最长74岁最小11岁

127老小認真學急救

（大山脚9日讯）红新月会威中县成人组第四分队联同甘榜勿刺社区管理理事会及武拉必中学家协，日前在武拉必中学举办“一户一急救员”课程，吸引127名来自各行各业、年龄介于11岁至74岁的学员参与。

74岁的学员黄来福说，“活到老，学到老”，他呼吁大众学习急救知识，在关键时刻能救人一命。

另一学员谢伟铭表示，自己热爱登山运动，学习急救知识能提升自救与助人的能力，称赞课程实用，希望未来能继续举办类似培训。

黄来福在活动尾声也获大会颁发“最佳学习精神奖”。

课程邀请3名资深讲师主讲，包括马来西亚红新月会杭州分会后助与采购主席陈明忠教官、红新月会威中县分会管理主席纪少奇教官、红新月会培训委员会副主席伍俊炫教官。

黄来福在活动现场也获大会颁发“最佳学习精神奖”。

■嘉宾与筹委于开幕仪式上合影，右起为陈思晴、沈琰羽、黄伟良、苏伟婷、陈润辉、曾靖娘、伍俊炫、陈明忠、纪少奇及Rescue Medic Sdn Bhd代表。

黄伟良：學會了能救命

武拉必州议员王丽丽的代表黄伟良市议员致词时说，“一户一急救员”是重要的生命教育，若每户家庭都有人掌握急救技能，就能在紧急时刻及时出手，挽救生命。

伍俊炫教官说，学习急救不只是选择，更是一份对家庭与社会的责任。他感谢主办单位推动课程，并感谢Rescue Medic Sdn Bhd借出AED训练器，让学员能实地操作模拟，“在黄金4分钟内勇敢施救，关键时刻守护生命”。

出席者包括工委会主席苏伟婷、人力资源部兼大山脚国会议员沈志强的代表陈润辉市议员、甘榜勿刺社区管理理事会主席曾靖娘、红新月会威中县分会救护服务主管巴欣蓓、武拉必中学家协副主席沈琰羽及红新月会威中县成人组第四分队指挥官陈思晴等人。（CSH）



主办方颁发纪念品给各单位，右起为陈思晴、沈琰羽、黄伟良、苏伟婷、陈润辉、曾靖娘、伍俊炫、陈明忠、纪少奇、惠借心脏除颤器的Rescue Medic代表。

威中武拉必急救员课程吸引家庭主妇学生参与

【大山脚8日讯】红新月会威中县成人组第四分队、甘榜勿刺乡管会及武拉必中学家协，日前在武拉必中学举办“一户一急救员”课程，吸引127名参与，学员来自各领域、家庭主妇及学生，年龄从11岁至74岁。

3位资深讲师与学员分享急救知识。马来西亚红新月会威中县分会后助与采购委员会，兼杭州后助与采购主席陈明忠教官，分享各项包扎技术、伤口处理、烧伤等。威中县分会主席纪少奇教官分享中毒、骨折及伤者搬运知识。红新月会培训委员会副主席、兼杭州培训与教育委员会主席伍俊炫教官，分享心肺复苏术及正确使用心脏体外除颤器。

74岁的黄来福说，活到老，学到老，呼吁人人都来学习急救知识，帮助有需要的人。

谢伟铭说，他喜欢运动，尤其是爬山、运动人士需有基本急救常识，因为在运动中可能会发生突发状况，如跌倒骨折、受伤或遇到心脏骤停等，希望能多学这门课程，让更多人学习急救。

武拉必州议员王丽丽的代表黄伟良市议员说，此课程是非常重要的生命教育，每户家庭至少有一名成员掌握基本急救技能，以便在突发状况中能第一时间伸出援手，稳定伤者状况。

伍俊炫教官在致词中说，学习急救不

74岁的黄来福（右）认真学习心肺复苏术，左为陈明忠。

是一个选择，更是一份对家人、社会的责任，在危机的时候敢于出手守住生命。大会感发感谢给3名教官，及最佳学习精神奖给黄来福。出席者尚有：工委会主席苏伟婷、人力资源部部长沈志强的代表陈润辉市议员、甘榜勿刺乡管会主席曾靖娘、红新月会威中县分会救护服务主管巴欣蓓、武拉必中学家协副主席沈琰羽、红新月会威中县成人组第四分队指挥官陈思晴等。■



一户一急救员 A FIRST AIDER IN EVERY HOME

06/07/2025 (星期日 Sunday)

8 AM - 5 PM

SMK Berapit

013-4807782, 018-9584580

报名方式 Registration:

每人收费150元 (Limited Participants 150 person, if full registration will close early)

课程截止日期 Register Due Date: 29.06.2025

网上报名链接 Online Register Form

急救课程内容 First Aid Course Content:

- 心肺复苏术 (CPR)
- 体外除颤器 (AED)
- 止血 Stop Bleeding
- 包扎伤口 Bandaging
- 骨折 Fracture
- 噎哽 Choking
- 中毒 Poisoning
- 烧伤 Burn


FINANCIAL HIGHLIGHTS

	FYE 2021	FYE 2022	FYE 2023	FYE 2024	FYE 2025
Revenue (RM'000)	34,116	50,738	45,432	54,570	48,564
Gross Profit (RM'000)	12,563	18,659	18,933	22,671	22,363
Profit Before Taxation (RM'000)	6,554	8,482	12,932	12,641	10,851
Profit After Taxation (attributable to owners of the parent) (RM'000)	5,087	6,426	10,315	8,991	8,133
EBITDA (RM'000)	8,096	10,833	14,591	14,330	12,977
Basic and Diluted EPS (sen)⁽¹⁾	1.36	1.72	2.76	2.40	2.18
Shareholders' Equity (RM'000)	15,739	52,679	62,994	71,985	80,118
Return on Equity	32.32%	12.20%	16.38%	12.49%	10.15%
Current Ratio (times)	1.23	5.78	11.68	8.20	9.13
Gearing Ratio (times)	1.67	0.15	0.06	0.01	-


Note:

(1) Computed based on the profit after taxation (attributable to equity holders of the Company) divided by the total number of issued shares of the Company of 373,910,000 shares.

Revenue (RM'000)




Profit Before Taxation (RM'000)




■ Profit Before Taxation (in RM'000) — PBT Margin (%)

Profit After Taxation (RM'000)



■ Profit After Taxation (in RM'000) — PAT Margin (%)

Basic Earnings Per Share (sen)



CHAIRMAN'S STATEMENT



"As the year drew to a close, UMediC Group Berhad ("UMC" or the "Company") continued to embark on its remarkable journey filled with strategic progress and pivotal developments cementing itself within the vast healthcare ecosystem. UMC and its subsidiaries ("Group") are essentially laying a vital foundation to build a stronger yet more resilient and fundamentally valuable enterprise for decades to come."

Dato' Seri Ng Chai Eng

Non-Independent Non-Executive Chairman



Dear esteemed shareholders,

On behalf of the Board, it is my immense pleasure to present you with UMC's fourth annual report for the financial year ended ("FYE") 31 July 2025.

As the past year unfolded, we have undergone several key strategic initiatives that have fundamentally prepared us for the next phase of growth. Despite the complexities of the broader market, our focus remained deeply rooted towards deepening our capabilities and expanding our physical footprint culminating in the significant expansion of our new facility. This effectively doubles our manufacturing prowess to cater to the overarching global demand for our medical consumables. Aside from manufacturing, this new facility unlocks a new frontier for the Group, following our foray into the medical services segment, solidifying our presence within the dynamic healthcare landscape and evolving us into a truly integrated healthcare provider. These critical milestones, supported by a conducive manufacturing environment alongside the increasing demand for quality healthcare positions UMC for sustained growth over the long-term horizon.

FINANCIAL PERFORMANCE

On the financial front, the Group managed to deliver a solid performance in FYE2025 having recorded a revenue of RM48.6 million primarily driven by the marketing and distribution segment. The segment contributed 66.3% of our revenue which was RM32.2 million followed by the manufacturing segment which accounted for the remaining 33.7% with RM16.4 million. This in turn resulted in a profit after tax (attributable to equity holders of the Company) of RM8.1 million, delivering an improved profit after tax margin of 16.7% over FYE2024, a result of our prudent cost structure and improved operational efficiencies through the adoption of new manufacturing technologies. In spite of the ongoing factory expansion which hindered our overall production capabilities paired with softer demand arising from the change in spending cycles, we still managed to achieve a commendable set of results attesting to our strong presence within the healthcare industry.

In terms of balance sheet, UMC remains in a strong and healthy position. With nominal borrowings, the Group maintains a net cash position of RM16.6 million, comprising cash and bank balances of RM11.6 million with the remaining RM5.0 million being proceeds from our initial public offering. Also, the current ratio of 9.1 times reflects solid liquidity and prudent financial management. Given the sound financial background of UMC, we are well-positioned to support the Group's future, prioritising our focus in optimising our production capabilities.

CHAIRMAN'S STATEMENT (CONT'D)

PROSPECTS AND OUTLOOK

Shifting the focus towards the future, our long-term growth trajectory remains intact backed by the Malaysian government's resolute focus on improving national healthcare standards. In fact, we are actively seizing the immense opportunities created by a confluence of accelerating factors such as the surge in demand for medical facility upgrades as well as Malaysia's status as the regional healthcare tourism hub alongside the pressing need to alleviate facility overcrowding. UMC is therefore poised to substantially deepen its role, transforming the country's rapidly evolving healthcare ecosystem and creating lasting value for our stakeholders and the community that we serve.

In line with these developments, our strategic venture into the medical services segment is part of our vertical expansion into the medical healthcare ecosystem and is synergistic in nature to our existing business offerings. Leveraging our extensive scale and active presence, we aim to address the gap and pain point among hospitals and local healthcare providers by offering services such as a dedicated care centre providing post-recovery care, ambulance solutions offering the complete infrastructure equipped with the latest medical devices as well as the establishment of a learning centre providing training to medical professionals. While contributions are expected to come gradually, we are laying down the foundation in order for us to capture the opportunities ahead over the longer-term horizon.

In terms of manufacturing, we have come a long way and have since achieved notable progress where we now have 4 products under our portfolio with HYDROX Prefilled Humidifier, HYDROX Prefilled Nebuliser, AIRDROX Inhaler Spacer and FLEXIDROX Sterile Water for Inhalation. Given our expanded product portfolio, our focus this year has been on prioritising developments to improve our manufacturing capabilities through major infrastructure enhancements which include a new state-of-the-art ISO 5 cleanroom, advanced blow-fill-seal technology, new packing room, and relocation of our warehouse operations. Paired with the introduction of advanced manufacturing technologies adopting a new aseptic manufacturing process, we are preparing ourselves to ramp up our production capabilities to cater to the anticipated increase in demand from both domestic and international markets.

With these strategic initiatives in place, UMC remains steadfast in its commitment to innovation and operational excellence. By capitalising on the expertise of our highly skilled workforce and strength of our diversified portfolio, we are well-positioned to sustain our competitive advantage and deliver long-term value to all stakeholders while contributing meaningfully to the advancement of Malaysia's healthcare ecosystem.

SUSTAINABILITY

With the growing global emphasis on sustainable practices, sustainability continues to be a cornerstone of our long-term business strategy and overall success. We remain steadfast in our commitment to integrating environmental, social, and governance ("ESG") principles into all aspects of our operations, ensuring that our growth generates lasting value for our stakeholders and the planet. We remain confident that the continuously evolving ESG landscape will guide and reinforce our initiatives, allowing us to refine our framework and ensure better alignment with international standards in the year ahead.

For a detailed account of our sustainability initiatives and progress, please refer to the Sustainability Statement on pages 47 to 75 where we outline the steps we are taking to drive meaningful impact and advance a more sustainable future.

APPRECIATION

As we close off the chapter for the year, we would like to extend our profound gratitude to all our valued stakeholders. Your unwavering trust and belief in UMC particularly the enduring confidence of our shareholders in our long-term vision has been the bedrock upon which we build our future. Your continuous support throughout this journey is what allowed us to unlock the true potential of our Group leading up to this point.

Above all, I would like to highlight the exceptional contributions of the entire UMC team. Your resilience, innovative spirit and adaptability were the true driving force that empowered us to successfully navigate the challenging industrial landscape this year. You have all been instrumental in bringing us to this pivotal point and I eagerly anticipate your continued contributions as we ascend new heights. United by our shared purpose and guided by our core values, we will relentlessly elevate our standards and advance our vision of excellence in healthcare.

Yours faithfully,

Dato' Seri Ng Chai Eng

Non-Independent Non-Executive Chairman

MANAGEMENT DISCUSSION AND ANALYSIS

OVERVIEW OF BUSINESS AND OPERATIONS

Company Profile and Principal Activities

UMediC Group Berhad (“UMC”, or the “Group”, or the “Company”) primarily functions as an investment holding entity with a diversified presence across the healthcare value chain. Through our subsidiaries, we are actively engaged in the marketing, distribution and after-sales servicing of a wide range of branded medical devices, laboratory equipment and consumables. We also develop and manufacture our own range of medical consumables, medical mounting solutions and cart solutions tailored to support diverse healthcare needs. Complementing these activities, we have ventured into healthcare services through the establishment of a healthcare centre and the provision of ambulance services.

This strategic diversification positions our Group to meet the rising demand for comprehensive, high-quality healthcare solutions, while creating opportunities for downstream integration. By harnessing synergies across our businesses, we are able to enhance operational efficiency and delivering more integrated solutions across the healthcare sector.

- **Marketing and distribution** – We specialize in the marketing and distribution of medical devices, along with the provision of after-sales services, to both public and private hospitals, healthcare service providers, and even non-medical business entities. UMediC Healthcare Sdn. Bhd. is the authorized distributor for leading international brands such as Philips, Mindray, and GE, offering a wide portfolio of critical-care and high-value products.

In FYE 2023, our Group strengthened its distribution segment through the strategic acquisition of a 70% stake in Patho Solutions (M) Sdn. Bhd. ("Patho"), a specialist in laboratory equipment and consumables, with core expertise in histopathology, immunology and cytology. Patho's capability to provide customized laboratory solutions significantly enhances our market reach and technical capabilities.

In FYE 2024, we further expanded our portfolio through the incorporation of Ateria Medika Sdn. Bhd., focusing on cutting-edge medical devices and consumables for interventional cardiology and radiology, and Akiteck (Malaysia) Sdn. Bhd., which specializes in the research, design, and development of medical mounting solutions and carts. Akiteck's key clientele comprises global medical device leaders in patient monitoring, ultrasound, CTG, and ECG systems, with a growing market presence in Malaysia and the wider Southeast Asian region.

In FYE 2025, we continued to broaden our service capabilities with the incorporation of Rescue Medic Sdn. Bhd., an 85%-owned subsidiary providing pre-hospital and emergency medical services. Its offerings encompass ambulance vehicle supply, emergency and non-emergency ambulance operations, and the provision of ambulance medical equipment.

These strategic developments mark a significant step forward in strengthening our presence across the healthcare value chain, enabling us to deliver holistic, patient-centric solutions and positioning the Group for long-term sustainable growth. Collectively, these expansions have broadened our product range, reinforced our technical and service capabilities, and enhanced our ability to provide comprehensive, end-to-end healthcare solutions in response to the growing global demand for advanced medical technologies.

- **Manufacturing** – We are deeply committed to the development, manufacturing, and marketing of innovative medical consumables, designed to meet the highest industry standards. Under UWHM Sdn. Bhd., our flagship products include the HYDROX series prefilled humidifiers, the HYDROX prefilled nebulizers, the AIRDROX series inhaler spacers and the FLEXIDROX water for inhalation bag. These products are exported to approximately 40 countries and manufactured in our state-of-the-art facility under strict compliance with rigorous standards set by relevant regulatory authorities. Notably, UWHM is the world's first company to obtain Halal certification for prefilled humidifiers, underscoring our commitment to innovation and inclusivity.



Our existing owned office and factory building located in Batu Kawan, Penang

MANAGEMENT DISCUSSION AND ANALYSIS (CONT'D)

OVERVIEW OF BUSINESS AND OPERATIONS (CONT'D)

Key Achievement

In 2024, we marked a pivotal milestone in our corporate journey by successfully transferring from the ACE Market to the Main Market of Bursa Malaysia Securities Berhad (“Bursa Securities”) on 29 April 2024. This achievement reflected the Group’s growth, maturity, and strengthened foundation of governance and financial stability. The transfer not only expanded our visibility to a broader investor base but also reinforced our commitment to innovation, efficiency, and long-term shareholder value creation.

Building on this momentum, 2025 witnessed another transformative achievement with the unveiling of our large-scale expansion at Batu Kawan Industrial Park on 15 August 2025. The new facility, which increases our production footprint from 30,000 square feet to 50,000 square feet, effectively doubles our manufacturing capacity and strengthens our role in advancing Malaysia’s healthcare future.

This expansion goes beyond manufacturing. It introduces three strategic components — the UMC Healthcare Centre, Rescue Medic Ambulance Services, and the UMC Learning Centre — furthering our evolution into an integrated healthcare solutions provider. The state-of-the-art facility, featuring an ISO 5 cleanroom and advanced blow-fill-seal technology, enhances our ability to deliver world-class medical consumables while complementing our growing presence in medical distribution, training, and emergency support services.

These achievements underscore our vision of creating a synergised and integrated healthcare supply chain powered by innovation and technology. As we continue to expand our reach both domestically and globally, the Group remains steadfast in delivering sustainable growth, improving healthcare accessibility, and enhancing the quality of human life.



Grand Launching Ceremony of UMediC Medical Services on 15 August 2025

Expansion Strategies

1. Incorporation of New Subsidiary



On 11 March 2025, UMC incorporated Rescue Medic Sdn. Bhd. (“Rescue Medic”), an 85%-owned subsidiary with a total cash and share capital of RM1,000,000. The establishment of Rescue Medic marks a significant step in our Group’s long-term growth strategy.

Rescue Medic focuses on supplying ambulance vehicles, providing both emergency and non-emergency ambulance services, and equipping ambulances with advanced medical devices. This diversification strengthens UMC’s integrated healthcare ecosystem and positions our Group to capture emerging opportunities in critical front-line services.

The timing of this move is significant. The Ministry of Health Malaysia has embarked on a large-scale replacement programme involving more than 590 ambulances in Phase 1 and an approved budget of RM304 million for Phase 2, coupled with growing demand for safe, modernised medical equipment to replace ageing assets. Rescue Medic is strategically positioned to support this nationwide upgrading initiative by supplying ambulance vehicles that meet stringent specifications and are fully equipped with high-quality paramedic and life-support equipment to ensure reliability, safety and optimal patient care.

By aligning our capabilities with national healthcare priorities, Rescue Medic not only enhances our service offerings but also reinforces our Group’s mission to deliver holistic, patient-centric solutions. This initiative strengthens UMC’s resilience, creates new recurring revenue streams, and positions us as a trusted partner in advancing Malaysia’s healthcare infrastructure.

MANAGEMENT DISCUSSION AND ANALYSIS (CONT'D)

OVERVIEW OF BUSINESS AND OPERATIONS (CONT'D)

2. Expansion of Operation Capabilities



Plant 1





Plant 2

In FYE 2025, UMC achieved major milestones in strengthening its manufacturing and operational capacity. Plant 2 was occupied in early 2025, marking a key step in our Group's long-term growth strategy.

Our monthly production capacity increased from 420,000 bottles of HYDROX prefilled humidifiers to 433,000 bottles, representing a 3% growth increase from the previous year. The HYDROX prefilled humidifier is used to humidify the respiratory gas for patients and mostly used in oxygen therapy such as oxygen concentrators, gas cylinder or wall gas outlets via a mask or cannula in homecare, hospital, extended care facilities or hospital environment.

This capacity expansion was supported by the completion of major infrastructure enhancements, including:

- A new state-of-the-art ISO 5 cleanroom to strengthen sterile production standards



- A new packing room to improve workflow and product turnaround time




MANAGEMENT DISCUSSION AND ANALYSIS (CONT'D)

OVERVIEW OF BUSINESS AND OPERATIONS (CONT'D)

2. Expansion of Operation Capabilities (Cont'd)

- The relocation of warehouse operations to Plant 2, providing additional storage capacity and streamlined logistics



During the year, UMC also introduced advanced manufacturing technologies that delivered significant operational improvements. These include faster lead times, aseptic manufacturing processes to enhance product safety, improved bottle designs, larger volume options without compromising shipping efficiency, and enhanced water quality standards. Collectively, these innovations enable UMC to produce higher-quality medical consumables more efficiently while meeting evolving customer needs.

With these enhancements, UMC is now better positioned to drive production efficiency and scale up manufacturing for its broader product range, including the HYDROX Prefilled Nebulizer, AIRDROX Inhaler Spacer, FLEXIDROX Water for Inhalation Bag, and future product innovations.

On the commercial front, UMC strengthened its presence in both domestic and international markets, building on its established customer base and reinforcing its position as a trusted supplier of medical consumables worldwide.

These operational enhancements not only reinforce UMC's commitment to delivering high-quality medical consumables but also underscore the Group's strategy of driving efficiency, scalability, and global competitiveness.

3. Establishment of UMC Healthcare Centre



UMC's subsidiary Evo Medik Sdn. Bhd. established the UMC Healthcare Centre, a premium 7,427 square foot facility at Pusat Perniagaan Vorteks, Simpang Ampat. The Centre is designed to deliver comprehensive, patient-centric care within a safe and comfortable environment.

The facility offers a wide spectrum of services, including post-operative care, chronic disease management, elderly care, and specialised rehabilitation programmes. Care packages are thoughtfully structured to suit individual needs, offering options such as day care, short-term care, respite care, and long-term assisted living. In addition, we extend our reach beyond the Centre through professional home care services, ensuring greater accessibility and flexibility for patients and families.

MANAGEMENT DISCUSSION AND ANALYSIS (CONT'D)

OVERVIEW OF BUSINESS AND OPERATIONS (CONT'D)

3. Establishment of UMC Healthcare Centre (Cont'd)

Beyond medical support, the UMC Healthcare Centre enhances the patient experience with a holistic approach that integrates lifestyle and wellness. Residents benefit from nutritious meals, engaging activities, and personalised support, supported by assisted facilities such as elevators, wheelchairs, and safety bars. To ensure continuity of care, the Centre also provides ambulance transportation and medical chaperone services when required.

The establishment of the UMC Healthcare Centre marks an important milestone for the Group's, strengthening UMC's position along the healthcare value chain and capturing opportunities in Malaysia's growing post-acute and elderly care market.



Sustainability and Climate Change Management



At the core of our business, sustainability is not just an operational goal but a fundamental principle that guides our long-term strategy. As part of our efforts to align with global sustainability standards and address the pressing issue of climate change, we have implemented several proactive measures. One of the most significant milestones in this journey is the installation of 420 solar panels with a total capacity of 231 kWp at Plant 1 in October 2023.


We had commenced the utilisation solar panels in December 2023, a strategic milestone that will allow us to reap the benefits of sustainable energy adoption. As we continue to expand our green energy initiatives, we remain dedicated to creating a positive environmental impact while simultaneously driving operational and financial growth.

MANAGEMENT DISCUSSION AND ANALYSIS (CONT'D)

OVERVIEW OF BUSINESS AND OPERATIONS (CONT'D)


Principal Markets

Our customer base comprises of public and private hospitals, other healthcare service providers as well as non-medical business entities. Malaysia, being our principal market, contributed approximately RM32.97 million (FYE 2024: RM36.16 million) or 67.90% (FYE 2024: 66.27%) of our revenue for FYE 2025, while the remaining revenue of RM15.59 million (FYE 2024: RM 18.41 million) or 32.10% (FYE 2024: 33.73%) was generated from the overseas markets. The FYE 2025 revenue by region is illustrated as below:



Our Journey

In 2025 and beyond, our unwavering commitment to our core values of Unity, Motivation, and Commitment remains the driving force behind our journey. These values form the foundation of our company, guiding our decisions and actions as we continue to expand and innovate in the healthcare industry.



With a remarkable track record spanning over two decades, we have consistently strived to be a leader in our field, delivering an integrated healthcare supply chain powered by advanced technology. Our goal is not just to provide medical products and services but to enhance the quality of human life on a global scale.

Our milestones, from our listing on the ACE Market in 2022 to our successful transition to the Main Market in 2024, reflect not just achievements but stepping stones toward an even greater purpose. Each milestone underscores our resilience, reinforces our commitment to innovation and operational excellence, and reaffirms our ambition to deliver sustainable value to all stakeholders.

Today, UMC is embarking on an exciting new chapter - evolving from a traditional marketing, distribution and manufacturing model into a diversified healthcare ecosystem that integrates both products and services. This strategic shift reinforcing our position as a holistic healthcare products and services provider and ensuring our relevance in meeting the growing demands of the market.

MANAGEMENT DISCUSSION AND ANALYSIS (CONT'D)

OVERVIEW OF BUSINESS AND OPERATIONS (CONT'D)

2002

- Incorporation of UMediC, principally involved in the marketing and distribution of medical supplies and dental-related products and devices

2003

- Diversified marketing and distribution to include imported medical devices
- Secured authorised distributorship rights from Goldway

2004

- Commenced distribution of ambulance and paramedic equipment as well as medical consumables

2005

- Commenced distribution of medical devices and consumables to general ward, and accident and emergency departments

2006

- Ceased the marketing and distribution of dental-related products and devices

2007

- Incorporation of Evo Medik to manage the marketing and distribution activities in the east coast region of Peninsular Malaysia

2009

- Setting up a marketing and distribution office located in Kota Bharu, Kelantan
- Commenced distribution of Philips Goldway branded patient monitors and colposcope

2010

- Setting up a marketing and distribution office in Johor Bahru
- Further expanded to Sarawak state
- Secured authorised distributorship rights from Philips

2011

- Ventured into the R&D and manufacturing of our own brand medical consumables
- Incorporation of U Medihealth to manage the marketing and distribution activities in Perak and Sabah states

2012

- Developed and commercialised our first HYDROX series prefilled humidifiers

2018

- Secured authorised distributorship rights from E-Medtest (M) Sdn Bhd and commenced distribution of Dameca branded general anaesthetic machines
- Ventured into Czech Republic, Myanmar, Pakistan, Kuwait, Moldova and Romania markets
- Commenced the development of our AIRDROX series inhaler spacers and HYDROX series prefilled nebulisers

2017

- Commenced distribution of Philips branded MRI-compatible patient monitors, medical consumables and sensors equipment
- Ventured into the South Africa, Chile, Ecuador and South Korea markets
- Commenced the development of sterile water for inhalation

2016

- Received the Best Channel Partner Performance, Value Segment for Patient Monitors appreciation award by Philips
- Established an in-house microbiology and chemical laboratory
- Ventured into India, Mauritius and Sri Lanka markets

2015

- Commenced distribution of Philips branded AEDs
- UMediC and Evo Medik received GDPMD certification from BSI
- UWHM granted a certificate of EC registration from BSI
- Received the Best Country Order Growth, Patient Care and Monitoring Solutions appreciation award by Philips for year 2015
- Ventured into Jordan and Saudi Arabia markets

2014

- Commenced distribution of Philips Goldway branded cardiocography monitors
- Commenced distribution of Philips branded clinically advanced patient monitors
- Ventured into Indonesia and Philippines markets

2013

- UWHM's QMS was assessed and accredited with ISO 9001:2008 and ISO13485:2003 under the scope of "manufacture of prefilled humidifier content with sterile purified water" from BSI
- Received the Halal certification for our prefilled humidifiers from Majlis Agama Islam Pulau Pinang
- Ventured into Thailand market

2019

- Secured authorised distributorship rights from Mindray, GE, Merit
- Commenced construction of our new office and factory building on the Batu Kawan Land
- UMediC's QMS was assessed and accredited with ISO 13485:2016 from BSI
- Ventured into Croatia, Singapore and the United Arab Emirates markets

2020

- Commenced distribution of Philips branded ultrasound machines
- Secured authorised distributorship rights from Care Vision Healthcare Pte Ltd
- Ventured into Costa Rica, Italy, Japan, Kenya and Netherlands markets
- Commenced the development of digital oxygen flowmeters and humidifier humidity sensors

2021

- Relocated our operations to our new office and factory building on the Batu Kawan Land
- Commenced distribution of Mindray branded neonatal ventilators
- Ventured into Bahrain and Brazil markets
- Developed our AIRDROX series inhaler spacers

2022

- Commercialised our AIRDROX series inhaler spacers
- Developed our sterile water for inhalation
- Ventured into Germany and Spain markets
- Listed on the ACE Market of Bursa Securities

2023

- Successfully acquired 70% of Patho Solutions (M) Sdn. Bhd.
- Expansion of new plant
- Confirmation of solar panels installation to address Sustainability and climate change matter

2024


- Successfully transferred to Main Market of Bursa Securities
- Incorporated 70% owned subsidiary, Akiteck (Malaysia) Sdn. Bhd. related parts
- Incorporated a 90% owned subsidiary, Ateria Medika Sdn. Bhd.

2025

- Incorporated 85% owned subsidiary, Rescue Medic Sdn. Bhd.
- Successfully launched UMC Healthcare Centre, Rescue Medic Ambulance Services and UMC Learning Centre

MANAGEMENT DISCUSSION AND ANALYSIS (CONT'D)

FINANCIAL REVIEW



For FYE 2025, our Group recorded revenue of RM48.56 million (FYE 2024: RM54.57 million). The marketing and distribution segment contributed RM32.20 million (FYE 2024: RM36.19 million), representing 66.30% of the Group's total revenue (FYE 2024: 66.32%). Meanwhile, the manufacturing segment contributed RM16.37 million (FYE 2024: RM18.38 million), accounting for the remaining 33.70% of total revenue (FYE 2024: 33.68%). We recorded profit before tax ("PBT") of RM10.85 million (FYE 2024: RM12.64 million). The decline in both revenue and PBT was attributable to lower contributions from the marketing and distribution segment as well as the manufacturing segment. This was primarily driven by softer demand for medical devices and consumables from both public and private hospitals, as well as healthcare service providers.

In FYE 2025, our Group recorded a PBT margin of 22.34%, slightly lower than 23.16% in FYE 2024. Profit after taxation attributable to equity holders of the Company ("PAT") stood at RM8.13 million (FYE 2024: RM8.99 million). Despite the lower PAT, the PAT margin improved marginally to 16.75% in FYE 2025 (FYE 2024: 16.48%), reflecting continued operational efficiency and prudent cost management.

As at 31 July 2025, our Group maintained a solid balance sheet with a net cash position of RM16.57 million⁽¹⁾.

Overall, our financial position remained healthy with a high current ratio of 9.13 times (FYE 2024: 8.20 times). The increase in our current ratio was mainly attributable to the reduction in our bank borrowings.

Note:

(1) Computed based on the sum of short-term funds and cash and bank balances and less current borrowing.

MANAGEMENT DISCUSSION AND ANALYSIS (CONT'D)

OPERATION REVIEW

CORPORATE STRATEGIES

Operational Efficiency


Our business and manufacturing activities are currently centered at our head office and factory complex located in Batu Kawan, Penang, strategically designed to enhance operational efficiency and scale to meet increasing market demand. The facility sits on a land area of approximately 126,852.68 square feet, with a built-up area of 70,216.26 square feet. It features a double-storey office building annexed with two single-storey factory buildings, providing ample space for both manufacturing and storage.

The current production floor allowing us to carry out our in-house manufacturing of key medical consumables such as the HYDROX and AIRDROX product series. By centralizing our manufacturing activities under one roof, we streamline operations, minimize downtime, and ensure stringent quality control throughout the production cycle. Additionally, the layout of the production floor is designed for flexibility, allowing for future expansion and the integration of new production lines as our product offerings grow.

To ensure seamless operations, our current storage area is designed for the safe and efficient handling of raw materials, finished goods, and distribution products. The proximity of the storage area to the production floor enhances the flow of materials and products, reducing transportation time and increasing overall productivity. This integrated approach allows for better inventory management and quicker response times to market demand, contributing to improved lead times for customers.

Out of the RM3.50 million IPO proceeds allocated for the construction of our new factory building, and this allocated funds was fully utilised with the excess amount of approximately RM0.17 million has been used for working capital purposes. This strategic expansion underscores our commitment to enhancing operational capabilities and meeting future business demands.

Domestic Presence and Reach



Our domestic presence and reach are strategically designed to cover key regions across Malaysia, as illustrated in the above map. At the heart of our operations is the head office and factory complex in Batu Kawan, which functions as the central hub for our manufacturing and distribution activities. Complementing this, we have expanded our services through the UMC Healthcare Centre and Rescue Medic Ambulance Services, both based in Batu Kawan. These initiatives strengthen our role as a holistic healthcare products and services provider while ensuring direct engagement with patients, customers and the broader community.

Marketing and Distribution Offices:

Currently, our marketing and distribution activities are supported by rented offices in Bandar Tun Razak, Kuala Lumpur, and Johor Bahru. These rented spaces do not include showrooms, limiting our ability to physically showcase our products to customers.

To strengthen our presence in these regions and tap into the potential business opportunities, we are planning to establish new marketing and distribution offices with dedicated showrooms in both Kuala Lumpur and Johor Bahru. These showrooms will allow us to demonstrate the functionality of our products to existing and potential customers, enhancing customer engagement and providing a hands-on experience.

MANAGEMENT DISCUSSION AND ANALYSIS (CONT'D)

OPERATION REVIEW (CONT'D)

CORPORATE STRATEGIES (CONT'D)

Sales Representatives:

In addition to our office presence, we have in-house sales representatives stationed in major cities across West Malaysia and East Malaysia, as shown on the map. This widespread sales network allows us to provide comprehensive coverage and personalized support to customers throughout the country, ensuring that our products and services are readily accessible.

UMC Healthcare Centre and Rescue Medic Ambulance Services:

Located in Batu Kawan, the UMC Healthcare Centre and Rescue Medic Ambulance Services expand our domestic footprint by strengthening our role as a holistic healthcare provider. The healthcare centre serves as a direct touchpoint with patients and customers, while the ambulance services enhance accessibility to community healthcare and ensure timely medical support. Together, these initiatives extend our presence beyond product distribution and reflect our commitment to developing a more integrated healthcare ecosystem.



New Product Development and Commercialisation

UWHM has established itself as a dedicated player in the respiratory care segment, with a portfolio of products designed to support oxygen therapy and related treatments. Since its incorporation, UWHM has successfully introduced the HYDROX Prefilled Humidifier, the AIRDROX series inhaler spacers, the HYDROX Prefilled Humidifier with Macro Nebulization System and the FLEXIDROX water for inhalation bag.

During the year under review, although no new products were launched, UWHM continued to invest in advancing its manufacturing technology to enhance efficiency, scalability, product quality, and consistency. This ongoing effort ensures that we remain well-positioned to meet evolving market needs and sustain the long-term growth of our manufacturing operations.

At the same time, we remain committed to anticipating and responding to market needs, ensuring that our product pipeline continues to drive healthcare innovation and address the dynamic requirements of the industry. Looking ahead, we are preparing to introduce the Digital Humidifier Monitoring Sensor, a new solution that will further strengthen our respiratory care portfolio.

In parallel, under Akiteck, we have expanded our product portfolio to cover wall mounts, anaesthesia machine configurations, architectural headwall adaptations, pole mounts, countertop mounts, standard and customizable mobile carts, computers on wheels and a full range of accessories. These solutions are designed for durability, flexibility, and ease of use, enabling healthcare providers to improve workflow efficiency and comfort.

Akiteck currently serves leading global medical device companies in patient monitoring, ultrasound, CTG and ECG systems. During the year under review, we secured our first distributor in Thailand and initiated discussions with other regional partners – marking an important step toward positioning Akiteck as a competitive player in the medical mounting and cart solutions segment.



Akiteck - Emergency Cart



Akiteck - Machine Trolley

MANAGEMENT DISCUSSION AND ANALYSIS (CONT'D)

OPERATION REVIEW (CONT'D)

CORPORATE STRATEGIES (CONT'D)


Product Portfolio Expansion

UMC continues to strengthen its role as a trusted partner to some of the world's leading medical device manufacturers. Through UMediC Healthcare Sdn. Bhd., we distribute advanced solutions from Philips, Mindray, and GE, offering a broad portfolio that spans patient monitoring systems, ultrasound, maternal and infant care, anaesthesia and resuscitation equipment, oxygen therapy, suction solutions, and life-support systems. With demand for medical devices expected to rise steadily, we are broadening our offerings to ensure that hospitals, healthcare providers, and even non-medical businesses have access to products that meet diverse specifications, features, and price points.

Our regional reach is further extended through Ateria Medika Sdn. Bhd., which represents leading global brands such as Acandis, Curatia, Bedal, PINS Medical, Firstkind, Civco, and Orbus Neich. These solutions cover interventional cardiology, neurology, radiology, and vascular surgery, equipping healthcare professionals with cutting-edge consumables and devices across Southeast Asia. Ateria Medika is also in advanced discussions to secure distributorship rights for a globally recognised company in blood transfusion solutions, covering both consumables and equipment.



Ateria Medika – DBS Device



Ateria Medika – VNS Device

Patho Solutions (M) Sdn. Bhd. has diversified beyond histopathology into autoimmune diagnostics, microbiology, digital pathology, and molecular diagnostics. A milestone in 2024 was its distribution agreement with AliveDx Suisse S.A., granting rights to introduce MosaiQ® and LumiQ® diagnostic platforms in Malaysia, Myanmar, and Cambodia, with future expansion into Singapore.

Building on this momentum, Patho entered into an exclusive distribution agreement with Accunome (Shanghai, China) in December 2024. As Accunome's first appointed distributor worldwide, Patho and UMC will collaborate to produce molecular testing kits in Penang for infectious disease diagnostics, targeting Malaysia, Southeast Asia, and the Middle East. With rising demand in areas such as influenza and HPV testing, this initiative positions us at the forefront of high-impact diagnostics. Plans are also underway to expand into Indonesia, including exclusive distribution of Accunome's PCR system, Dxcellent 12.

Additionally, Patho have entered into a collaboration with CYTOWIZ to manufacture Liquid-Based Cytology reagents in Penang. These reagents will be distributed worldwide, with the exception of China, due to the country's strict regulatory requirements. Further discussions are in progress for an exclusive distributorship across Southeast Asia.

Looking ahead, we remain committed to expanding our distribution network by continuously engaging with new principals and suppliers. This strategy not only strengthens our product portfolio but also positions us as a key provider of innovative healthcare solutions across Malaysia and the wider region.

MANAGEMENT DISCUSSION AND ANALYSIS (CONT'D)

CHALLENGES & RISKS

Economic and Market Environment

The healthcare industry is growing due to factors such as rising patient admissions driven by chronic diseases, an aging population, and better access to healthcare products and services due to higher income levels and medical insurance uptake. Increased public and private healthcare spending also contributes to this growth. However, any reduction in healthcare expenditure may impact hospital supplies and equipment demand, potentially affecting our Group's financial performance.

To address these challenges, our Group is actively exploring opportunities to expand and commercialize products under our own brand. This strategy ensures that our product offerings stay aligned with market needs, while complementing existing products. Our new products are designed to be cross-marketed to our current customers, enhancing value and strengthening our market presence.

Advances in artificial intelligence (AI), miniaturization, and digital health devices are rapidly transforming medical technology, creating both opportunities and competition. Geopolitical tensions, particularly in China, have led companies to seek new markets like Southeast Asia. As global players enter the region, our Group is focused on expanding our product pipeline and leveraging AI and digital health solutions to remain competitive in this dynamic landscape.

Foreign Currency Exchange Fluctuation

We are exposed to foreign currency exchange risks arising from any appreciation or depreciation of the denominated foreign currencies against our Group's reporting currency as approximately 34% of our Group's revenue are denominated in foreign currencies.

To manage the foreign exchange risks, our Group monitors closely the movement of the foreign exchange. Our Group has entered into forward foreign currency contracts as well as maintain foreign currency accounts whereby collections arising from foreign sales are used to settle purchases in the same foreign currency. This would provide, to a certain extent, a natural hedge against the foreign exchange fluctuations

Human Capital

We recognize that our employees are our most valuable asset, and the continued success of our Group depends significantly on their efforts, commitment, skills, and the values they create. As our business operations grow, attracting and retaining the right talent is critical to driving our Group to new levels of performance.

However, the competitive landscape in Batu Kawan, where numerous multinational corporations are situated, presents challenges in talent acquisition and retention. The presence of these global firms not only intensifies competition for top-tier professionals but also increases the risk of losing current employees who may be attracted to the diverse opportunities and potentially higher remuneration packages offered by larger corporations.

To address these challenges, we are committed to investing in our employees' professional development, enhancing our recruitment processes, and regularly reviewing our remuneration and benefits packages to remain competitive. We also prioritize upholding human and labour rights and providing a safe, supportive work environment that fosters employee well-being and productivity.

Additionally, our Group places a strong emphasis on succession planning and facilitating skills transfer, ensuring operational continuity and the long-term success of the organization. We will continue to engage in ongoing workforce planning and discussions to ensure that we remain well-positioned to attract, retain, and nurture talent despite the competitive pressures in our region.

MANAGEMENT DISCUSSION AND ANALYSIS (CONT'D)

DIVIDEND

Our Group presently does not have any formal dividend policy. However, it is the intention of our Board to retain adequate reserves for our future growth as well as to reward our shareholders with participation in the profits of our Group. As we are an investment holding company, our ability to pay dividends will depend on the dividends or other distributions that we receive from our subsidiaries. Any declarations and payment of dividends in the future will be at the discretion of our Board.

FORWARD-LOOKING STATEMENT

Given the Malaysian government's sustained commitment to advancing national healthcare standards, UMC remains optimistic about its growth outlook. Key drivers include the rising demand for facility upgrades, the expansion of healthcare tourism, and the urgent need to address overcrowding in healthcare facilities – all of which reinforce the Group's pivotal role in the evolving healthcare landscape.

Under Budget 2025, the government allocated RM45.3 billion to the Ministry of Health, a 10% increase from the previous year's RM41.2 billion, making it the second-largest budget allocation. Of this, RM1.35 billion has been earmarked for upgrading and repairing healthcare facilities. This strong policy support underscores the government's emphasis on delivering quality healthcare and creates a favourable environment for both public and private sector growth.

Malaysia's medical device industry is also on a promising trajectory, driven by a favourable manufacturing base and a globally recognized healthcare system. In line with this, the Health Ministry has launched Phase 1 of its ambulance replacement programme, involving 590 ambulances and 41 patient transport vehicles at a cost of RM265.5 million. Phase 2 has also been approved, with an additional allocation of RM304 million. These developments further reinforce UMC's growth outlook in the coming financial periods.

Looking ahead, UMC has outlined a three-phase roadmap to drive sustainable growth and long-term value creation. In Phase 1, the Group will focus on strengthening its foundation by enhancing medical product manufacturing and exports to ensure stability and resilience. Phase 2 will see UMC expand into healthcare services, introducing elderly rehabilitation programmes as well as intelligent non-emergency ambulance services equipped with integrated dispatch platforms, real-time tracking, and digital health records. Moving into Phase 3, UMC aims to establish a comprehensive smart healthcare ecosystem that seamlessly integrates manufacturing, services, and digital platforms. Key initiatives under this phase include home-based remote health management solutions, IoT-connected devices, AI-driven early warning systems, and long-term care services. In addition, the Group plans to pursue cross-border collaborations and exportable service models, positioning itself as a regional hub for smart healthcare.

Through this phased strategy, UMC is positioning itself at the forefront of healthcare advancements. Guided by a strong focus on international expansion, innovation, and elevating standards of care, the Group is committed to creating meaningful impact. Our future success will continue to be built on the strength of our people, our values, and our dedication to improving lives through healthcare innovation.

BOARD OF DIRECTORS



from left to right

Tan Chye Suan

Independent Non-Executive Director

Dr. Pakirisamy Baskaran A/L P Thangavelu

Independent Non-Executive Director

Dato' Seri Ng Chai Eng

Non-Independent Non-Executive Chairman

Lim Taw Seong

Executive Director/Chief Executive Officer

Lee Yee Wooi

Independent Non-Executive Director

Dato' Dr. Teh Keng Hwang

Independent Non-Executive Director

Ng Sze Hui

Alternate Director to Dato' Seri Ng Chai Eng

PROFILE OF DIRECTORS



Dato' Seri Ng Chai Eng

Non-Independent Non-Executive Chairman



62



Male



Malaysian

Qualification

- Malaysian Skills Certificate Level 1 (formerly known as Sijil Kecekapan Ketukangan Peringkat Asas)
- Malaysian Skills Certificate Level 2 (formerly known as Sijil Kecekapan Ketukangan Peringkat Pertengahan)
- Certificate in Administrative Management - Centre for Business Studies (London)
- Certificate in Production and Quality Control Management - Centre for Business Studies (London)

Date first appointed to the Board

7 October 2021

Membership of Board Committee

None

Working Experience and Occupation

- 1982-1983: Apprentice electrician - Mattel (Malaysia) Sdn Bhd
- 1985-1990: Senior Technician - GUH Electrical Appliances Sdn Bhd (formerly known as Leader Electrical Appliances Manufacturing Sdn Bhd)
- 1990: Plant Manager - GUH Electrical Appliances Sdn Bhd (formerly known as Leader Electrical Appliances Manufacturing Sdn Bhd)
- 1990-Present: Co-founder - UWC Holding Sdn Bhd (now a subsidiary company of UWC Berhad)
- 2018 - Present: Group CEO of UWC Berhad

Present Appointment

- Advisor for the Federation of Malaysian Foundry and Engineering Industries Associations (FOMFEIA)
- Industry Relations Chairman of Penang Premium Business Enterprise Association (PPBEA)
- Chairman of Sekolah Jenis Kebangsaan (C) Beng Teik Pusat
- Executive Director/Group Chief Executive Officer of UWC Berhad
- Director of all subsidiaries of UWC Berhad
- Director of several private limited companies

Any family relationship with any director and/or major shareholder of UMC

- Father of Ng Sze Hui, his Alternate Director
- Uncle of Lim Taw Seong, our Executive Director/Chief Executive Officer

Any conflict of interests that the person has with UMC

None

Other than traffic offences, the list of convictions for offences within the past five (5) years and particulars of any public sanction or penalty imposed by the relevant regulatory bodies during financial year

None

Number of board meetings attended in the financial year

5/5

PROFILE OF DIRECTORS (CONT'D)



Lim Taw Seong

Executive Director/Chief Executive Officer



47



Male



Malaysian

Qualification

- Bachelor of Engineering (Mechanical) - Universiti Teknologi Malaysia

Date first appointed to the Board

22 April 2021

Membership of Board Committee

None

Working Experience and Occupation

- 2002-2004: Sales Executive – UMediC Healthcare (formerly known as UWC Healthcare Sdn Bhd)
- 2004-2006: Sales Manager - UMediC Healthcare (formerly known as UWC Healthcare Sdn Bhd)
- 2006-2021: Director - UMediC Healthcare (formerly known as UWC Healthcare Sdn Bhd)
- 2021-Present: Executive Director/Chief Executive Officer - UMC

Present Appointment

- Director of several private limited companies

Any family relationship with any director and/or major shareholder of UMC

- Nephew of Dato' Seri Ng Chai Eng, our Non-Independent Non-Executive Chairman
- Cousin of Ng Sze Hui, the Alternate Director to Dato' Seri Ng Chai Eng

Any conflict of interests that the person has with UMC

None

Other than traffic offences, the list of convictions for offences within the past five (5) years and particulars of any public sanction or penalty imposed by the relevant regulatory bodies during financial year

None

Number of board meetings attended in the financial year

5/5

PROFILE OF DIRECTORS (CONT'D)



Dr. Pakirisamy Baskaran A/L P Thangavelu

Independent Non-Executive Director



63



Male



Malaysian

Qualification

- Bachelor of Medicine and Surgery - University of Madras, India
- Masters of Obstetrics and Gynaecology - University of Malaya

Date first appointed to the Board

7 October 2021

Membership of Board Committee

- Audit and Risk Management Committee (Member)
- Remuneration Committee (Member)
- Nomination Committee (Chairman)

Working Experience and Occupation

- 1990-1991: House Officer - Hospital Sultanah Aminah, Johor Bahru
- 1991-1993: Medical Officer in the Paediatric Surgical Unit of the Department of Surgery - Queen Elizabeth Hospital, Kota Kinabalu
- 1998-2003: Junior Specialist - Maternity Hospital, Kuala Lumpur
- 2004-2010: Consultant - Maternity Hospital, Kuala Lumpur
- 2010-2016: Senior Consultant Obstetrician and Gynaecologist and a Maternal Fetal Medicine Specialist - Maternity Hospital, Kuala Lumpur
- Present: Resident consultant in Gleneagles Hospital Kuala Lumpur and a visiting consultant in Subang Jaya Medical Centre, Damai Service Hospital (HQ) as well as in several other hospitals in the Klang Valley

Present Appointment

- Director of several private limited companies

Any family relationship with any director and/or major shareholder of UMC

None

Any conflict of interests that the person has with UMC

None

Other than traffic offences, the list of convictions for offences within the past five (5) years and particulars of any public sanction or penalty imposed by the relevant regulatory bodies during financial year

None

Number of board meetings attended in the financial year

5/5

PROFILE OF DIRECTORS (CONT'D)



Tan Chye Suan

Independent Non-Executive Director



57



Female



Malaysian

Qualification

- Bachelor of Laws – LL.B (Hons) - University of Malaya
- Advocate and Solicitor of the High Court of Malaya

Date first appointed to the Board

7 October 2021

Membership of Board Committee

- Audit and Risk Management Committee (Member)
- Remuneration Committee (Chairman)
- Nomination Committee (Member)

Working Experience and Occupation

- 1993-1995: Advocate and Solicitor - Messrs Ban Eng, Anual & Foong
- 1995-1999: Partner - Messrs Lim Huck Aik & Co
- 1999: Co-founder - Messrs See, Ramsun & Tan
- Present: Managing Partner - Messrs See, Ramsun & Tan

Present Appointment

- Member of the Disciplinary Committee of the Advocates' & Solicitors' Disciplinary Board
- Honorary Treasurer in Women Centre for Change
- Honorary Secretary in Pertubuhan Gabungan Pertubuhan-pertubuhan Wanita Pulau Pinang
- Committee Member of Alumni Convent Light Street, Penang
- Deputy President of Federation of Women's Lawyers of North Malaya Penang
- Independent Non-Executive Director - Emits Berhad

Any family relationship with any director and/or major shareholder of UMC

None

Any conflict of interests that the person has with UMC

None

Other than traffic offences, the list of convictions for offences within the past five (5) years and particulars of any public sanction or penalty imposed by the relevant regulatory bodies during financial year

None

Number of board meetings attended in the financial year

5/5

PROFILE OF DIRECTORS (CONT'D)



Lee Yee Wooi

Independent Non-Executive Director



53



Male



Malaysian

Qualification

- Bachelor of Accounting (Hons) - University of Malaya
- Registered member of the Malaysia Institute of Accountants

Date first appointed to the Board

7 October 2021

Membership of Board Committee

- Audit and Risk Management Committee (Chairman)
- Remuneration Committee (Member)
- Nomination Committee (Member)

Working Experience and Occupation

- 1997-1999: Tax Assistant - Ernst & Young
- 1999-2002: Tax Consultant - Ernst & Young
- 2002: Finance Analyst - Smart Modular Technologies Sdn Bhd
- 2002: Accounts/Finance Manager - Scope Manufacturers (M) Sdn Bhd
- 2004-2009: Financial Controller - Scope Industries Berhad
- 2009-2013: Financial Director - Transform Electrical Industry Sdn Bhd
- 2016-2019: Director – Prestij Gemilang Sdn Bhd
- 2013-2022: Director – Income Sector Sdn Bhd
- 2019-2023: Accountant – Biochem Laboratories Sdn Bhd
- 2022-2024: Non-Independent Non-Executive Director - HHRG Berhad
- 2019-Present: Director – Amanpuri Leisure Sdn Bhd
- 2020-Present: Director – Tarzan Travel (M) Sdn Bhd

Present Appointment

- Independent and Non-Executive Director of Mclean Technologies Berhad
- Director of several private limited companies

Any family relationship with any director and/or major shareholder of UMC

None

Any conflict of interests that the person has with UMC

None

Other than traffic offences, the list of convictions for offences within the past five (5) years and particulars of any public sanction or penalty imposed by the relevant regulatory bodies during financial year

None

Number of board meetings attended in the financial year

5/5

PROFILE OF DIRECTORS (CONT'D)



Dato' Dr. Teh Keng Hwang

Independent Non-Executive Director



72



Female



Malaysian

Qualification

- Clinical Fellowship Paediatric Critical Care Medicine – University of Toronto, Canada
- Membership of the Royal Colleges of Physicians of the United Kingdom - University of Glasgow, United Kingdom
- Bachelor of Medicine and Bachelor of Surgery – University of Malaya

Date first appointed to the Board

5 October 2023

Membership of Board Committee

None

Working Experience and Occupation

- 1978-1979: House officer – General Hospital Penang
- 1979-1984: Medical Officer - General Hospital Alor Setar, Sungai Petani and Penang in Paediatrics
- 1984-1985: Attachment – Royal Hospital for Sick Children Yorkhill Glasgow
- 1985-1988: Consultant Paediatrician - Hospital Kuala Terengganu
- 1988-1997: Consultant Paediatrician - Hospital Alor Setar, Kedah
- 1997-1998: Fellowship Training - Paediatric Intensive Care at the Critical Care Unit of the Hospital for Sick Children (SickKids) Toronto Canada
- 1998-2012: Consultant Paediatrician and Paediatric Intensivist - Hospital Alor Setar, Kedah

Working Experience and Occupation (Cont'd)

- 2012-2016: Consultant Paediatrician and Paediatric Intensivist - Hospital Sultan Abdul Halim, Sungai Petani, Kedah
- 2017-present: Lecturer (Professor of Paediatrics) - University Islam Antarabangsa Sultan Abdul Halim Muadzam Shah, Kuala Ketil, Kedah

Present Appointment

- Lecturer (Professor) of University Islam Antarabangsa Sultan Abdul Halim Muadzam Shah (UniSHAMS)

Any family relationship with any director and/or major shareholder of UMC

None

Any conflict of interests that the person has with UMC

None

Other than traffic offences, the list of convictions for offences within the past five (5) years and particulars of any public sanction or penalty imposed by the relevant regulatory bodies during financial year

None

Number of board meetings attended in the financial year

5/5

PROFILE OF DIRECTORS (CONT'D)



Ng Sze Hui

Alternate Director to Dato' Seri Ng Chai Eng



29



Female



Malaysian

Qualification

- Bachelor of Laws - London School of Economics and Political Science
- Master of Laws and Bar Professional Training Course - City, University of London
- Admitted to the Bar of England and Wales by the Honourable Society of the Middle Temple
- Advocate and Solicitor of the High Court of Malaya
- Registered trademark agent
- Registered industrial design agent
- Medtech Professional Certificate In Manufacturing Excellence - AMMI

Date first appointed to the Board

6 March 2023

Membership of Board Committee

None

Working Experience and Occupation

- 2020: Wong & Partners (a member firm of Baker McKenzie International)
- 2020-2021: Azmi & Associates (a member firm of TerraLex Worldwide)
- 2021- 2022: Legal and Corporate Adviser – UMC
- 2023 – present: Partner - Messrs Ng Law Firm
- 2023- present: Legal & Product Development Manager (Jan – Mar) and Legal Compliance Adviser (Mar-present) – UMC

Present Appointment

- Member of the Inns of Court Malaysia (ICM)
- Member of the Federation of Malaysian Manufacturers (FMM) Youth Committee
- Director of a private limited company
- Partner of a legal firm

Any family relationship with any director and/or major shareholder of UMC

- Daughter of Dato' Seri Ng Chai Eng, our Non-Independent Non-Executive Chairman
- Cousin of Lim Taw Seong, our Executive Director/Chief Executive Officer

Any conflict of interests that the person has with UMC

None

Other than traffic offences, the list of convictions for offences within the past five (5) years and particulars of any public sanction or penalty imposed by the relevant regulatory bodies during financial year

None

Number of board meetings attended in the financial year

5/5

PROFILE OF DIRECTORS (CONT'D)

Training Programs attended by our Director

The following are the seminars, conferences, exhibitions, workshops attended by all our Directors as at FYE 2025.

Name of Directors	Mode of Training	Title
Dato' Seri Ng Chai Eng	Webinar	<ul style="list-style-type: none"> Driving Export Competitiveness: A Sustainability Perspective from Malaysia and Singapore
	Webinar	<ul style="list-style-type: none"> HSBC Global Privat Banking 2025 Mid-Year Investment Outlook
Lim Taw Seong	Webinar	<ul style="list-style-type: none"> UOB Market Outlook: Implications of Trump 2.0
	Webinar	<ul style="list-style-type: none"> Transfer Pricing 2024 - Evolution or Revolution
	External	<ul style="list-style-type: none"> Impact of 'Liberation Day' tariffs on Asia
	Webinar	<ul style="list-style-type: none"> Impact of 'Liberation Day' tariffs on Malaysia
	Webinar	<ul style="list-style-type: none"> Q-CPR and Data Management Webinar
	Internal briefing	<ul style="list-style-type: none"> AED & CPR Training
	Internal briefing	<ul style="list-style-type: none"> Anti Bribery and Corruption Policy Refreshment Training
Dr. Pakirisamy Baskaran A/L P Thangavelu	Internal briefing	<ul style="list-style-type: none"> Safety, Health, and Environment policy
	External	<ul style="list-style-type: none"> IntelliVue Patient Monitor Introduction, Value-Mid Segment Patient Monitor Introduction, Introduction to Clinical Care areas and patient measurement
Tan Chye Suan	External	<ul style="list-style-type: none"> Board Ethics: Growing Concerns from New Technology, Stakeholder Interests & Conflict of Interest
	External	<ul style="list-style-type: none"> Ancillary Relief: How Do We Do it by Bar Council
	External	<ul style="list-style-type: none"> A Neuro Leadership Conference: The Brain & Leadership by ITD World
	External	<ul style="list-style-type: none"> Program Registrar Of Societies Care Outreach
	External	<ul style="list-style-type: none"> Program Sistem Taksiran Sendiri Cukai Keuntungan Harta Tanah (STS CKHT) Melalui Portal MyTax by Penang Bar Committee & LHDN
	External	<ul style="list-style-type: none"> Taklimat bagi Panduan Praktikal E-Invois untuk Firma-firma Guaman bersama-sama Topik-topik Berkenaan by Penang Bar Committee & LHDN
Lee Yee Woon	Webinar	<ul style="list-style-type: none"> An Introduction To & An Overview of the PDPA 2010 By Malaysian Bar Council
	External	<ul style="list-style-type: none"> IME Innovation Day 2025
	External	<ul style="list-style-type: none"> Empowering Growth : Strategies 2 Future-Proof Your Business
	External	<ul style="list-style-type: none"> Affin Market Outlook : Propelling Malaysia Forward
	External	<ul style="list-style-type: none"> Utilising HRDF Levy to Improve Employees Productivity
	External	<ul style="list-style-type: none"> Unlock Smart Manufacturing Potential
	External	<ul style="list-style-type: none"> Cobot Innovation Roadshow
	Webinar	<ul style="list-style-type: none"> 2025 1H Market Outlook - Public Bank
	Webinar	<ul style="list-style-type: none"> Travel and Tour Enhancement Course TTEC
	External	<ul style="list-style-type: none"> Malaysia Smart Manufacturing Awards 2025
	Webinar	<ul style="list-style-type: none"> CTOS x MDI Webinar: Mufli-Jalan Keluar Dari Jerat Hutang
	External	<ul style="list-style-type: none"> CTOS SME Biz Day Penang 2025
	External	<ul style="list-style-type: none"> Public Bank Investment Talk Penang 2025
	External	<ul style="list-style-type: none"> The 36th Malaysia International Machinery Fair (MIMF 2025)
	External	<ul style="list-style-type: none"> Electronics Manufacturing Expo Asia (EMAX) 2025

PROFILE OF DIRECTORS (CONT'D)

Training Programs attended by our Director (Cont'd)

Name of Directors	Mode of Training	Title
Dato' Dr. Teh Keng Hwang	Webinar	<ul style="list-style-type: none"> Mandatory Accreditation Programme Part II: Leading for Impact (LIP)
	External External	<ul style="list-style-type: none"> Malaysian Pediatric Congress Generic Instructor Course
Ng Sze Hui	Webinar	<ul style="list-style-type: none"> Medtech Professional Certificate in Manufacturing Excellence: Process Validation
	Webinar	<ul style="list-style-type: none"> Medtech Professional Certificate in Manufacturing Excellence: Lean Manufacturing
	Webinar	<ul style="list-style-type: none"> Microsoft Excel - Beginner to Intermediate Level
	Webinar	<ul style="list-style-type: none"> Building Professional Etiquette and Personal Grooming
	Internal briefing	<ul style="list-style-type: none"> World Health Day
	Webinar	<ul style="list-style-type: none"> Pharmaceutical Water System (Process Control Vs. Quality Control)
	External	<ul style="list-style-type: none"> GS1 Malaysia Programme Hirarc for Small Businesses: Strengthening Compliance with DOSH Regulations
	Internal briefing Webinar	<ul style="list-style-type: none"> CPR and AED Talk & Training Solutions for Sterility Assurance in Aseptic Manufacturing

Remuneration

The following are the remuneration breakdown of all directors as at FYE 2025.

Name of Directors	Salaries (RM'000)	Fees (RM'000)	Bonus (RM'000)	Employee Provident Fund and Social Security Organisation (RM'000)	Allowances (RM'000)	Share Grant Scheme Expense (RM'000)	Total (RM'000)
Dato' Seri Ng Chai Eng	-	60	-	-	1	-	61.0
Lim Taw Seong	300	-	50	37.2	96	-	483.2
Dr. Pakirisamy Baskaran A/L P Thangavelu	-	30	-	-	0.5	-	30.5
Tan Chye Suan	-	30	-	-	0.5	-	30.5
Lee Yee Wooi	-	30	-	-	0.5	-	30.5
Dato' Dr. Teh Keng Hwang	-	30	-	-	0.5	-	30.5
Ng Sze Hui	131	-	22	17	30	-	200.0

PROFILE OF KEY SENIOR MANAGEMENT

Ng Hui Hooi

Financial Controller

Age	Gender	Nationality
49	Female	Malaysian

Qualification

- Bachelor of Commerce, majoring in Accountancy - Deakin University in Australia
- Certified Practising Accountant (CPA) from CPA Australia
- Member of the Malaysian Institute of Accountants

Date first appointed to the Key Senior Management

1 April 2021

Working experience and Occupation

- 2000-2004: Auditor - Wong Liu & Partners
- 2004: Accountant - Sin Tiong Lee Food Industry Sdn Bhd
- 2004-2007: Accounts Manager - Wangsaga Industries Sdn Bhd (a subsidiary of Tek Seng Holdings Berhad)
- 2007-2008: Assistant Finance Manager - Texchem Resources Berhad
- 2008-2018: Finance Manager - UWC Holdings Sdn Bhd (now a subsidiary company of UWC Berhad)
- 2018-2021: Financial Controller - UWC Berhad
- 2021-Present: Financial Controller - UMC

Present Appointment

None

Any family relationship with any director and/or major shareholder of UMC

None

Any conflict of interests that the person has with UMC

None

Other than traffic offences, the list of convictions for offences within the past five (5) years and particulars of any public sanction or penalty imposed by the relevant regulatory bodies during the financial year

None

Kong Yoen Hoo

Sales Vice President

Age	Gender	Nationality
47	Male	Malaysian

Date first appointed to the Key Senior Management

1 May 2021

Working experience and Occupation

- 2003-2006: Engineer - Zama Corporation Ltd
- 2006-2007: Project Engineer - DPL Holdings Ltd
- 2007-2021: Branch Manager - Evo Medik
- 2021-Present: Sales Vice President - UMC

Present Appointment

None

Any family relationship with any director and/or major shareholder of UMC

None

Any conflict of interests that the person has with UMC

None

Other than traffic offences, the list of convictions for offences within the past five (5) years and particulars of any public sanction or penalty imposed by the relevant regulatory bodies during the financial year

None

PROFILE OF KEY SENIOR MANAGEMENT (CONT'D)

Lim Suat Gim

Sales Vice President

Age

41

Gender

Female

Nationality

Malaysian

Qualification

- Bachelor of Science degree with Honours in Biochemistry - Universiti of Malaya

Date first appointed to the Key Senior Management

1 May 2021

Working experience and Occupation

- 2007: Quality Assurance Executive - Public Packages (NT) Sdn Bhd
- 2007-2010: Sales Executive – UMediC Healthcare
- 2010-2021: Branch Manager – Actimed
- 2021-Present: Sales Vice President - UMC

Present Appointment

None

Any family relationship with any director and/or major shareholder of UMC


None

Any conflict of interests that the person has with UMC

None

Other than traffic offences, the list of convictions for offences within the past five (5) years and particulars of any public sanction or penalty imposed by the relevant regulatory bodies during the financial year

None



CORPORATE GOVERNANCE OVERVIEW STATEMENT

Our Board is committed to implement and maintain high standards of corporate governance practices that are premised on the notions of transparency, accountability and integrity with a view to enhance stakeholders' value. As such, our Board strives to adopt the substance behind corporate governance prescriptions and not merely the form.

The disclosures in this Corporate Governance ("CG") Overview Statement are made pursuant to Rule 15.25 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad ("Bursa Securities") ("MMLR") and the Corporate Governance Guide (4th Edition) issued by Bursa Securities.

The objective of this CG Overview Statement is to provide an overview of the application of the corporate governance practices of our Group during the FYE 2025. In accordance with the Malaysian Code on Corporate Governance ("MCCG") the main principles governing these governance practices are as outlined below:

Principle A	Principle B	Principle C
Board Leadership and Effectiveness	Effective Audit and Risk Management	Integrity in Corporate Reporting and Meaningful Relationship with Stakeholders

We have also provided specific disclosures on the application of each Practice in its CG Report which is made available on our Company's website at www.umedic.com.my.

In order to achieve a granular understanding of our Group's governance framework and practices, this CG Overview Statement should also be read in tandem with other statements in this Annual Report, namely the Statement on Risk Management and Internal Control, Audit and Risk Management Committee Report, Sustainability Statement and Management Discussion and Analysis as the depth or relevance of applying certain corporate governance promulgations may be better explained in the context of the respective statements.

PRINCIPLE A: BOARD LEADERSHIP AND EFFECTIVENESS

1. Board Responsibilities

Our Board is entrusted to oversee the overall management of the business affairs of our Group; determine all major policies; ensure effective strategies and management are in place; assess the performance of our Group and our management team; and review the systems of risk management and internal control of our Group. When implementing the business plan, our Executive Director/ Chief Executive Officer is responsible for executing corporate decisions made by our Board while the Non-Executive Directors scrutinize the management performance by providing independent views and advice in the interests of the shareholders at large.

To ensure that the obligations to our shareholders and other stakeholders are understood, our Board has defined and collectively reviewed and approved the roles and responsibilities as well as the schedule of reserved matters in the Board Charter. In order to assist the Board in the oversight function on specific responsibility areas, our Board has established three (3) Board Committees, namely Audit and Risk Management Committee ("ARMC"), Nomination Committee ("NC") and Remuneration Committee ("RC"). Governed by their respective Terms of References, the Board Committees report to our Board on their meeting proceedings and deliberations as well as make recommendations to our Board on the matters under their purview. Our Board ensures our Directors have unrestricted access to the advice and services of Senior Management and Company Secretary and may obtain independent professional advice at our Company's expense in order to discharge their duties effectively.


Our Group has formed a Sustainability Committee and Sustainability Working Group to assist our Board in overseeing the formulation, implementation and effective management of our Company's sustainability strategies.

CORPORATE GOVERNANCE OVERVIEW STATEMENT (CONT'D)

PRINCIPLE A: BOARD LEADERSHIP AND EFFECTIVENESS (CONT'D)

1. Board Responsibilities (Cont'd)

Governance Framework



Performance evaluations of our Board and Senior Management in addressing our Company's material sustainability risks and opportunities has been conducted for the financial year under review.

Our Board Chairman instils good governance practices, leadership and effectiveness in our Board through chairing of board and shareholders meetings and deliberating together with our Board members on board matters and policies. The position of Board Chairman and Chief Executive Officer are held by different individuals. Our Board is assisted by a qualified and competent Chartered Secretary who is an associate member of Malaysian Institute of Chartered Secretaries and Administrators ("MAICSA"). The Company Secretary assists our Board in discharging its duties in regard to compliance with regulatory requirements, guidelines, legislations and the principles of best corporate governance practices.

During the year, our Board has reviewed and approved the following:

- Report by Audit and Risk Management Committee Chairman, Nomination Committee Chairman and Remuneration Committee Chairman;
- Approval of quarterly results;
- Approval of contents of annual report;
- Review and approval of the Board Charter, Code of Conduct, Anti Bribery and Anti Corruption Policy and Whistleblowing Policy;
- Business updates by the Executive Director/Chief Executive Officer;
- Re-appointment of external auditors; and
- Variation of utilization of proceeds raised from the initial public offerings ("IPO").

Our Board has established the Anti-Bribery and Anti-Corruption Policy in keeping with the commitment set forth to prevent and detect bribery and corruption. Our Group takes a zero-tolerance approach to bribery and corruption and is committed to acting professionally, fairly and integrity in all business dealings and relationships wherever our Group operates and expects the individuals and organization our Group works with to uphold and adopt the same approach. In FYE 2025, all board members and employees have made annual attestation to re-affirm the understanding and commitment on Anti-Bribery Programme.

As an additional measure to safeguard the integrity of our Group, our Board has defined its Whistleblowing Policy to provide guidance for stakeholders to report genuine concerns of any possible improprieties pertaining to financial reporting, compliance, malpractices and unethical business conduct within our Group. In addition, our Board has also defined its Code of Conduct which serves as a tool for our Board to convey and instil its values into the organization.

Our Board Charter, Terms of Reference of the Board Committees, Directors' Fit and Proper Policy, Anti Bribery and Anti Corruption Policy, Whistleblowing Policy and Code of Conduct and Ethics are also posted on our Company's website at www.umedic.com.my.

CORPORATE GOVERNANCE OVERVIEW STATEMENT (CONT'D)

PRINCIPLE A: BOARD LEADERSHIP AND EFFECTIVENESS (CONT'D)

2. Board Composition

The appointment of Board is based on objective criteria, merit and with due regards for diversity in skills, experience, age, cultural background and gender. When considering appointment of directors, the Nomination Committee will consider the following attributes in the recruitment and screening process:

- Skills, knowledge, expertise and experience;
- Professionalism;
- Integrity;
- Boardroom diversity (including gender diversity); and
- In the case of candidates for the position of Independent Non-Executive Directors, the committee should also evaluate the candidates' ability to discharge such responsibilities/ functions as expected from Independent Non-Executive Directors.

Presently, our Board is led by Non-Independent Non-Executive Chairman. Our Board consists of six (6) members, i.e. one (1) Non-Independent Non-Executive Director, one (1) Executive Director/ Chief Executive Officer, four (4) Independent Non-Executive Directors. Our current Board composition complies with Rule 15.02 of MMLR that requires at least one-third (1/3) of the Board consists of Independent Directors. The profile of each Director is presented in page 25 to 31 of this Annual Report.

Our Board recognises the importance of gender diversity of at least 30% women directors in our Company. Currently, there are two (2) female Directors (equivalent to 33.3% of the board composition) sitting on our Board.

The above is in line with MMLR which stipulate the inclusion of at least one female Director on the Board, as well as MCCG Practice 5.9, which recommended that at least 30% of the Board is comprised of women director. This reflects the Company's strong commitment to promoting gender diversity and fostering inclusive leadership at the highest level.

Our Board is mindful that any gender representation should be in the best interest of the Company. Our Board is committed to workplace diversity and has established a Diversity Policy which aims to set out approach to achieve diversity on our Company's Board and workforce.

As stated in the Terms of Reference of the Nomination Committee, one of the duties of Nomination Committee is to properly document all assessments and evaluations and report to our Board all the results of the assessments and evaluations on an annual basis. During FYE 2025, the Nomination Committee had reviewed the size, composition and principal functions of each Board Committee. Additionally, the results of self-evaluation by all Directors had been reviewed and the results are satisfactory. The Nomination Committee thereby concluded that the performance of the current Board, coupled with the experiences, competencies of each Director enable the Board to discharge their duties and responsibilities effectively. The outcome of the assessment had been presented to our Board subsequently.

Our Board understands that quality of information affects the effectiveness of our Board to oversee the conduct of business and to evaluate the Management's performance of our Group. Information and materials that are important to our Board's understanding of the business to be conducted at a Board or committee meeting will be distributed to the Directors in order to provide ample time for review beforehand. As stated in the Board Charter, notice of Board meetings shall be issued at least five (5) business days prior to the meeting. Upon conclusion of meeting, the Company Secretary will ensure that accurate and proper records of the proceedings and resolutions passed are recorded and the minutes is circulated to the Board members before the next meetings.

During FYE 2025, there were five (5) board meetings held and all the Board Papers were circulated to our Board in timely manner. Our Directors' attendance at the Board & Committees meetings during FYE 2025 were as follows:

Director	Number of Meetings held			
	Board	ARMC	NC	RC
Dato' Seri Ng Chai Eng	5/5	-	-	-
Mr. Lim Taw Seong	5/5	-	-	-
Dr. Pakirisamy Baskaran A/L P Thangavelu	5/5	5/5	1/1	1/1
Ms. Tan Chye Suan	5/5	5/5	1/1	1/1
Mr. Lee Yee Wooi	5/5	5/5	1/1	1/1
Dato' Dr Teh Keng Hwang	5/5	-	-	-
Ms. Ng Sze Hui	5/5	-	-	-

CORPORATE GOVERNANCE OVERVIEW STATEMENT (CONT'D)

PRINCIPLE A: BOARD LEADERSHIP AND EFFECTIVENESS (CONT'D)

2. Board Composition (Cont'd)

All Directors have successfully met the minimum 50% attendance requirement in respect of Board meetings as stipulated by MMLR. The Board expressed its satisfaction with the dedication and time commitment demonstrated by its Directors in FYE 2025 towards fulfilling their roles and responsibilities effectively.

Directors were encouraged and afforded the opportunity to upskill and keep themselves abreast with the market and regulatory changes throughout the financial year. During the FYE 2025, our Directors attended continuous professional development programme covering various topics ranging from financial, changes in statutory and regulatory requirements, governance, sustainability and industry knowledge. During FYE 2025, our Directors attended the following training programmes:

Director	Training Attended
Dato' Seri Ng Chai Eng	<ul style="list-style-type: none"> Driving Export Competitiveness: A Sustainability Perspective from Malaysia and Singapore; HSBC Global Private Banking 2025 Mid-Year Investment Outlook.
Mr. Lim Taw Seong	<ul style="list-style-type: none"> UOB Market Outlook: Implications of Trump 2.0; Transfer Pricing 2024 - Evolution or Revolution; Impact of 'Liberation Day' tariffs on Asia; Impact of 'Liberation Day' tariffs on Malaysia; Q-CPR and Data Management Webinar; AED & CPR Training; Anti Bribery and Corruption Policy Refreshment Training; Safety, Health, and Environment policy; IntelliVue Patient Monitor Introduction, Value-Mid Segment Patient Monitor Introduction, Introduction to Clinical Care areas and patient measurement.
Dr. Pakirisamy Baskaran A/L P Thangavelu	<ul style="list-style-type: none"> Board Ethics: Growing Concerns From New Technology, Stakeholder Interests & Conflict of Interest.
Ms. Tan Chye Suan	<ul style="list-style-type: none"> Ancillary Relief: How Do We Do it by Bar Council; A Neuro Leadership Conference: The Brain & Leadership by ITD World; Program Registrar Of Societies Care Outreach; Program Sistem Taksiran Sendiri Cukai Keuntungan Harta Tanah (STS CKHT) Melalui Portal MyTax by Penang Bar Committee & LHDN; Taklimat bagi Panduan Praktikal E-Invois untuk Firma-firma Guaman bersama-sama Topik-topik Berkenaan by Penang Bar Committee & LHDN; An Introduction To & An Overview of the PDPA 2010 By Malaysian Bar Council.
Mr. Lee Yee Wooi	<ul style="list-style-type: none"> IME Innovation Day 2025; Empowering Growth : Strategies 2 Future-Proof Your Business; Affin Market Outlook : Propelling Malaysia Forward; Utilising HRDF Levy to Improve Employees Productivity; Unlock Smart Manufacturing Potential; Cobot Innovation Roadshow; 2025 1H Market Outlook - Public Bank; Travel and Tour Enhancement Course TTEC; Malaysia Smart Manufacturing Awards 2025; CTOS x MDI Webinar : Mufliis-Jalan Keluar Dari Jerat Hutang; CTOS SME Biz Day Penang 2025; Public Bank Investment Talk Penang 2025; The 36th Malaysia International Machinery Fair (MIMF 2025); Electronics Manufacturing Expo Asia (EMAX) 2025.

CORPORATE GOVERNANCE OVERVIEW STATEMENT (CONT'D)

PRINCIPLE A: BOARD LEADERSHIP AND EFFECTIVENESS (CONT'D)

2. Board Composition (Cont'd)

Director	Training Attended
Dato' Dr. Teh Keng Hwang	<ul style="list-style-type: none">• Mandatory Accreditation Programme Part II: Leading for Impact (LIP);• Malaysian Pediatric Congress;• Generic Instructor Course.
Ms. Ng Sze Hui	<ul style="list-style-type: none">• Medtech Professional Certificate in Manufacturing Excellence: Process Validation;• Medtech Professional Certificate in Manufacturing Excellence: Lean Manufacturing;• Microsoft Excel - Beginner to Intermediate Level;• Building Professional Etiquette and Personal Grooming;• World Health Day;• Pharmaceutical Water System (Process Control Vs. Quality Control);• GS1 Malaysia Programme Hirc for Small Businesses: Strengthening Compliance with DOSH Regulations;• CPR and AED Talk & Training;• Solutions for Sterility Assurance in Aseptic Manufacturing.

3. Remuneration

Our Board has put in place a Remuneration Policy to set out principles to be used in recommending the remuneration package of the Non-Executive Directors, Executive Director, Chief Executive Officer and Financial Controller, in order to attract, motivate and retain talent. As stated in the Remuneration Policy, the remuneration of the Independent Non-Executive Directors to be determined in accordance with their experience and the level of responsibilities assumed in the Board Committees, their attendance, performance and expertise they bring to our Board, whilst the remuneration of the Executive Directors and Senior Management will be based on the individual's and Group's performance. The Remuneration Policy is available on our Company's website at www.umedic.com.my.

Our Board has made a detailed disclosure on named basis for the remuneration of individual directors in Practice 8.1 of the CG Report. The Company has opted not to disclose the detailed remuneration of its key senior management team due to the confidentiality and sensitivity of such information. Public disclosure may expose the Company to the risk of talent poaching by competitors, which could disrupt leadership stability and strategic continuity. The Company remains committed to fair, competitive, and performance-linked remuneration practices aligned with its long-term objectives.

PRINCIPLE B: EFFECTIVE AUDIT AND RISK MANAGEMENT

1. ARMC

The members of ARMC comprise of fully Independent Non-Executive Directors. The Chairman of the ARMC is distinct from the Chairman of the Board so as to promote unfettered objectivity during our Board's review of the ARMC's findings and recommendations. The current ARMC composition meets the requirements of Rule 15.09 of MMLR where the ARMC Chairman, Mr. Lee Yee Wooi is a member of Malaysia Institute of Accountant since 2000. The present composition of the ARMC allows it to possess the requisite level of financial literacy and business acumen to have a sound understanding of the financial matters of our Group as well as an understanding of the latest developments in financial reporting, accounting and auditing standards.

None of the members of the ARMC are former audit partners of the current external audit firm of our Group. As stated in the Terms of Reference of the ARMC, the Committee is mindful of the minimum three (3) years cooling off period best practice under the MCG when considering the appointment of former key audit partner from its current external audit firm to ensure that the review of our Group's financial statements and the performance and independence of the External Auditors are being done objectively by the Committee.

Before the commencement of the current financial year audit, the ARMC has reviewed and deliberated with the External Auditors on their audit planning memorandum, covering the audit risk areas, approach, emphasis and timeline. The ARMC also noted the External Auditors' independence check and confirmation procedures carried out in the firm as well as no conflict of interest for rendering their non-audit services to our Group presently.

CORPORATE GOVERNANCE OVERVIEW STATEMENT (CONT'D)

PRINCIPLE B: EFFECTIVE AUDIT AND RISK MANAGEMENT (CONT'D)

1. ARMC (CONT'D)

Full details of the ARMC's duties and responsibilities are stated in its Terms of Reference which is made available on our Company's website at www.umedic.com.my and the detailed disclosure on the role and activities undertaken by the ARMC during the financial year is provided in the ARMC Report on page 80 to 81 of this Annual Report.

2. Risk Management and Internal Control Framework

In an ever-evolving and disruptive market landscape, it is imperative for our Group to be well-equipped to face any existing and emerging risks that could threaten business continuity. A Group-wide Enterprise Risk Management ("ERM") Framework has been established to support the timely identification, evaluation, action development, reporting and management of principal business risks. The ERM Framework includes formalized processes, policies and procedures surrounding the implementation, monitoring and review of our Group's internal control systems.

The Internal Audit Function is outsourced to YNC Business Consulting Sdn Bhd ("YNC"), an independent professional firm. There is no other engagement between our Group and YNC which may create conflict of interest or impair their objectivity and independence. The internal audit engagement shall be led by the Executive Director, Ms. Phoon Yee Min, who is a Certified Internal Auditor ("CIA"), member of Association of Chartered Certified Accountants ("ACCA") and member of Malaysia Institute of Accountants ("MIA"). She has accumulated over 20 years of experience in Audit and Advisory engagement. She provides overall direction for the internal audit engagement and is responsible for all stages of the internal audit work. She also maintains contact with our Management to ensure open communication is practiced and all internal audit works are carried out effectively and in a timely manner. She is further supported by other YNC professional staffs. All the personnel deployed by YNC do not have any family relationship or conflicts of interest with our Group that could impair their objectivity and independence during the course of their work. The Internal Auditors execute the internal audit work based on a risk-based internal audit plan which is approved by the ARMC before the commencement of work. The Internal Auditors conduct their work in consideration of the broad principles of the International Professional Practice Framework ("IPPF") of Institute of Internal Auditors covering the conduct of the audit planning, execution, documentations, communication of findings and consultation with key stakeholders. The Internal Auditors will report their observations and findings according to the approved Internal Audit Plan to the ARMC.

A detailed narrative of our Group's risk management and internal control framework, including the internal audit function is presented in the Statement on Risk Management and Internal Control on page 76 to 79 of this Annual Report.

PRINCIPLE C: INTEGRITY IN CORPORATE REPORTING AND MEANINGFUL RELATIONSHIP WITH STAKEHOLDERS

1. Engagement with Stakeholders

Our Board always ensures there is effective, transparent and timely communication with the stakeholders. Shareholders and other stakeholders are kept informed of the latest developments of our Group via announcements to Bursa Securities, annual reports, quarterly financial results, circulars to shareholders and press releases.

In addition, our Company maintains a corporate website at www.umedic.com.my to promote accessibility of information to our Group's diverse stakeholder groups. Our Board ensures that the website is regularly updated with recent announcements, past and current reports to shareholders as well as news and press releases pertaining to our Group. Any comments, queries and suggestions can be directed to a designated e-mail address, namely ir@umedic.com.my.

In addition, we also utilise social media network as a platform for disseminating messages of our Company.

Our Group also periodically organises investor relation activities such as conferences and briefing sessions targeted at market analysts and fund managers to allow for constructive and informative communication with shareholders and potential investors.

Detailed information regarding stakeholder engagement methods can be found in the Sustainability Statement, which is available in the Annual Report.

CORPORATE GOVERNANCE OVERVIEW STATEMENT (CONT'D)

PRINCIPLE C: INTEGRITY IN CORPORATE REPORTING AND MEANINGFUL RELATIONSHIP WITH STAKEHOLDERS (CONT'D)

2. Conduct of General Meetings

AGM serves as the primary platform for shareholders to engage our Board and Senior Management in a productive two-way dialogue. Shareholders are accorded with the opportunity to put forward questions and seek clarifications on the broad areas of our Group's performance, business activities and outlook during a question and answer session held during the AGM.

For our 4th AGM held on 15 January 2025, the notice of AGM was dated on 29 November 2024, which goes above and beyond the standard 28 days notification period. This proactive approach showcases our dedication to facilitating shareholders' involvement and preparedness. For the upcoming AGMs, we will continue to ensure the notice will be circulated to the shareholders at least 28 days prior to the meeting.

Our Board recognises its accountability to shareholders, underlining the imperative to foster active engagement and deliver meaningful responses to the shareholders' queries. In demonstration of this commitment, all the Directors, the Chairman of our Board and Board Committees as well as the Financial Controller, Company Secretary and External Auditors attended the 4th AGM. Throughout the AGM, Ms. Ng Sze Hui, the alternate director of Dato' Seri Ng Chai Eng presented our Company's business overview, financial highlights and the future outlook of our Company. Further, the shareholders were given with ample and sufficient opportunity to pose their queries and our Company ensured that all the questions were answered.

Shareholders who were unable to attend the AGM were advised that they can appoint proxies to attend and vote on their behalf by completing the proxy form enclosed in the Annual Report and depositing it at the office of the Share Registrar before the time for holding the meeting or any adjournment thereof. The guideline to appointing a proxy was outlined in the notice of AGM. All resolutions set out in the Notice of AGM were put to vote by poll. Our Company had appointed independent scrutineer to validate the vote cast in the AGM. The outcome of the AGM was announced to Bursa Securities on the same meeting day, which is 15 January 2025.

Our Company is mindful of the requirement to circulate the minutes of the general meeting no later than 30 business days after the general meeting. The minutes of 4th AGM duly confirmed and signed by the Chairman were uploaded on our Company's website at www.umedic.com.my, not later than 30 business days after the AGM.

Our Board will continually review our Group's governance practices to ensure our Group meets the expectations of regulators and stakeholders.

This CG Overview Statement was approved by the Board on 7 November 2025.

SUSTAINABILITY REPORT

INTRODUCTION

We are pleased to present our fourth Sustainability Statement (“Sustainability Statement” or the “Statement”) for the financial reporting period from 1 August 2024 to 31 July 2025 (“FYE 2025”), providing an overview of our Group’s sustainability initiatives and practices, highlighting our economic, environmental, social and governance impacts.

This Sustainability Statement has been prepared as required under the Main Market Listing Requirement (“MMLR”) and in accordance with the Sustainability Reporting Guide (“Guide”) 3rd Edition issued by Bursa Malaysia Securities Berhad (“Bursa Securities”).

Our Group has been guided by the principles outlined in the Guide for our sustainability practices. This guide helps us understand how to make sustainability a natural part of our organization. It also assists us in recognizing, assessing, and handling important Economic, Environmental, Social and Governance (“EESG”) risks and opportunities. Our sustainability practices aim to generate long term benefits to our stakeholders in terms of business continuity and value creation. Besides, we strongly support the UN 17 Sustainability Development Goals (“UN SDGs”) and such goals will be progressively integrated into our sustainability practices.

REPORTING PERIOD AND SCOPE OF REPORTING

This Statement covers the sustainability performance of our core business operations for the FYE 2025 unless stated otherwise. Where possible, information from previous years has been included to provide comparative data. Our core business operations comprise of marketing and distribution of various branded medical devices and consumables as well as the provision of after-sales service for all our products. We are also involved in developing, manufacturing and marketing of our medical consumables. As part of our long-term growth strategy, we have also expanded into healthcare services through the establishment of a healthcare centre and the introduction of ambulance services.

REPORTING FRAMEWORK

This Statement has been prepared in accordance with the Sustainability Reporting Guide (3rd edition) and Toolkits released by Bursa Securities. This Statement should be read alongside with other sections in this Annual Report namely Management Discussion and Analysis, Corporate Governance Overview Statement and Statement on Risk Management and Internal Control as sustainability efforts may be better contextualised and narrated in the respective sections.

STATEMENT OF ASSURANCE

There is no external assurance on seeking an independent evaluation of performance data published in this Statement. Regular audits/ reviews are in place in relation to the policies and procedures quoted in this Statement. This Statement is reviewed and approved by our Board.

AVAILABILITY

This Statement is made available on our Company’s website at www.umedic.com.my.

FEEDBACKS

To continuously improve on our sustainability efforts, we welcome and encourage our stakeholders to provide feedback pertaining to this Statement or our sustainability practices and initiatives. Please email us at ir@umedic.com.my.




SUSTAINABILITY REPORT (CONT'D)

COMMITMENT TO SUSTAINABILITY

Our corporate vision is to provide an integrated healthcare supply chain with advanced technology, which ultimately improve the quality of human life.





Our corporate mission is to be the trusted and preferred partner for all our stakeholders, which include our investors, suppliers, customers, employees and the communities.

At UMC, we uphold our core values which guide us in our work and businesses.

Core Values	Description
Unity 	<ul style="list-style-type: none"> We combine technology with talents across different segments of our businesses to create cost-effective solutions that drive growth; We respect, honour and value our stakeholders based on their professional contributions without discrimination; and We communicate openly and conduct our work transparently to ensure traceability.
Motivation 	<ul style="list-style-type: none"> We are determined to achieve our goals, regardless of all the obstacles and difficulties; We believe that nothing is impossible with a willing attitude and hard work; and We adapt to changes and innovate effectively alongside the market trends.
Commitment 	<ul style="list-style-type: none"> We practise integrity to deliver high-quality solutions on time; We take accountability and great pride in our work; and We are committed to excellence, intelligent planning and focused effort to enhance our productivity.

SUSTAINABILITY PRACTICES

In line with the Guide, our Group's sustainability is viewed in the context of EESG. The terms of EESG can be explained as follows:


Economic 	An organisation's impacts on the economic conditions of its stakeholders and on economic systems at local, national, and global levels. It does not focus on the financial condition of the organisation. Note: These may include the organisation's procurement practices, or community investment.
Environmental 	An organisation's impact on living and non-living natural systems, including land, air, water and ecosystems. Note: These may include the organisation's usage of energy and water.
Social 	The impacts an organisation has on the social systems within which it operates. Note: These may include the organisation's relationships with communities, employees, consumers, etc.
Governance 	An organisation's influence on the systems and structures that govern its operations, including the rules, regulations, and ethical standards it adheres to. Note: These may include the organisation's commitment to transparency, accountability, and ethical behaviour in its decision-making processes.

SUSTAINABILITY REPORT (CONT'D)

SUSTAINABILITY GOVERNANCE

Our Board is committed to sustainability practices in our organisation and has appointed Mr. Lim Taw Seong, Executive Director/ Chief Executive Officer, to lead the sustainability development efforts. Mr. Lim Taw Seong is responsible for identifying material sustainability matters and formulating the related sustainability initiatives. He provides strong stewardship towards the implementation of the sustainability initiatives within our Group and he is supported by a number of sub-committees to aid him to discharge this responsibility effectively. Together, Mr. Lim Taw Seong and the sub-committees form the Sustainability Committee which ensures that sustainability practices are embedded and integrated into our Group's business operations rather than as a standalone basis, to ensure continuity, relevance and sustainability of the practices.




The reporting governance structure and roles and responsibilities are as follows:

Governance	Roles and Responsibilities
Board of Directors 	<ul style="list-style-type: none"> Oversees the sustainability efforts and initiatives of our Group; Reviews and endorses our Group's material sustainability matters; Reviews and endorses the sustainability initiatives proposed by the Sustainability Committee; Reviews and endorses the annual sustainability report for inclusion in our annual report; and Sets strategies that support long-term value creation and includes strategies on EESG considerations underpinning sustainability.
Sustainability Committee (Chaired by Mr. Lim Taw Seong, Executive Director/ Chief Executive Officer; supported by representatives from relevant department/ function)	<ul style="list-style-type: none"> Identifies material sustainability matters that are relevant to our Group's business operations; Proposes sustainability initiatives and measures to be implemented across our Group; Implements sustainability initiatives that have been approved by our Board; and The Chairman reports the overall progress of our Group's sustainability efforts to our Board.

STAKEHOLDER ENGAGEMENT






A stakeholder is essentially an individual or a group that has an effect on, or is affected by our Group and our activities. Naturally, our stakeholders influence the way we carry out our business activities and how we formulate our strategies to meet their expectations and to generate long term benefits to our stakeholders in terms of business sustainability and value creation.

The table below lists the needs of our different stakeholder groups and how we engaged and addressed their needs.

Stakeholder Groups	Areas of Interest	Engagement Methods	Engagement Frequency
Investor/ Shareholders 	<ul style="list-style-type: none"> Return on investment Business prospects Future roadmap Corporate governance 	<ul style="list-style-type: none"> Annual general meeting Quarterly reporting Company's website Roadshow/ Investor briefing Whistleblowing policy, Shareholder communication policy, Corporate disclosure policy and Investor relation policy 	<ul style="list-style-type: none"> Monthly, quarterly, annually
Directors 	<ul style="list-style-type: none"> Return on investment Business prospects Future roadmap Corporate governance 	<ul style="list-style-type: none"> Board of Directors meetings Business updates and CEO reports Company events 	<ul style="list-style-type: none"> Quarterly, annually
Management 	<ul style="list-style-type: none"> Human capital Financial performance Production performance Business strategy 	<ul style="list-style-type: none"> Continuous management progress meeting and reporting On-going interaction Company events 	<ul style="list-style-type: none"> Daily, weekly, monthly, quarterly, annually

SUSTAINABILITY REPORT (CONT'D)

STAKEHOLDER ENGAGEMENT (CONT'D)

Stakeholder Groups	Areas of Interest	Engagement Methods	Engagement Frequency
Employees 	<ul style="list-style-type: none"> Competitive salary and benefits package Occupational safety and health Clear line of reporting and proper communication channel Work - life balance Career path and opportunities 	<ul style="list-style-type: none"> Employee handbook Monthly employee meetings Employee satisfaction survey and feedback Performance appraisal Internal training and development Engagement with employees Occupational safety and health programme Anti Bribery and Anti Corruption briefing 	<ul style="list-style-type: none"> Daily, weekly, monthly, quarterly, annually
Customers 	<ul style="list-style-type: none"> Product quality Reliable delivery Competitive prices Technical advancement Customer service and responsiveness 	<ul style="list-style-type: none"> Customer feedback/ survey After sales service Customer periodic visit/ audit Customer evaluation on suppliers Training and development Customer survey 	<ul style="list-style-type: none"> Daily, weekly, monthly, quarterly, annually
Suppliers/ vendors/ business partners 	<ul style="list-style-type: none"> Procurement policy and procedures Product cost Industry standard and requirement Prompt payments within credit period Business prospects and financial stability 	<ul style="list-style-type: none"> Disseminate procurement policy and procedures Supplier evaluation and assessment on suitability of vendors Reinforcement of code of conduct for ethical practices Supplier periodic visit and audit 	<ul style="list-style-type: none"> Daily, weekly, monthly, quarterly, annually
Local communities/ societies 	<ul style="list-style-type: none"> Impact of operations on surrounding environment Corporate social responsibility Corporate governance 	<ul style="list-style-type: none"> Engagement with local communities Provide job opportunities Pay attention to 3Rs (reduce, reuse and recycle) 	<ul style="list-style-type: none"> On an as needed basis and driven by events
Governments/ Regulatory authorities 	<ul style="list-style-type: none"> Compliance with existing laws Standards and certification 	<ul style="list-style-type: none"> Updates on rules and regulations Consultation with authorities Attendance at relevant seminars and conferences Member of the Federation of Malaysia Manufacturers Member of Association of Malaysian Medical Industries ("AMMI") 	<ul style="list-style-type: none"> Monthly, quarterly, annually


MATERIALITY ASSESSMENT

Our materiality assessment process enables us to identify and assess key risks and opportunities to ensure long-term sustainable growth. We have been integrating Bursa Securities' Common Sustainability Matters as part of our materiality assessment since FYE 2022. Our first materiality assessment was conducted in FYE 2022, by gathering inputs from our internal stakeholders such as employees and representatives from different functional groups. External stakeholders were not directly involved in the materiality process, but rather represented through internal knowledge of the ongoing stakeholder dialogues.

SUSTAINABILITY REPORT (CONT'D)

MATERIALITY ASSESSMENT (CONT'D)

In FYE 2025, we conducted a comprehensive sustainability materiality assessment by distributing survey forms to gather feedback from our selected stakeholders, namely our key senior management, the Board of Directors, employees, investors, customers, suppliers and government. Based on the feedback collected, we developed a materiality matrix to illustrate the relative importance of each material sustainability matter. During the assessment, we have identified and prioritised the 16 material sustainability matters. The identified material sustainability matters and its materiality matrix are illustrated as below:





















Looking ahead, our Group is committed to conducting periodic reviews of our material sustainability matters, ensuring they align with the dynamic business environment and evolving expectations of stakeholders.

SUSTAINABILITY REPORT (CONT'D)

UNITED NATION'S SUSTAINABLE DEVELOPMENT GOALS ("UN SDGS")

The UN SDGs are the blueprint that set by United Nations with collection of 17 interlinked global goals to achieve a better and more sustainable future for all. Our Group is committed to support and fulfil the UN SDGs. We believe in the symbiotic partnership between business, regulatory and society in achieving sustainability in our organisation.

We focus on aligning our efforts to adopt the UN SDGs which are relevant to our operations. The table below showcases how our sustainability initiatives are aligned with the UN SDGs.

Sustainability Matters	Sustainability Goals	FYE 2025 Performance
ECONOMIC AND GOVERNANCE		
<ul style="list-style-type: none"> Product Quality Customer Satisfaction Supply Chain Management Innovation Data Protection and Privacy Corporate Governance and Ethics     	<ul style="list-style-type: none"> Deliver quality products and services which meet customers' requirements and expectations Promote local procurement Deliver financial values to shareholders such as growth in revenue and earnings and dividend pay out Uphold the high standard of corporate governance and ethics 	<ul style="list-style-type: none"> No major customer complaints received 61% procurement with local suppliers Zero complaints concerning breaches of customer privacy and losses of customer data Zero confirmed cases for corruption
ENVIRONMENTAL		
<ul style="list-style-type: none"> Environmental Compliance Energy and Climate Management Water Management Waste Management      	<ul style="list-style-type: none"> Compliance with local regulatory requirements for scheduled waste disposal Efficient in energy management Efficient in water management Efficient in waste management 	<ul style="list-style-type: none"> Zero cases reported for non-compliance and breach of environmental regulations
SOCIAL		
<ul style="list-style-type: none"> Equal Employment Opportunities Development and Talent Retention Employee Benefits and Welfare Human and Labour Rights Occupational Safety and Health Corporate Social Responsibility       	<ul style="list-style-type: none"> Provide equal employment and career growth opportunities for all irrespective of gender, race, religion and disabilities Provide employment with development and talent retention Zero tolerance to discrimination and harassment Protection of human and labour rights Provide safe and health work environment Support local communities through Corporate Social Responsibility programs 	<ul style="list-style-type: none"> Zero cases reported for forced or child labour, discrimination, harassment, breach of human and labour rights 5,524.30 hours of training to employees Zero substantiated complaints concerning human rights violations Zero cases of work-related fatalities Organised regular employee wellness programme Contributed RM1,300 in charity initiatives which benefited 2 institutions

SUSTAINABILITY REPORT (CONT'D)

ECONOMIC AND GOVERNANCE




Product Quality

Our Group places emphasis on the quality of products that we manufacture. Our production facility adheres to the highest standards required by the relevant authorities. We take great pride in our numerous accreditations, including **ISO 9001:2015**, **ISO 13485:2016** and **EN ISO 13485:2016**. In addition, we have also received the **Good Distribution Practice for Medical Devices** (“GDPMD”) and the **Halal certification** for our prefilled humidifiers. We were also accredited with a **certificate of EC registration** from BSI, which certifies that our manufactured medical consumables comply with the European Commission health, safety and environment protection legislation, under the **European Commission 93/42/EEC**.



Beyond compliance, we continuously seek to enhance product quality by exploring and adopting advanced manufacturing technologies. This includes the use of aseptic manufacturing processes to minimise contamination risks, improvements in bottle design to ensure better usability and safety, and the enhancement of water quality standards in our production processes. These initiatives underscore our commitment to innovation and to delivering products that meet the evolving needs of healthcare providers and patients.

An overview of the key internal controls for ensuring product quality and safety is illustrated as follows:

Internal Controls	Description
<p>New product development</p> 	<p>For new product, they will be sent for laboratory and clinical testing to assess its quality prior to submitting an application to the relevant authorities for approvals. If the product does not meet the quality during the laboratory and clinical testing, we will improve the product quality based on the feedback and undergo further laboratory and clinical testing.</p>
<p>Manufacturing process inspection</p> 	<p>First shot will be inspected during the initial machine setup. In Process Quality Control (“IPQC”) will be performed.</p>
<p>Finished products and outgoing inspection</p> 	<p>Quality check on finished products including namely leak test and sterility will be performed prior to sending for packing.</p> <ul style="list-style-type: none"> Leak tests are performed where a sample prefilled humidifier is placed into a pressurised press jig and checks performed manually to test the seal on the front and back tubes of prefilled humidifier for leakage. Sterility tests are performed at our microbiology laboratory or any other qualified contract laboratory where a sterilised sample is collected and tested for the presence of micro-organisms. The sample meets the requirements for sterility if there are no presence of micro-organisms after 14 full days of incubation.

SUSTAINABILITY REPORT (CONT'D)

ECONOMIC AND GOVERNANCE (CONT'D)

Customer Satisfaction

Customer satisfaction is important to spur the establishment of loyal customers. The customers' loyalty and trust in our Group significantly reduce the likelihood of them switching suppliers while the goodwill generated among these customers will translate into more business opportunities through their recommendation to other prospective customers.

It is our current practice to carry out post-market surveillance activities on an on-going basis to collect data, evaluate and identify the need to take any action to ensure our products continue to be safe and well-performing as well as opportunities to improve the product quality.

The awards and recognitions that the Group has received over the years serve as an acknowledgement of our efforts and commitment to our products.

List of awards and recognitions:

- Best Country Order Growth, Patient Care & Monitoring Solution Malaysia (by Philips in 2015);
- Best Channel Partner Performance, Value Segment for Patient Monitors (by Philips in 2016);
- Rising Star Award (by Mindray in 2020);
- Best Innovation Award (by Malaysia Technology Expo 2020);
- Growth Breakthrough Award (by Mindray in 2021); and
- Outstanding Industry Participation Awards – Medical Device Industry (2025).



Awards and Recognitions



Outstanding Industry Participation Awards received during the "Upskilling Grant for Aerospace and Medical Devices Industries" Closing Ceremony, hosted by CREST on 18 February 2025

Market Presence

To consistently grow our market share, our Group places strong emphasis on building and maintaining close relationships with our customers and suppliers. We regularly visit our customers to engage with them, gather valuable feedback, and strengthen our market presence. The insights obtained from these engagements form part of our database to shape our business strategies and identify opportunities for expansion. These ongoing interactions not only reaffirm our unwavering commitment to meeting customer needs and expectations but also enhance satisfaction, trust, and loyalty. By fostering these strong personal connections, we strengthen our influence within our markets and contribute to mutual growth and long-term success.

To showcase our wide range of medical devices, we have established a dedicated showroom at our headquarters, where products such as Patient Monitors, MRI-Compatible Patient Monitors, Ultrasound Machines, Maternal and Infant Care Equipment, Ventilators and other medical solutions are on display. This provides customers and stakeholders with an opportunity to experience our products firsthand and appreciate the quality, innovation, and reliability we deliver.



SUSTAINABILITY REPORT (CONT'D)

ECONOMIC AND GOVERNANCE (CONT'D)

Market Presence (Cont'd)

Our Group has already established marketing and distribution offices in Kuala Lumpur and Johor to broaden our domestic market coverage. Looking ahead, we are actively planning to expand our market footprint further by setting up additional offices in other strategic locations. Beyond Malaysia, we have also engaged distributors across the Southeast Asia region to promote and distribute our own brand of products, thereby extending our presence into international markets and creating new growth avenues.

We also recognise the importance of participating in exhibitions and trade shows, which serve as a vital platform to raise brand awareness, showcase our products and services, and connect with potential customers in both local and overseas markets. These events provide us with valuable insights into evolving market trends, customer preferences, and the latest technological developments.

The exhibitions and trade shows that our Group participated in during FYE 2025 are listed below:



Annual Scientific Meeting on Intensive Care (“ASMIC”) 2024 at Shangri-La Hotel, Kuala Lumpur
6 - 8 September 2024



MEDICA 2024 at Messe Düsseldorf, Germany
11 - 14 November 2024



APHM International Healthcare Conference & Exhibition 2025 at KLCC, Kuala Lumpur
9 - 11 June 2025



Obstetrical and Gynaecological Society of Malaysia (“OGSM”) 2025 at Setia Spice



Convention Centre, Penang
10 - 13 July 2025



MyAnaesthesia 2025 - 62nd MSA-CoA Annual Scientific Congress at Shangri-La Hotel, Kuala Lumpur
1 - 3 August 2025

SUSTAINABILITY REPORT (CONT'D)

ECONOMIC AND GOVERNANCE (CONT'D)

Supply Chain Management

New Supplier Selection

As part of our supplier management activities, we are committed to ensure that all new suppliers are assessed through our supplier selection, qualification and evaluation procedures. The selection of supplier must be done through the Supplier Selection and Qualification Report and will be based on the risks associated with the medical devices.

Our Anti Bribery and Anti Corruption Policy states our commitment to dealing with suppliers in a fair, honest and professional manner while seeking best values for the business. Potential suppliers are treated on an equal basis and no unmerited favouritism is to be shown in the procurement of goods and services. Employees and business associates shall not enter into any contract on behalf of our Group or for our Group's benefits where the entry into the contract is in any way affected by a breach of Anti Bribery and Anti Corruption Policy as well as any applicable law and regulations. We will avoid dealing with prospective suppliers known for offering or providing bribes while suppliers will be made known to our Anti Bribery and Anti Corruption Policy and encourage them to adhere to similar high standards of corporate responsibility. Procurement practices shall be made in accordance with our Group's Control of External Providers Procedure and External Providers Information Procedure. Risk assessment on supplier should be carried out in accordance with the Control of External Providers Procedures and this will include an assessment of bribery risk.

Supplier Evaluation

We evaluate our selected suppliers on an annual basis to enhance the suppliers' performance and quality. Below are the key criteria used in our supplier evaluation:

- Number of supplier lot rejected;
- Number of supplier late delivery; and
- Time of price increase.

Responsible Supply Chain

Suppliers are required to sign the Supplier Code of Conduct and Compliance Declaration Form. The Supplier Code of Conduct sets out the requirements expected of suppliers regarding compliance with laws and regulations, corruption and bribery, social and working conditions, child labour, and the outside environment. The main objective is to partner with suppliers to ensure full compliance with these requirements as they, in turn, apply them to their own employees, agents, subcontractors, suppliers with whom they work with in the delivery of goods and services to our Group.

The key issues addressed in the Supplier Code of Conduct are as below:

Key Issues	Description
Compliance with Laws and Regulations	<ul style="list-style-type: none">• Comply with all applicable national and international laws and regulations, including the International Labour Organization and the internationally recognised Base Code of Labour standards, industry standards and all other relevant statutory requirements whichever requirements impose the highest standard of conduct.
Doing Business with Integrity	<ul style="list-style-type: none">• Conduct their business in accordance with the highest ethical standards with timely delivery.• Comply with all applicable laws and regulations concerning corruption, bribery, fraud and unfair and prohibited business practices.
Representation	<ul style="list-style-type: none">• Provide an honest, accurate and open representation of its organisation, its qualification, experience and capabilities.• Disclose if requested, accurate reference of previous work undertaken. Where references of previous work undertaken cannot be disclosed due to confidentiality obligations, suppliers shall reasonably endeavour to obtain the appropriate permissions and shall at a minimum disclose such information without breaching such obligations of confidentiality.

SUSTAINABILITY REPORT (CONT'D)

ECONOMIC AND GOVERNANCE (CONT'D)

Supply Chain Management (Cont'd)



Responsible Supply Chain (Cont'd)


Key Issues	Description
Quality	<ul style="list-style-type: none"> Any goods supplied shall be without fault and of the best available design, quality, material and workmanship, be fit for any purpose held out by the supplier and representatives. Any services supplied shall be provided by appropriately qualified and trained personnel, with due care and diligence.
Privacy, Freedom of Expression and Data Protection	<ul style="list-style-type: none"> Recognize and respect privacy and freedom of expression within the supplier's operation. Use due skill, care and diligence to implement adequate and document security controls and take necessary precautions to protect any data against unauthorized or unlawful processing and against accidental loss, destruction, damage, alteration or disclosure.
Social and Working Condition	<ul style="list-style-type: none"> Recognize and be committed to upholding the human rights of their employees and treat them with dignity and respect as understood by the international community.
Environment	<ul style="list-style-type: none"> Recognize that environmental responsibility is integral to producing high quality products. Comply with all applicable environmental laws, regulations and industry standards.

Local vs Foreign Procurement

In our commitment to promote the sustainability of the local economy, our Group prioritises the procurement of goods and services from local suppliers who meet our stringent standards. This approach not only supports local business but also has a positive environmental impact by minimising transportation needs, thereby indirectly contributing to a reduction in carbon emissions. In FYE 2025, our local procurement stood at 61% whereby our foreign procurement spending amounted to 39%.

The proportion of spending on local and foreign suppliers is illustrated as below:

Proportion of spending	Unit	FYE 2023	FYE 2024	FYE 2025
Local suppliers 	%	83%	56%	61%
Foreign suppliers 	%	17%	44%	39%



SUSTAINABILITY REPORT (CONT'D)

ECONOMIC AND GOVERNANCE (CONT'D)

Innovation

We use various types of technologies to develop and manufacture our own medical consumables as follows:

Technology	Description
Enterprise Resource Planning System	Computer software programme that an organisation in the provision of production-based or distribution business uses to manage day-to-day business activities such as accounting, procurement, order management, supply chain operations and manufacturing with the core function of accounting.
Fill-seal-leak Test Machine	A fully automated medical product packaging technology that fills, seals and performs a fill leak test on sealed parts to ensure that it is leak tight.
Adaptor Automated Assembly Line	An adaptor assembly line comprises multiple modules including rubber insertion station, cap insertion station and packaging that adapts to the production process.
BWT OSMOTRON® PRO	A skid-mounted system for the production of pharmaceutical water that meets the current United States Pharmacopeia Convention and European Pharmacopoeia requirements.
BWT LOOPO	A system for the distribution, sanitisation, control and monitoring of purified and highly purified water or water-for-injection circulation systems.

Technology	Description
FEDEGARI Steam Air Steriliser	A technology used for the counter pressure sterilisation of aqueous solutions in sealed containers.
OMRON Collaborative Robot System	A technology designed to share the same workspace with humans and can be easily switched for any task including pick and place processes etc.
Zalpa Autonomous Guided Vehicle ("AGV")	Installed AGV to transfer trolley between clean room and production room to reduce ergonomic injury, increase throughput, reduce machine dwell time, eliminate errors, improve material traceability and allow employees to focus on tasks given.
Vision Inspection System	A technology which could help to ensure all outgoing goods in accurate quantity, eliminate human error, and all goods are in place properly.

SUSTAINABILITY REPORT (CONT'D)

ECONOMIC AND GOVERNANCE (CONT'D)

Data Protection and Privacy

Our business model relies heavily on the trust of our stakeholders in safeguarding their data. Our IT systems are equipped with comprehensive security features to protect against cyber threats, safeguard our databases, and ensure the confidentiality of customer, supplier, and employee information. We implement integrated data protection and information security strategies to manage risks effectively and maintain operational resilience.

We recognise that cybersecurity is an evolving challenge. Accordingly, our IT Policy is reviewed and updated from time to time to strengthen controls and remain aligned with industry best practices, technological advancements, and regulatory requirements.

Some of the key measures and controls currently in place include:

- Our Password Policy requires the use of strong passwords, with mandatory changes every 90 days and restrictions on password reuse to minimise the risk of compromise;
- A Disaster Recovery Plan has been documented and is tested at least once a year to ensure critical operations can continue in the event of system failures or major disruptions;
- Regular data backups are conducted, securely stored offsite, and periodically tested to confirm integrity and recovery effectiveness;
- User access is tightly governed through an Access Limit Register, with management and IT approvals required before privileges are granted. Access rights are continuously monitored and reviewed to prevent unauthorised use;
- Up-to-date anti-virus protection is deployed across all devices and network access points, with continuous monitoring in place to prevent and detect new threats;
- All IT assets are centrally tracked, properly maintained, and subject to annual inspections, with strict rules applied to their use, transfer, and handling;
- Only licensed software approved and installed by the IT Department is permitted, ensuring compliance and preventing the use of unauthorised or pirated applications;
- Our Internet and Email Policy sets clear protocols for responsible use, helping to minimise exposure to malicious content and upholding the Group's professional image. Employees are prohibited from activities that could introduce risks such as malware, copyright infringements, or reputational harm; and
- A Social Media Usage Policy guides employees representing the company online, requiring adherence to guidelines that protect the Group's brand and reputation while maintaining clear boundaries between personal and professional use.



In FYE 2025, there were no reports of major cyber security violations and no complaints concerning breaches of customer privacy and losses of customer data.

	Unit	FYE 2023	FYE 2024	FYE 2025
Reports of major cyber security violations	Number	0	0	0
Substantiated complaints concerning breaches of customer privacy and losses of customer data	Number	0	0	0

Corporate Governance and Ethics

Our Board has continuously pursued the advancement of sound governance by implementing policies that not only comply with the latest regulatory requirements but also adhere to the core principles of best corporate governance practices. These requirements and practices include, but are not limited to, the Listing Requirements of Bursa Securities and the principles of the Malaysian Code on Corporate Governance ("MCCG") 2021.

Below are our key policies and governance framework, which are readily accessible to the public on our website at www.umedic.com.my.



SUSTAINABILITY REPORT (CONT'D)

ECONOMIC AND GOVERNANCE (CONT'D)

Corporate Governance and Ethics (Cont'd)

Code of Conduct

Our Code of Conduct is formulated for Directors, key management and employee to reflect our corporate value on commitment of integrity, responsibility, diligence and professionalism. The Code of Conduct is formulated to enhance the standard of corporate governance and corporate behaviour with the intention of achieving the following aims:

- To encourage high expected standards of honesty, integrity, ethical and law-abiding behaviour of Directors;
- To uphold the spirit of responsibility and social responsibility in line with the legislation, regulations and guidelines for administrating a company; and
- To provide guidance to our Board to maintain the confidence of shareholders and other stakeholders on our Company's integrity.

Our Code of Conduct governs the rules implemented for Conflict of Interest, Confidentiality, Insider Information and Securities Trading, Protection of Assets and Funds, Compliance, Directorships in Other Companies, Gifts and Hospitality, Anti Bribery and Anti Corruption, Safety, Health and Environment. We communicated these Code of Conduct to all Directors and employees to ensure the uphold with our core value.

Stakeholders are encouraged to report the incidents via whistleblowing channel should they know of or suspect any violation of the Code of Conduct. In FYE 2025, there were no non-compliance cases and breach of Code of Conduct.

Anti Bribery and Anti Corruption Policy

We take a zero-tolerance approach to bribery and corruption and are committed to acting professionally, fairly and integrity in all our business dealings and relationships wherever we operate and expect the individuals and organisation we work with to uphold and adopt the same approach. Our Employee Handbook states that our Group reserves the right to undertake disciplinary action against an employee who committed bribery and corruption.


We pride ourselves on our reputation for acting fairly and ethically wherever we do business. Our reputation is built on our values as a company, the values of our employees and our collective commitment to acting with integrity throughout our organization.

With the implementation of the new Section 17A of the Malaysian Anti-Corruption Commission ("MACC") Act 2009 which introduces corporate liability provision for bribery and corruption offences that came into effect on 1 June 2020, we have established Anti Bribery and Anti Corruption Policy. We condemn corruption in all its forms and we will not tolerate it in our business or in those we do business with. It is our policy to conduct all of our business in an honest and ethical manner. Employees are required to sign the Acknowledgement of Anti Bribery and Corruption Policy as evidence that they have read and understood the Anti Bribery and Anti Corruption Policy and will abide by the requirements set out in the said policy.

The prevention, detection and reporting of bribery is the responsibility of each employee and employee must report any activity or conduct which is not complying to Anti Bribery and Anti Corruption Policy as well as the applicable law and regulations, through whistleblowing channel. Stakeholders are encouraged to report the incidents via whistleblowing channel should they aware of or suspect any bribery and corruption activities.

Similarly, our Code of Conduct also recognise that involvement in bribery by any Directors and employees will adversely affect the image and reputation of our Company and hence there is a clear need to create a corporate culture of good corporate governance free of bribery and other forms of corruption.

Throughout the year, we organised anti corruption training to brief our employees on our Group policies and procedures pertaining to anti bribery and anti corruption measures, reaffirming our commitment to upholding highest ethical standards within our organisation.



SUSTAINABILITY REPORT (CONT'D)

ECONOMIC AND GOVERNANCE (CONT'D)

Corporate Governance and Ethics (Cont'd)

Anti Bribery and Anti Corruption Policy (Cont'd)

The percentage of employees who have received training on anti-corruption by employee category is illustrated as below:

	Unit	FYE 2023	FYE 2024	FYE 2025
Executive	%	70	95	90
Non-Executive	%	13	30	16
Manager and above	%	100	100	95

In FYE 2025, there were no confirmed incidents of corruption.

	Unit	FYE 2023	FYE 2024	FYE 2025
Confirmed incidents of corruption	Number	0	0	0

Our commitment to anti-corruption extends beyond our workforce, our Supplier Code of Conduct emphasis that our suppliers are equally accountable for conducting business in accordance with the highest ethical standards and complying with all relevant laws and regulations pertaining to corruption and bribery.

Currently, we have not conducted a comprehensive corruption risk assessment. Nevertheless, during the annual enterprise risk management exercise, we examine corruption risk. We will review the necessity of performing a comprehensive corruption risk assessments in the future.

	Unit	FYE 2023	FYE 2024	FYE 2025
Percentage of operations assessed for corruption-related risks	%	0	0	0

Whistleblowing Policy

Our Board has defined the Whistleblowing Policy for our Group, which provides guidance for stakeholders to report genuine concerns of any possible improprieties pertaining to financial reporting, compliance, malpractices and unethical business conduct within our Group. The Whistleblowing Policy aims to instil confidence on and assure our employees that they will be protected from possible reprisals or victimization that if they raise concerns in good faith, and believing them to be true. The types of concerns can be reported through whistleblowing mechanism includes but not limited to the following:

- Financial malpractice, impropriety or fraud;
- Corruption, bribery or blackmail;
- Failure to comply with laws or regulations or group/ company policies and procedures;
- Criminal offences and miscarriage of justice;
- Endangerment of an individual's health and safety;
- Falsification or destruction of business or financial records or misrepresentation or suppression of financial information; or
- Concealment of any or a combination of the above.

In FYE 2025, there were no whistleblowing reports being reported.

ENVIRONMENT

Environmental Compliance

We are aware of our responsibilities to protect the environment where we operate in and we believe in preserving the environment for the future generation whilst meeting the needs of our stakeholders. We are committed to sustainability development goals and to comply with all applicable environmental laws and regulations. We continuously develop and maintain a sustainable mechanism to protect the environment by managing our energy consumption, water consumption, waste generated throughout our businesses.

In FYE 2025, there were no non-compliance cases and breach of environmental regulations.

SUSTAINABILITY REPORT (CONT'D)

ENVIRONMENT (CONT'D)

Energy and Climate Management

Carbon emissions are a major contributor to climate change, a critical global issue. Therefore, we are committed to an ongoing initiative aimed at reducing our carbon footprint. This initiative includes reducing electricity consumption to combat climate change. As part of our commitment to this cause, in October 2023, we have installed 420 solar panels with a total capacity of 231 kWp at our current plant, the installation of solar panels at our company serves as a tangible manifestation of our firm commitment to sustainability, as well as our proactive approach to mitigating the risks posed by climate change.

We had commenced the utilisation of solar panels in December 2023, a strategic milestone that will allow us to reap the benefits of sustainable energy adoption. As we move closer to this target date, we look forward to reaping the environmental, financial, and reputational rewards of our commitment to sustainability and climate change mitigation.

Furthermore, we also integrate climate-related risks into our Group's overall risk management. Through a rigorous risk assessment process, we evaluated the potential risks and their impacts on our business operation, ensuring that we have strategies in place to navigate the challenges posed by climate change.

Electricity Consumption	Unit	FYE 2023	FYE 2024	FYE 2025
Total electricity consumption	kWh	1,070,528	1,024,819	936,229
Revenue	RM	45,432,437	54,570,002	48,564,379
Percentage of electricity consumption over revenue	%	2.36	1.88	1.93

Note: Consumption of electricity is measured based on the quantities consumed according to the electricity bill.

Petrol Consumption	Unit	FYE 2023	FYE 2024	FYE 2025
Total petrol consumption – RON95	Litre	67,428.25	80,155.63	89,468.09
Total petrol consumption – Diesel	Litre	1,819.58	506.24	745.80
Total petrol consumption	Litre	69,247.83	80,661.87	90,213.89
Revenue	RM	45,432,437	54,570,002	48,564,379
Percentage of petrol consumption over revenue	%	0.15	0.15	0.19

Note: Consumption of petrol is measured based on the petrol claimed.

Scope 1, direct CO₂ emissions: emissions come from the consumption of petrol and diesel for vehicles, calculated based on the reported fuel quantities.

Scope 2, indirect CO₂ emissions: emissions come from the consumption of electricity, calculated based on the energy quantities.

Emissions Type	Unit	FYE 2023	FYE 2024	FYE 2025
Direct Emissions (Scope 1)	tCO ₂ e	167.38	194.53	217.62
Indirect Emissions (Scope 2)	tCO ₂ e	626.26	599.52	547.69
Total	tCO ₂ e	793.64	794.05	765.31
Revenue	RM	45,432,437	54,570,002	48,564,379
Percentage of Scope 1 over revenue	%	0.0004	0.0004	0.0004
Percentage of Scope 2 over revenue	%	0.0014	0.0011	0.0011

Note:

- The GHG emission for Scope 1 is calculated using the emission factor obtained from IPCC Fifth Assessment Report, while the default emissions factors were based on IPCC Guidelines for National Greenhouse Gas Inventories (2006).*
- The GHG emission for Scope 2 is calculated using the emission factor obtained from 2017 Clean Development Mechanism ("CDM") Electricity Baseline for Malaysia.*

SUSTAINABILITY REPORT (CONT'D)


ENVIRONMENT (CONT'D)

Energy and Climate Management (Cont'd)

We support all minor activities in our operation which do not appear to be significant but also can help in fighting climate change such as planting in office, placing friendly reminder posters to users of electricity, encouraging employees to drive green vehicles (by providing designated parking space for green vehicles), putting photocopy machines into sleep mode during period of inactivity, purchasing energy saving equipment and etc. Through these minor activities, we able to contribute in preserving energy and reducing air pollution.



Outdoor plantations



Energy saving poster near switches



Designated parking space for green vehicles

Water Management

Our operation sites utilise water from water supply companies with developed water distribution structure and we do not withdraw surface water from rivers, lakes, natural ponds, groundwater from wells, quarry water or sea water. Presently, our operations are not located in water stressed areas and our production activities do not cause water pollution. Nevertheless, our Group is committed to contribute to better water management and protect clean water. We place friendly reminder posters to users of our water. To further solidify our dedication to sustainability, we have installed a rainwater harvesting tank at our Batu Kawan plant. This initiative allows us to harness a natural resource for various purposes including gardening and sanitary purposes.

Water Consumption	Unit	FYE 2023	FYE 2024	FYE 2025
Total water consumption	m ³	11,674	19,159	11,118
Revenue	RM	45,432,437	54,570,002	48,564,379
Percentage of water consumption over revenue	%	0.0257	0.0351	0.0229

Note: Consumption of water is measured based on the quantities consumed according to the water bill.



Save water posters



Rainwater harvesting tank

SUSTAINABILITY REPORT (CONT'D)

ENVIRONMENT (CONT'D)

Waste Management

Our Code of Conduct emphasises that all employees shall at all times be committed to prevent wasteful use of natural resources, protect the environment by minimizing and mitigating environmental impacts throughout the life cycle of operations. We are aware of our responsibility to reduce the waste generation and hence we manage our wastes through reduction, reuse and recycling of wastes. For instance, we reuse wooden pallet to build signatories in our warehouse, print documents on recycled papers (which do not contain confidential data) and etc. These initiatives have reduced the consumption of new material which leads to cost savings and effective use of materials.

We also trained our employees to differentiate different types of waste so they can segregate the waste based on the types and identify the appropriate treatment or disposal method.

Waste Management	Unit	FYE 2023	FYE 2024	FYE 2025
Waste diverted from disposal	Mt	198.39	177.60	186.32
Waste directed to disposal	Mt	-	-	-
Total waste generated ^{N1}	Mt	198.39	177.60	186.32

^{N1} Waste covers plastic, paper, and metal. General waste that is directed to disposal was not tracked as the volume was assessed to be insignificant.

SOCIAL



Equal Employment Opportunity

We strive to provide equal employment opportunity for all employees as we believe that true innovation and growth are built on a culture that respects diversity, inclusion and equality. We have implemented a standard recruitment procedure which will ensure the proper identification and recruitment of new talent to join our organisation to contribute to the growth of our business. All employment decisions are based on business needs and job requirement regardless of age, race, gender, religion, nationality, marital status, pregnancy, disability or any other status protected by the local laws or regulations. Bonuses, increments, benefits and promotions are provided to our employees benchmarked against set KPIs, purely based on merits and aligned with the principles of equal employment opportunities.


SUSTAINABILITY REPORT (CONT'D)

SOCIAL (CONT'D)

Equal Employment Opportunity (Cont'd)


In FYE 2025, we recorded a total of 166 employees (FYE 2024: 165 employees) and the details of the employee profile are presented as below:

**Gender Distribution %
(FYE 2024)**




■ Male ■ Female

**Gender Distribution %
(FYE 2025)**




■ Male ■ Female

**Age Distribution %
(FYE 2024)**




■ Under 30 ■ Between 30-50 ■ Above 50

**Age Distribution %
(FYE 2025)**




■ Under 30 ■ Between 30-50 ■ Above 50

**Permanent vs Temporary %
(FYE 2024)**



■ Permanent ■ Temporary

**Permanent vs Temporary %
(FYE 2025)**



■ Permanent ■ Temporary

SUSTAINABILITY REPORT (CONT'D)

SOCIAL (CONT'D)

Equal Employment Opportunity (Cont'd)

	FYE 2023	FYE 2024	FYE 2025
Employee Distribution	Percentage (%)	Percentage (%)	Percentage (%)
By Gender			
Male	52	65	65
Female	48	35	35
By Age			
Under 30	64	61	53
Between 30-50	34	37	45
Above 50	2	2	2
Permanent vs Temporary			
Permanent	100	100	100
Temporary	-	-	-
Employee Category			
Executive	57.38	49.70	46.99
Non-Executive	31.96	42.42	30.36
Manager and above	10.66	7.88	12.65
By Gender – Employee Category			
Executive – Male	22.13	24.24	23.49
Executive – Female	35.25	25.45	23.49
Non-Executive – Male	23.76	36.97	34.34
Non-Executive – Female	8.20	5.46	6.03
Manager and above – Male	5.74	4.24	7.23
Manager and above – Female	4.92	3.64	5.42
By Age – Employee Category			
Executive – Under 30	39.35	33.94	29.52
Executive – Between 30-50	16.39	14.55	17.47
Executive – Above 50	1.64	1.21	-
Non-Executive – Under 30	22.94	26.06	22.89
Non-Executive – Between 30-50	9.02	16.36	17.47
Non-Executive – Above 50	-	-	-
Manager and above – Under 30	1.64	0.61	0.60
Manager and above – Between 30-50	8.20	6.06	10.24
Manager and above – Above 50	0.82	1.21	1.81


SUSTAINABILITY REPORT (CONT'D)

SOCIAL (CONT'D)


Equal Employment Opportunity (Cont'd)

The details of the Board of Directors profile are presented as below:


**Gender Distribution %
(FYE 2024)**




**Gender Distribution %
(FYE 2025)**



**Age Distribution %
(FYE 2024)**



**Age Distribution %
(FYE 2025)**



	FYE 2023	FYE 2024	FYE 2025
Employee Distribution	Percentage %	Percentage %	Percentage %
By Gender			
Male	83	67	67
Female	17	33	33
By Age			
Under 50	17	17	17
50 and above	83	83	83

SUSTAINABILITY REPORT (CONT'D)

SOCIAL (CONT'D)

Development and Talent Retention

We believe in empowering our employees by having in place a standard operating procedure on training and personnel development. By providing appropriate training to our employees, it helps our employees achieve excellence in their respective fields, enable them to prepare for future, result in better customer service, productivity improvements, better efficiency and better workplace safety practices.

On annual basis, Annual Training Plan will be developed to plan both internal and external trainings to be conducted. In FYE 2025, we have carried out a total of **5,524.30** hours (FYE 2024: 4,273.90 hours) of training with an average of 33.28 training hours per employee (FYE 2024: average 25.90 training hours per employee).

Training Hours	Unit	FYE 2023	FYE 2024	FYE 2025
By Employee Category				
Executive	Hour	2,090	3,437.10	3,963.80
Non-Executive	Hour	12	193.90	253.00
Manager and above	Hour	349.50	642.90	1,307.50
Total	Hour	2,451.50	4,273.90	5,524.30

Training Types	Description
Orientation	<ul style="list-style-type: none"> One time programme to welcome new employees. The topics cover company overview, key corporate policies and conduct, overview of benefits and attendance, paperwork, health and safety procedures. Facility tour helps new employees to get acquainted with new workplace.
On-the-Job (OJT) Training	<ul style="list-style-type: none"> Focus on departmental goals by delivering the necessary skills, knowledge, and core competencies to new employees to perform the task efficiently. Mentoring programme drives rich learning and development for both mentees and mentors.
Technical Skills Training	<ul style="list-style-type: none"> It is job-specific training which focus on building employee's prerequisite technical skills and competencies relevant to his role. Regular training is conducted to keep abreast of latest development.
Soft Skills Training	<ul style="list-style-type: none"> Soft skill development training is carried out periodically to enable our employees to work together as a team for the benefit of their own and the organisation's success. The training module covers the topics such as leadership, communication, teamwork, collaboration, time management, problem-solving and etc..
Mandatory Training	<ul style="list-style-type: none"> All employees are required to undergo Safety and Health Training. All employees are expected to discharge their respective duties in line with our standards and policies.

As an integral component of our talent retention strategies, we are committed to fostering the growth of high potential employees, facilitating their development into senior positions within our Group. We conduct performance appraisals and it is our Company policy to first consider promoting suitable employees within our Company as far as possible before turning to recruitment from the external sources.

In line with this, in 2025, eight of our team members successfully completed the Medtech Professional Certificate in Manufacturing Excellence, organised by the Association of Malaysian Medical Industries ("AMMI"). This programme offered valuable insights into healthcare management and manufacturing, with a strong focus on best practices and industry standards in the medical device sector. Enriched by industry experts, the certification has further strengthened our team's capabilities and broadened their perspectives on manufacturing excellence.

SUSTAINABILITY REPORT (CONT'D)

SOCIAL (CONT'D)

Development and Talent Retention (Cont'd)




We are proud of our employees' achievements and will continue to invest in continuous professional development. By empowering our people, we aim to drive innovation, enhance operational efficiency, and contribute to the advancement of healthcare delivery.

We observe a reduction in our employee turnover in FYE 2025, compared to the previous year.

Employee Turnover	Unit	FYE 2023	FYE 2024	FYE 2025
By Employee Category				
Executive	Number	16	24	13
Non-Executive	Number	13	8	14
Manager and above	Number	1	1	1
Total	Number	30	33	28

We actively collaborate with schools and universities through industrial visits, providing students with the opportunity to gain real-world exposure, expand their knowledge, and experience our operations first-hand.

In April 2025, we had the pleasure of welcoming enthusiastic undergraduates from the Biomedical Engineering Student Club, Universiti Malaya ("BMESC"), to our headquarters in Penang. The visits offered students an immersive experience, including guided tours of our facilities, product showcases, and live demonstrations led by our experts. These sessions not only highlighted our innovative medical technologies but also provided valuable insights into our industry, culture, and core values.



Industrial visit by students from Biomedical Engineering Student Club, University of Malaya (28 April 2025)

Employee Benefits and Welfare

We aim to provide a conducive working environment for our employees, supporting them in pursuing reasonable standard of lifestyle and work life balance. We adhere to the Employment Act 1955 which is the main legislation on labour matters in Malaysia. We provide competitive remuneration packages and benefits to attract and retain good talents.

To promote a healthy working life, we believe in providing a balanced work-life environment to all our employees to enable them to have more time for their family and/or to pursue and advance their areas of interest. In this respect we do not encourage overtime work unless it is absolutely necessary such as to meet customer's order or regulatory deadlines. All our employees are entitled to national and state public holidays. In addition, our employees are entitled to annual leave, medical leave, maternity leave and etc. The details of employee benefits and welfare are outline as follows:

SUSTAINABILITY REPORT (CONT'D)

SOCIAL (CONT'D)

Employee Benefits and Welfare (Cont'd)

Statutory Benefits	Leave Provision	Employment Benefits & Welfare	Facilities
<ul style="list-style-type: none"> Adhere to minimum wages Statutory contributions (EPF, SOCSO, EIS and Income Tax) Annual salary increment Performance bonus Service awards Overtime payments National and state public holidays 	<ul style="list-style-type: none"> Annual leave Medical leave Hospitalization leave Maternity leave Marriage leave Paternity leave Compassionate leave 	<ul style="list-style-type: none"> Outpatient medical benefits Group Hospitalization and Surgical Insurance Group Personal Accident Insurance Newborn baby gift Mileage claim Travel expenses claim 	<ul style="list-style-type: none"> Car park Cafeteria Pantry Sports Dedicated parking space for disabled employees Dedicated parking space for employees with green vehicles Personal lockers Prayer rooms



SUSTAINABILITY REPORT (CONT'D)

SOCIAL (CONT'D)

Employee Benefits and Welfare (Cont'd)



SUSTAINABILITY REPORT (CONT'D)

SOCIAL (CONT'D)

Employee Benefits and Welfare (Cont'd)



2025 Hari Raya Aidilfitri Celebration

Human and Labour Rights

Basic human rights shall be universally protected by any responsible business. Our human rights practices are clearly stated in our Code of Conduct and Employee Handbook and all employees are expected to adhere to these high standards. Our actions implemented to avoid, prevent and mitigate human and labour rights issues include, but are not limited to the following:

✓ Dedicated resources to oversee human and labour rights matters

We will not tolerate the use of child or forced labour under no circumstances. Our HR department oversees the issues regarding human rights and ensure there are no forced and child labour within our operations. In this regard, our hiring process requires candidates to furnish photocopy of identity card which our HR department will able to verify the age and not process the hiring of underage labour.

✓ Established policies

We maintain a working environment with zero tolerance towards unethical labour practices. Accordingly, we prohibit conduct that constitutes or that could lead to or contribute to harassment based on age, race, gender, religion, nationality, marital status, pregnancy, disability or sexual orientation. Our Sexual Harassment Policy in Employee Handbook states that our Group will take all reasonable steps to ensure that the Sexual Harassment Policy is observed by all employees and any other persons who have contacts with employees. Based on our Discipline Management Policy, sexual harassment is considered as major misconduct.

SUSTAINABILITY REPORT (CONT'D)

SOCIAL (CONT'D)

Human and Labour Rights (Cont'd)

✓ Grievance management

We have established Grievance Management procedures where employee who feels violated or sexually harassed or discriminated can report the incidence or event to the respective Department Manager or file the grievances through formal channel to HR department. The HR department will investigate immediately and should there be any sufficient evidence to prove that the alleged sexual harassment did take place, our Group has the option to suspend the accused employee immediately to facilitate further investigation. If an employee is found guilty, he or she shall be terminated from employment without notice.

In FYE 2025, there were no substantiated complaints concerning human rights violations and cases reported for child labour, discrimination or harassment incidents.

	Unit	FYE 2023	FYE 2024	FYE 2025
Substantiated complaints concerning human rights violations	Number	0	0	0

Occupational Safety and Health

We are committed to provide a safe and healthy environment for all employees and customers while within our company premises. We have complied to the best of our ability the existing laws and regulations relevant to our operations such as Occupational Safety and Health Act 1994, Environmental Quality Act 1974, Factories and Machinery Act 1967, Fire Services Act 1988 and Prevention and Control of Infectious Diseases Act 1988.

Our Safety, Health and Environmental Policy states that all employees are required to adhere to the established policies and procedures pertaining to the Safety, Health and Environmental. Our employees are required to always adopt a Safety First attitude while performing their job and promptly report any potentially hazardous conditions. Safety, Health and Environment Team will identify potential hazards in workplace, eliminate and reduce the identified hazards through Risk Assessment and Risk Control. The team convenes regular meetings to address and deliberate upon all matters pertaining to safety within our workplace.

The team will also provide the necessary training to increase the consciousness of Safety, Health and Environment among the employees. During the financial year, we have also conducted trainings such as First Aid, CPR and AED training to our employees to raise awareness and knowledge about life-saving techniques.

	Unit	FYE 2023	FYE 2024	FYE 2025
Number of employees trained on health and safety	Number	48	124	49

At UMC, we recognise that employee well-being is essential to sustaining a motivated and productive workforce. In 2025, we organised two health screening and awareness programmes at our office, coinciding with World Health Day and beyond.

The first session, on 7 April 2025, included a health talk on "Practice Healthy Eating & Active Lifestyle," stretching exercises, and complimentary screenings for BMI, SpO₂, blood sugar, and blood pressure, supported by medical professionals from UMC Healthcare Centre and UMediC Ambulance.

SUSTAINABILITY REPORT (CONT'D)

SOCIAL (CONT'D)

Occupational Safety and Health (Cont'd)



Following the positive response, a second session was held on 7 May 2025, offering similar screenings together with healthy lifestyle promotions and freshly prepared fruit and vegetable juices.

These initiatives reflect our commitment to raising awareness of lifestyle-related health risks and encouraging proactive habits. Moving forward, we remain dedicated to strengthening employee wellness as part of our broader goal of fostering a healthier, more energised, and resilient workforce.



In June 2025, we organised a CPR and AED Awareness Training at our headquarters in Penang to strengthen life-saving knowledge and preparedness among our employees. The session equipped attendees with the skills to recognise cardiac arrest, perform hands-only CPR at the recommended rhythm, and operate the HeartStart HS1 AED with confidence.

SUSTAINABILITY REPORT (CONT'D)

SOCIAL (CONT'D)

Occupational Safety and Health (Cont'd)

The training was further enriched by practical insights shared by our facilitator and concluded with active participation from all attendees. By building essential emergency response capabilities, this initiative reflects our commitment to fostering a culture of safety and preparedness, empowering individuals to respond effectively in critical situations.



CPR & AED Training at the Headquarters in Batu Kawan (4 June 2025)

Our Group also established Emergency Preparedness and Response Procedure to prepare people, equipment and develop procedures to prevent and mitigate safety and health risks caused during accidents, dangerous occurrence or potential emergency situations.

There were no work injuries in FYE 2025.

	Unit	FYE 2023	FYE 2024	FYE 2025
Number of work-related fatalities	Number	0	0	0
Lost time incident rate	Number	0	0	0



TV display at production area showing safety rules

SUSTAINABILITY REPORT (CONT'D)

SOCIAL (CONT'D)

Corporate Social Responsibility

We believe in the philosophy of giving back to society to show our gratitude and appreciation for our success and in giving, we strengthen the local communities which will contribute to nation building and at the same time helps to create a culture of giving among our employees.

Over the years, we have donated Automated External Defibrillators (“AED”) to Dialysis Centre, Religious Organisation, Sport Societies, Ambulance Communities, Care Homes, Old Folks Homes, Fire and Rescue Associations, Community Townhalls, Schools and etc. We have also been providing public trainings for AEDs.



Public training on CPR and AEDs at Balathandayuthapani Temple also known as Waterfall Temple



A First Aider in Every Home Program

SUSTAINABILITY REPORT (CONT'D)

SOCIAL (CONT'D)

Corporate Social Responsibility (Cont'd)


The highlights of our Corporate Social Responsibility endeavours during this period are outlined below:

	Unit	FYE 2023	FYE 2024	FYE 2025
Total amount invested in the community	RM	-	1,600	1,300
Total number of beneficiaries of the investment in community	Number	-	1 organisation	2 institutions

Extending Care to the Community

In 2025, UMC continued its commitment to community welfare through a series of festive charity initiatives in Penang.

On 22 January 2025, in conjunction with Chinese New Year, we visited Shine Home Association in Bukit Mertajam, a home for individuals with disabilities. Our volunteers delivered care boxes filled with festive items and essential household supplies, bringing warmth and cheer to the residents. In addition, we collected and donated RM500 to support the home’s needs. The visit also gave us valuable insights into the challenges faced by the home, which relies heavily on public support to sustain its operations.



This was followed by a Hari Raya Aidilfitri initiative on 25 March 2025 at Rumah Bakti Kasih Ayah Bonda, also in Bukit Mertajam. To support the 16 orphans residing there, UMC contributed RM800 in cash, alongside groceries, daily necessities, and used clothing, ensuring they too could celebrate the festive season with joy.



These initiatives reflect our commitment to extending care and compassion to those in need, while fostering inclusivity and community spirit during meaningful occasions.

SUSTAINABILITY REPORT (CONT'D)

Indicator	Measurement Unit	2025
Bursa (Anti-corruption)		
Bursa C1(a) Percentage of employees who have received training on anti-corruption by employee category		
Executive	Percentage	90.00
Non-executive	Percentage	16.00
Manager and above	Percentage	95.00
Bursa C1(b) Percentage of operations assessed for corruption-related risks	Percentage	0.00
Bursa C1(c) Confirmed incidents of corruption and action taken	Number	0
Bursa (Community/Society)		
Bursa C2(a) Total amount invested in the community where the target beneficiaries are external to the listed issuer	MYR	1,300.00
Bursa C2(b) Total number of beneficiaries of the investment in communities	Number	2
Bursa (Diversity)		
Bursa C3(a) Percentage of employees by gender and age group, for each employee category		
Age Group by Employee Category		
Executive Under 30	Percentage	29.52
Executive Between 30-50	Percentage	17.47
Executive Above 50	Percentage	0.00
Non-executive Under 30	Percentage	22.89
Non-executive Between 30-50	Percentage	17.47
Non-executive Above 50	Percentage	0.00
Manager and above Under 30	Percentage	0.60
Manager and above Between 30-50	Percentage	10.24
Manager and above Above 50	Percentage	1.81
Gender Group by Employee Category		
Executive Male	Percentage	23.49
Executive Female	Percentage	23.49
Non-executive Male	Percentage	34.34
Non-executive Female	Percentage	6.03
Manager and above Male	Percentage	7.23
Manager and above Female	Percentage	5.42
Bursa C3(b) Percentage of directors by gender and age group		
Male	Percentage	67.00
Female	Percentage	33.00
Under 50	Percentage	17.00
50 and above	Percentage	83.00
Bursa (Energy management)		
Bursa C4(a) Total energy consumption	Megawatt	936.23
Bursa (Health and safety)		
Bursa C5(a) Number of work-related fatalities	Number	0
Bursa C5(b) Lost time incident rate ("LTIR")	Rate	0.00
Bursa C5(c) Number of employees trained on health and safety standards	Number	49
Bursa (Labour practices and standards)		
Bursa C6(a) Total hours of training by employee category		
Executive	Hours	3,964
Non-executive	Hours	253
Manager and above	Hours	1,307
Bursa C6(b) Percentage of employees that are contractors or temporary staff	Percentage	0.00
Bursa C6(c) Total number of employee turnover by employee category		
Executive	Number	13
Non-executive	Number	14
Manager and above	Number	1
Bursa C6(d) Number of substantiated complaints concerning human rights violations	Number	0
Bursa (Supply chain management)		
Bursa C7(a) Proportion of spending on local suppliers	Percentage	61.00

Internal assurance External assurance No assurance

(*)Restated

SUSTAINABILITY REPORT (CONT'D)

Indicator	Measurement Unit	2025	
Bursa (Data privacy and security)			
Bursa C8(a) Number of substantiated complaints concerning breaches of customer privacy and losses of customer data	Number	0	
Bursa (Water)			
Bursa C9(a) Total volume of water used	Megalitres	11.118000	
Bursa (Waste management)			
Bursa C10(a) Total waste generated	Metric tonnes	186.32	
Bursa C10(a)(i) Total waste diverted from disposal	Metric tonnes	186.32	
Bursa C10(a)(ii) Total waste directed to disposal	Metric tonnes	0.00	
Bursa (Emissions management)			
Bursa C11(a) Scope 1 emissions in tonnes of CO ₂ e	Metric tonnes	217.62	
Bursa C11(b) Scope 2 emissions in tonnes of CO ₂ e	Metric tonnes	547.69	
Bursa C11(c) Scope 3 emissions in tonnes of CO ₂ e (at least for the categories of business travel and employee commuting)	Metric tonnes	0.00	Note (i)

Note:

(i) C11 (c) - A value of 0 indicates that only Scope 1 and Scope 2 emissions are currently tracked. Scope 3 emissions data will be captured in the future as we enhance our readiness and data collection capabilities.

Internal assurance

External assurance

No assurance

(*)Restated

STATEMENT ON RISK MANAGEMENT AND INTERNAL CONTROL

1. Introduction

Our Board acknowledges the importance of maintaining good risk management and internal control system within our Group and is pleased to present its Statement on Risk Management and Internal Control for the financial year ended (“FYE”) 31 July 2025 and up to the date of approval of this statement disclosed pursuant to the Rule 15.26(b) of Main Market Listing Requirement (“MMLR”) and Malaysian Code on Corporate Governance 2021 (“MCCG”). This statement was prepared by taking into account of the Statement on Risk Management and Internal Control: Guidelines for Directors of Listed Issuers (“the Guidelines”).


2. Board Responsibilities

Our Board recognises the importance of risk management and maintaining a sound internal control system for our Group to safeguard the shareholders’ investment and our Group’s assets, and to discharge their stewardship responsibilities in identifying and reviewing risks and ensuring the implementation of appropriate systems to manage these risks. Our Board, in discharging its responsibilities, is fully committed to maintain appropriate risk management and internal controls system and for reviewing their adequacy and effectiveness so as to provide assurance on the achievement of the objectives of our Group. However, in view of the limitations that are inherent in any risk management system, the system is designed to manage, rather than to eliminate, the risk of failure to achieve the business objectives of our Group. Accordingly, the system can only provide reasonable and not absolute assurance against material misstatement, losses or fraud.

Our Board has delegated the oversight of the risk management and the internal control function to the Audit and Risk Management Committee (“ARMC”) which is comprised solely of Independent Non-Executive Directors. The ARMC is tasked to determine that there is a robust process in place for identifying, managing and monitoring critical risks, oversee execution of that process and ensure it is continuously improved as the business environment changes. On a periodic basis, our Board, via the ARMC, evaluates the adequacy and operating effectiveness of the risk management and internal control system and, where appropriate, requires the Management to implement pertinent controls to address emerging issues or areas of control deficiencies. The process has been in place for the financial year under review and up to the date of approval of this Statement for inclusion in this Annual Report.

3. Risk Management Framework

Our Group has established an Enterprise Risk Management (“ERM”) framework in Risk Management Handbook which serves as a methodical approach for identifying, evaluating, managing and documenting key operational risks in our Group. It sets out the principles, structure, roles and responsibilities, approach and measurement criteria. The Risk Management processes are embedded in the operation and business processes. These processes are performed by key senior management in their course of work and matters reported to our Chief Executive Officer, ARMC and Board of Directors. The reporting structure is outlined as below:



Notes :

- - - Functional Report

..... Independent Feedback

STATEMENT ON RISK MANAGEMENT AND INTERNAL CONTROL (CONT'D)

3. Risk Management Framework (Cont'd)

Our risk assessment was outsourced to an independent professional firm to assist our Board and Management in updating our Group's key business risks, including climate change risk and integrity risk, which could affect its strategic, operational and reputational well-being via ERM assessment activities.

The ERM assessment activities encompasses:-

- Discussions with Executive Directors and Senior Management to identify our Group's strategic concerns and to align risk assessment procedures accordingly;
- Evaluate the risk rating by considering the potential impact and likelihood of risk occurrence, effectiveness of controls and action plans taken to manage the risks to the desired level; and
- Assess and document the Management's controls for key business risks identified.

The results of ERM assessment, which encompassed the updates since the last assessment and management action plans, were presented to the Management and subsequently reported to the ARMC and Board for further deliberation. The management action plans include proposed measures to mitigate weaknesses in the control environment as well as corresponding treatment measures to manage the material exposures identified. To ensure effective risk management, our Management and Heads of Department have been entrusted with the responsibility to manage identified risks within defined parameters. This delegation empowers our skilled teams to proactively and proficiently navigate potential challenges while fostering a culture of accountability and adaptability across the organisation.

4. Internal Audit Function

Our Group has outsourced the internal audit function to YNC Business Consulting Sdn. Bhd. ("YNC"), an independent professional firm, which is independent of the activities and operations of our Group as an Internal Auditor to review the adequacy and sufficiency of systems, procedures and controls of our Group. The firm is free from any relationships or conflicts of interest, which could impair its objectivity and independence of the internal audit function. The firm does not have any direct operational responsibility or authority over any of the activities audited. Functionally, the Internal Auditors report directly to the ARMC. The primary responsibility of the Internal Auditors is to assist our Board and the ARMC in reviewing and assessing management systems of internal control and procedures. The ARMC reviews and approves the Internal Audit Engagement and fees to ensure the independence and objectivity of the Internal Auditors.

The Internal Audit engagement by YNC is led by Ms. Phoon Yee Min, who is a Certified Internal Auditor ("CIA"), member of Association of Chartered Certified Accountants ("ACCA") and member of Malaysia Institute of Accountants ("MIA"). She has accumulated over 20 years of experience in Audit and Advisory engagement. She provides overall direction for the internal audit engagement and is responsible for all stages of the internal audit work. She also maintains contact with the Management to ensure open communication is practised and all internal audit works are carried out effectively and in a timely manner. All the personnel deployed by YNC do not have any family relationship or conflicts of interest with our Group that could impair their objectivity and independence during the course of their work.

The Internal Auditors execute the internal audit work based on a risk-based internal audit plan which will be approved by the ARMC before the commencement of work. The Internal Auditors conduct their work in consideration of the broad principles of the International Professional Practice Framework ("IPPF") of Institute of Internal Auditors covering the conduct of the audit planning, execution, documentations, communication of findings and consultation with key stakeholders.

During the financial year under review, the Internal Auditors conducted an internal audit focusing on Supply Chain Management. The observations noted during the internal audit, together with the recommendations, were reported to Management and subsequently presented to the ARMC. The total cost incurred for the internal audit function during the financial year under review was approximately RM24,000.

STATEMENT ON RISK MANAGEMENT AND INTERNAL CONTROL (CONT'D)

5. Other Internal Control Processes

Apart from risk management and internal audit, the system of internal controls of our Group also comprises the following key elements:

a. Organisation Structure and Limit of Authority

Our Group has an organisational structure that well defines lines of responsibility, delegation of authority, segregation of duties and flow of information, aligned to the operational requirements of the business of our Group within management, which provides the levels of accountability and responsibility of the respective job functions of management.

Our Group has established authorisation limits and approval levels for management to follow including those requiring approval from our Board.

b. Policies and Procedures

Standard Operating Procedures ("SOP") and various policies are formalised to serve as a guiding principle to all employees within our Group for their day-to-day activities to safeguard the assets of our Group against material losses. The policies and procedures shall be periodically reviewed and updated to cater to the changing business environment and operational requirements, and statutory reporting needs. Our Group has also documented policies and procedures to regulate relevant key processes in compliance with the following:

- ISO 9001:2015;
- ISO 13485:2016;
- EN ISO 13485:2016;
- Good Distribution Practice for Medical Devices ("GDPMD");
- Halal certification; and
- European Commission health, safety and environment protection legislation ("European Commission 93/42/EEC").

c. Integrity and Ethical Value

The tone from the top on integrity and ethical value are enshrined in the formal Code of Conduct ("the Code") established and approved by our Board. The Code forms the foundation of the integrity and ethical value of our Group.

Integrity and ethical value expected from the employees are incorporated in the Employee Handbook whereby the ethical behaviours expected with customers and of suppliers as well as employees to carry out their duties and responsibilities assigned are also established and formalised in the Handbook.

In line with Section 17A of the Malaysian Anti-Corruption Commission Act 2009, a formal Anti Bribery and Anti Corruption Policy had been put in place to prevent the risk of bribery and conflict of interest within our Group with a Whistleblowing Policy implemented for all stakeholders to raise genuine concerns about possible improprieties in matters of unethical behaviour, malpractices, illegal acts or failure to comply with regulatory requirements at the earliest opportunity.

d. Board of Directors/ Board Committee Meetings

The role, functions, composition, operation and processes of our Board are guided by the Board Charter. Board Committees, namely ARMC, NC and RC are established with terms of references clearly outlining their functions and duties delegated by our Board. ARMC assists our Board to review the effectiveness of the ongoing monitoring processes on risk and control matters for areas within their scope of work.

Meetings of our Board and respective Board Committees are carried out on a scheduled basis to review the performance of our Group, from financial and operational perspective.

e. Employee Handbook

Guidelines on human resource management are in place to ensure the ability of our Group to operate in an effective and efficient manner by employing and retaining adequate competent employees possessing the necessary knowledge, skill and experience in order to carry out their duties and responsibilities assigned effectively and efficiently.

Performance evaluations are carried out for all levels of staff to identify performance gaps, for training needs identification and talent development.

Emphasis is placed on enhancing the quality and ability of employees through a wide variety of training programs and workshops to enhance their knowledge and expand the employees' competency level in executing daily jobs. Relevant trainings and courses are provided to personnel across all functions to maintain a high level of competency and capability.

STATEMENT ON RISK MANAGEMENT AND INTERNAL CONTROL (CONT'D)

5. Other Internal Control Processes (Cont'd)

f. Information and Communication

Our Group has put in place effective and efficient information and communication infrastructures and channels, i.e., computerised systems, secured intranet and electronic mail system, so that operation data and management information can be communicated timely and securely to dedicated personnel within our Group for decision making and for communication with relevant external stakeholders for execution and information collection. Our Management and Board meetings are held for effective two-way communication of information at different level of management and our Board.

g. Monitoring and Review Activities

Our Executive Director/Chief Executive Officer is closely involved in the daily operations regularly reviews the operational information. Our Group conducts quarterly management meeting which is chaired by our Executive Director/Chief Executive Officer and attended by the various Head of Departments to review and discuss on various matters covering operational, financial, business development and human resources areas.

h. Company Secretary

The Company Secretary provides the necessary advice and guidance on matters relating to the Constitution of our Company, Board policies and procedures, and compliance with relevant regulatory requirements, codes or guidance.

6. Review of the Statement by External Auditors

The external auditor has reviewed this Statement on Risk Management and Internal Control as required under Paragraph 15.23 of Bursa Malaysia Securities Berhad's Main Market Listing Requirements. The limited assurance review was performed in accordance with Malaysian Approved Standard on Assurance Engagements, ISAE 3000 (Revised) Assurance Engagements Other than Audits or Reviews of Historical Financial Information other than Audits or Reviews of Historical Financial Information and Audit Assurance Practice Guide 3 ("AAPG 3") Guidance for Auditors on Engagements to Report on the Statement on Risk Management and Internal Control Included in the Annual Report. AAPG 3 does not require the external auditors to form an opinion on the adequacy and effectiveness of the risk management and internal control systems of the Group.

Based on their procedures performed, the external auditors have reported to the Board that nothing has come to their attention which causes them to believe that this Statement is not prepared, in all material respects, in accordance with the disclosures required by paragraph 41 and 42 of the Statement on Risk Management and Internal Control: Guidelines for Directors of Listed Issuers, nor is factually inaccurate.

7. Conclusion

Our Board has received assurance from the Chief Executive Officer that the risk management and internal control system adopted by our Group is operating adequately and effectively, in all material aspects, based on their observations in the course of their management of daily operations of our Group. Our Board is of the view that the risk management and internal control systems are operating satisfactorily and effectively to safeguard the interest of stakeholders and assets of our Group for the financial year under review, and have not resulted in any material losses, contingencies or uncertainties that would require disclosure in the annual report of our Company. Our Board continues to take measures to review and, where necessary, enhance the risk management and internal control systems of our Group to meet the strategic objectives of our Group.

Our Board is committed to maintaining a sound internal control system and an effective risk management throughout our Group and reaffirms its commitment to continuously review and where necessary, enhance further the risk management and internal control systems.

This Statement on Risk Management and Internal Control is made in accordance with a resolution passed in our Board of Directors' meeting held on 7 November 2025.

AUDIT AND RISK MANAGEMENT COMMITTEE REPORT

COMPOSITION AND DESIGNATION

Lee Yee Wooi

Chairman
(Independent Non-Executive Director)

Dr. Pakirisamy Baskaran A/L P Thangavelu

Member
(Independent Non-Executive Director)

Tan Chye Suan

Member
(Independent Non-Executive Director)

Our members of the Audit and Risk Management Committee (“ARMC” or “Committee”) comprise wholly Independent Non-Executive Directors.

Our ARMC Chairman, Lee Yee Wooi is a member of Malaysian Institute of Accountants.

Members of our Committee are financially literate, with diverse background, experience and knowledge in accountancy, business management, commercial and corporate laws.

TERMS OF REFERENCE

Following are the details of our ARMC’s terms of reference. The terms of reference are also posted at our Company’s website at www.umedic.com.my.

ATTENDANCE

During the financial year ended 31 July 2025, there were Five (5) meetings held. These meetings were attended by all members of ARMC.

SUMMARY OF ACTIVITIES

The activities undertaken by our ARMC in discharging its duties and functions during the financial year 2025 are summarised as follows:

a. Reviewing External Audit Planning Memorandum and the Independence of the External Auditors

Our ARMC conducted three (3) times of private dialogue session with the external auditors without the presence of Executive Directors on 4 September 2024, 8 November 2024 and 5 June 2025 respectively.

Before the commencement of the current financial year audit, our ARMC has reviewed and deliberated with the External Auditors on their audit planning memorandum, in particular the audit risk areas, approach, emphasis and timeline.

b. Reviewing Audited Financial Statements

Our ARMC has reviewed the Audited Financial Statements for the financial year ended 31 July 2024 together with the Reports of Directors and Auditors on 8 November 2024 before presentation to the Board for approval and for release to the authorities and public.

c. Reviewing the Interim Financial Results

Our ARMC has reviewed the financial statements and the quarterly results, cash flows, and financial positions with management. During this review, our Financial Controller was invited to present and respond to questions raised by the ARMC on the financial performance and significant financial reporting concerning compliance with applicable approved accounting standards and other regulatory requirements. Based on the clarifications and answers provided by our management, our ARMC resolved to present the quarterly results to our Board for consideration and approval.

AUDIT AND RISK MANAGEMENT COMMITTEE REPORT (CONT'D)

SUMMARY OF ACTIVITIES (Cont'd)

d. Reviewing the Related Party Transactions and Conflict of Interest

In order to safeguard the interest of our Group and its minority shareholders, and to mitigate any potential conflict of interest, our ARMC has reviewed the related party transactions and conflict of interest situation that may arise within the Company or the Group.

e. Reviewing the Internal Audit Functions

The ARMC has reviewed and approved the Internal Audit Plan FYE 2025 presented by Internal Auditor on 8 November 2024. The Internal Auditor reported its findings together with the management action plan and recommendations to the ARMC for review on 5 June 2025. The ARMC also reviewed the adequacy of the scope, function, competency and resources of the internal audit functions, and ensures that it has the necessary authority to carry out its work. The ARMC and Management work closely with the outsourced internal audit function to review the internal control issues and ensure that significant issues are brought to the attention of the Board.

f. Reviewing the Audit and Risk Management Committee Report, Corporate Governance Report, Corporate Governance Overview Statement, Statement on Risk Management and Internal Control, and Sustainability Statement.

Our ARMC has reviewed the Audit and Risk Management Committee Report, Corporate Governance Report, Corporate Governance Overview Statement, Statement on Risk Management and Internal Control, and Sustainability Statement prior to recommending the same for Board's approval for inclusion in the Annual Report 2024 on 8 November 2024.

INTERNAL AUDIT FUNCTION

During the FYE 2025, our Group has outsourced the internal audit function to YNC Business Consulting Sdn Bhd ("YNC"), an independent professional firm, which is independent of the activities and operations of our Group as its Internal Control Review Consultant to review the adequacy and sufficiency of systems, procedures and controls of our Group. The annual cost incurred for our Group's internal audit function is RM24,000.

Functionally, the Internal Auditors report directly to our ARMC. The primary responsibility of the Internal Auditors is to assist our Board and our ARMC in reviewing and assessing the effectiveness of management systems of internal control and procedures. Our ARMC reviews and approves the Internal Audit Engagement and fees to ensure the independence and objectivity of the Internal Auditors.

The Internal Auditors will execute the internal audit work based on a risk-based internal audit plan which will be approved by our ARMC before the commencement of work. The Internal Auditors will conduct their work in consideration of the broad principles of the International Professional Practice Framework ("IPPF") of Institute of Internal Auditors covering the conduct of the audit planning, execution, documentations, communication of findings and consultation with key stakeholders.

During the financial year under review, one internal audit cycle was completed, which covered the following audit scopes of work to evaluate the effectiveness of the internal control systems:

No.	Audit Area	Reporting Date
1.	Supply Chain management	5 June 2025

Findings arising from the internal audit exercise with recommendation and management action plan were reported and discussed at the ARMC meeting on 5 June 2025.

NOMINATION COMMITTEE STATEMENT

COMPOSITION AND DESIGNATION

Chairman : Dr. Pakirisamy Baskaran A/L P Thangavelu
(Independent Non-Executive Director)

Member : Tan Chye Suan
(Independent Non-Executive Director)

Lee Yee Wooi
(Independent Non-Executive Director)

TERMS OF REFERENCE

The terms of reference of our Nomination Committee (“NC” or “Committee”) are also posted at our Company’s website at www.umedic.com.my.

ATTENDANCE

During the financial year ended 31 July 2025, there was one (1) meeting held. This meeting was attended by all members of NC.

SUMMARY OF ACTIVITIES

On 4 September 2024, our NC reviewed the outcome of an annual evaluation process on the Board, Board Committees and individual Directors that reviews their performance and assesses their effectiveness and contribution during the year under review. The assessment is administered using questionnaires that incorporate a range of criteria including Board composition, skills and competencies, meeting conduct and administration as well as self and peer evaluation model with an eye towards improvement opportunities. Our NC evaluated each individual Director taking into consideration of their skillsets, experience, competence and commitment required of them to discharge their respective role and is satisfied with the performance of all the directors.

NC has conducted a review on the term of office and performance of the ARMC and each of the members individually for FYE 2025. Upon its assessment, the NC is satisfied and has recommended to the Board that the ARMC and its members have discharged their duties in accordance with the ARMC’s terms of reference.

In addition, NC also reviewed and is satisfied with the current Board structure, size and composition which ensured appropriate balance and size of non-executive participation as well as having the right mix of skill sets and diversity of experience. Our NC and Board are supportive of gender diversity to comprise 30% woman directors as recommended by the Malaysian Code on Corporate Governance and currently there are two (2) female Directors (equivalent to 33.3% of the board composition) sitting on our Board.

NC has also assessed and recommended to the Board of the proposed re-election and re-appointment of Dr. Pakirisamy Baskaran A/L P Thangavelu and Ms Tan Chye Suan by the shareholders at the forthcoming AGM after reviewing their skill and experience.

DIRECTORS' RESPONSIBILITY STATEMENT

Our Directors are responsible to ensure the annual audited financial statement of our Group and of our Company are drawn up in accordance with applicable Financial Reporting Standards, the provisions of the Companies Act 2016 and the Paragraph 15.26(a) of the Main Market Listing Requirements ("MMLR") of Bursa Malaysia Securities Berhad ("Bursa Securities") so as that give a true and fair view of the state of affairs of our Group and of our Company at the end of the financial year, and of the financial performance and cash flows of our Group and of our Company for the financial year.

In preparing the financial statements for the financial year ended 31 July 2025, our Directors have: -

- adopted appropriate accounting policies and applied consistently;
- made judgements and estimates that are reasonable and prudent;
- ensure all applicable Malaysian Financial Reporting Standards have been complied with; and
- prepared the financial statements on a going concern basis.

Our Directors are responsible to ensure that our Group and our Company maintain proper accounting records which disclose the financial position of our Group and of our Company with reasonable accuracy to ensure that the financial statements comply with the Companies Act 2016.

Our Directors are responsible for taking reasonable steps to ensure that appropriate systems are in place to safeguard the assets of our Group and of our Company to prevent and detect fraud and other irregularities.

ADDITIONAL COMPLIANCE INFORMATION

1. UTILISATION OF PROCEEDS

UMC listed on the ACE Market of Bursa Securities (“Listing”) on 26 July 2022. As part of the listing exercise, our Company undertook a public issue of 97,224,300 new ordinary shares at an issue price of RM0.32 per share, raising gross proceeds of RM31.11 million (“IPO proceeds”). On 5 June 2025, the Company announced the variation and extension of time for the Company's utilisation of the above proceeds up to 4 December 2025.

As at 31 July 2025, our utilisation of the IPO Proceeds is as follows:

Details of the use of proceeds	Estimated timeframe for the use of proceeds upon Listing ⁽ⁱ⁾	Revised timeframe for utilisation ⁽ⁱⁱ⁾	Proposed Utilisation RM'000	Allocation of IPO Proceeds upon listing (revised) RM'000	Actual Utilisation RM'000	Percentage Utilised %
Capital expenditure						
(i) Construction of new factory building	Within thirty (30) months		3,500	3,500	3,500 ⁽ⁱⁱⁱ⁾	100.00
(ii) Setting up new marketing and distribution offices	Within thirty-six (36) months		6,800	-	-	-
(iii) Purchase of machinery and system, and expansion of cleanroom		Within six (6) months	-	5,500	467	8.49
			10,300	9,000	3,967	44.08
Repayment of bank borrowings ^(iv)	Within six (6) months	Within six (6) months	9,000	9,300	9,300	100.00
Working capital	Within thirty-six (36) months	Within six (6) months	8,662	9,662	9,662	100.00
Estimated listing expenses	Within two (2) months		3,150	3,150	3,150	100.00
Total			31,112	31,112	26,079	

Notes:

- (i) From the date of Listing on 26 July 2022.
- (ii) From the date of this announcement on 5 June 2025.
- (iii) As stated in Section 3.7.1(i) of the Prospectus, the excess amount of approximately RM0.17 million has been used for working capital purposes.
- (iv) Including lease liabilities owing to financial institutions.

ADDITIONAL COMPLIANCE INFORMATION (CONT'D)

2. AUDIT AND NON-AUDIT FEES

The amount of audit and non-audit fees incurred for services rendered to our Group for the FYE 2025 by our Company's Auditors are as follows:

Category	Audit Fees (RM)	Non-Audit Fees (RM)*
Company	31,100	6,500
Subsidiaries	62,400	-
	93,500	6,500

Notes:

* Non-Audit fees include review of Statement on Risk management and Internal Control.

3. RECURRENT RELATED PARTY TRANSACTION

There was no recurrent related party transaction entered into by our Group during FYE 2025.

4. MATERIAL CONTRACTS

There were no material contracts entered into by our Group involving the interest of our Directors, Chief Executive who is not a Director and major shareholders, either still subsisting as at 31 July 2025 or entered into since the end of the previous financial year.

5. EMPLOYEE SHARE GRANT SCHEME ("SGS")

On 1 February 2023, our Company established and implemented an employees' Share Grant Scheme of up to 15% of the total number of issued shares of UMC (excluding treasury shares) at any point of time during the duration of the scheme period for the eligible Directors and employees of the UMC and its subsidiary companies (excluding subsidiary companies which are dormant) ("SGS"). The SGS shall be in force for a period of ten (10) years from the effective date.

During the financial year, no SGS shares were issued by our Company.

FINANCIAL STATEMENTS

87	Directors' Report
94	Statement by Directors
94	Statutory Declaration
95	Independent Auditors' Report To The Members
98	Statements of Financial Position
99	Statements of Profit or Loss and Other Comprehensive Income
100	Consolidated Statement of Changes in Equity
101	Statement of Changes in Equity
102	Statements of Cash Flows
105	Notes to the Financial Statements

DIRECTORS' REPORT

The Directors have pleasure in submitting their report and the audited financial statements of the Group and of the Company for the financial year ended 31 July 2025.

PRINCIPAL ACTIVITIES

The Company is principally engaged as investment holding company. The principal activities of subsidiaries are mainly developing, manufacturing, marketing, design, assembly, import, export, distribution of medical devices and medical mounting solutions products as well as provision of after-sale services, and operating of nursing homes and healthcare centres. The details of the subsidiaries are set out in Note 7 to the financial statements.

There have been no significant changes in the nature of the activities of the Company and its subsidiaries during the financial year.

RESULTS

	Group RM	Company RM
Profit/(Loss) for the financial year	<u>8,264,189</u>	<u>(343,859)</u>
Attributable to:		
Equity holders of the Company	8,133,578	(343,859)
Non-controlling interests	<u>130,611</u>	<u>0</u>
	<u>8,264,189</u>	<u>(343,859)</u>

DIVIDEND

No dividend has been paid, declared or proposed by the Company since the end of the previous financial year.

The Directors do not recommend any payment of dividend for the current financial year ended 31 July 2025.

RESERVES AND PROVISIONS

There were no material transfers to or from reserves or provisions during the financial year.

ISSUE OF SHARES AND DEBENTURES

The Company did not issue any new shares or debentures during the financial year.

OPTIONS GRANTED OVER UNISSUED SHARES

No options were granted to any person to take up unissued ordinary shares of the Company during the financial year.

DIRECTORS' REPORT (CONT'D)

SHARE GRANT SCHEME ('SGS')

On 1 February 2023, the Company established and implemented an employees' Share Grant Scheme ("SGS"). The SGS shall be in force for a period of ten (10) years from the effective date.

The salient features and terms of the SGS are as follows:

- (i) The Board of Directors ('Board') shall appoint the SGS Committee to administer the SGS. The SGS Committee shall be vested with such powers and duties conferred upon it by the Board and the Board may determine all matters pertaining to the SGS Committee, including its duties, power and limitations;
- (ii) The maximum number of shares which may be made available under the SGS shall not in aggregate exceed fifteen percent (15%) of the total number of issued shares of the Company (excluding treasury shares, if any) at any point of time during the SGS period;
- (iii) The aggregate maximum number of SGS shares that may be allocated to the executive directors and senior management of the Group shall not be more than seventy percent (70%);
- (iv) The aggregate maximum shares allocated to any eligible individual executive director or employee who, either singly or collectively through persons connected with him/her, holds twenty percent (20%) or more of the total number of issued shares of the Company (excluding treasury shares, if any), shall not be more than ten percent (10%) of the maximum number of shares which may be made available under the SGS;
- (v) Subject to the discretion of the SGS Committee, an employee or a director of the Group who fulfils the relevant conditions of the By-Laws of the SGS shall be eligible to participate in the SGS ("Grantees");
- (vi) The number of SGS shares to be allocated to the Grantees shall be determined by the SGS Committee at its sole discretion after taking into consideration factors which may include the Grantees' position, job performance, seniority, duration of service, potential for future development and contribution to the Group and/or such other factors as the SGS Committee deems fit; and
- (vii) The Shares to be issued and/or transferred to the Grantees pursuant to the SGS will rank *pari passu*, in all respects with the existing shares, save and except that the shares will not be entitled to any dividends, rights, allotments and/or other distributions which may be declared, made or paid, where the entitlement date is before the date of issuance and/or transfer of the abovementioned shares.

The Company did not issue or grant any SGS during the financial year.

DIRECTORS

The Directors who have held office during the financial year and up to the date of this report are as follows:

Dato' Seri Ng Chai Eng*

Lim Taw Seong*

Dr. Pakirisamy Baskaran A/L P Thangavelu

Tan Chye Suan

Lee Yee Wooi

Dato' Dr. Teh Keng Hwang

Ng Sze Hui (Alternate Director to Dato' Seri Ng Chai Eng)

*These Directors of the Company are also Directors of subsidiaries of the Company.

DIRECTORS' REPORT (CONT'D)

DIRECTORS (CONT'D)

The Directors who have held office during the financial year and up to the date of this report are as follows: (Cont'd)

Subsidiaries of UMediC Group Berhad (excluding those Directors listed above)

Dato' Lau Chee Kheong
 Lai Eng Seong
 Tiam Kian Peng
 Lai Yuen Yan
 Yap Teck Lee
 Ng Kah Boon (Appointed on 11 March 2025)
 Tan Xiao Hui (Appointed on 11 March 2025)

DIRECTORS' INTERESTS

The Directors holding office at the end of the financial year and their beneficial interests in the ordinary shares of the Company during the financial year ended 31 July 2025 as recorded in the Register of Directors' Shareholdings kept by the Company under Section 59 of the Companies Act 2016 in Malaysia were as follows:

	[----- Number of ordinary shares -----]			
	Balance as at 1.8.2024	Bought	Sold	Balance as at 31.7.2025
Shares in the Company				
Direct interests:				
Dato' Seri Ng Chai Eng	20,402,200	80,657,154	(10,105,935)	90,953,419
Lim Taw Seong	19,102,700	57,321,632	(14,000,000)	62,424,332
Dr. Pakirisamy Baskaran				
A/L P Thangavelu	300,000	0	0	300,000
Tan Chye Suan	300,000	0	0	300,000
Lee Yee Wooi	300,000	0	0	300,000
Ng Sze Hui (Alternate Director to Dato' Seri Ng Chai Eng)	300,000	0	0	300,000
Indirect interests:				
Dato' Seri Ng Chai Eng*	192,627,220	0	(192,327,220)	300,000
Lim Taw Seong #	192,327,220	0	(192,327,220)	0

Deemed interest through shares held in UMediC Capital Sdn. Bhd. by virtue of Section 8(4) of the Companies Act 2016 in Malaysia.

* Deemed interest through shares held in UMediC Capital Sdn. Bhd. by virtue of Section 8(4) of the Companies Act 2016 in Malaysia and the shares held by his daughter, Ng Sze Hui pursuant to Section 59(11)(c) of the Companies Act 2016 in Malaysia.

By virtue of Dato' Seri Ng Chai Eng and Lim Taw Seong interests in the ordinary shares of the Company, these Directors were deemed to be interested in the ordinary shares of all the subsidiaries to the extent that the Company has an interest.

Other than those disclosed above, none of the other Director holding office at the end of the financial year held any interest in the ordinary shares of the Company and of its related corporations during the financial year.

DIRECTORS' REPORT (CONT'D)

DIRECTORS' BENEFITS

Since the end of the previous financial year, none of the Directors have received or become entitled to receive any benefit (other than those benefits included in the aggregate amount of remuneration received or due and receivable by the Directors) by reason of a contract made by the Company or a related corporation with the Director or with a firm of which the Director is a member, or with a company in which the Director has a substantial financial interest, other than the following:

- (a) Certain Directors who may be deemed to derive benefits by virtue of trade transactions entered into with companies in which certain Directors have substantial financial interests; and
- (b) Certain Directors who received remuneration from the subsidiaries as Directors of the subsidiaries.

There were no arrangements made during and at the end of the financial year, to which the Company is a party, which had the object of enabling the Directors to acquire benefits by means of the acquisition of shares in or debentures of the Company or any other body corporate.

DIRECTORS' REMUNERATION

Directors' remuneration of the Group and of the Company for the financial year ended 31 July 2025 were as follows:

	Group RM	Company RM
Fee	180,000	180,000
Salaries and other emoluments	633,510	3,000
Contributions to defined contribution plan	51,744	0
Social security contributions	1,092	0
Other benefits	125	0
	<u>866,471</u>	<u>183,000</u>

INDEMNITY AND INSURANCE FOR DIRECTORS, OFFICERS AND AUDITORS

There were no indemnity given to or insurance effected for the Directors, officers and auditors of the Group and of the Company during the financial year.

OTHER STATUTORY INFORMATION REGARDING THE GROUP AND THE COMPANY

(I) AS AT END OF THE FINANCIAL YEAR

- (a) Before the financial statements of the Group and of the Company were prepared, the Directors took reasonable steps:
 - (i) to ascertain that proper action had been taken in relation to the writing off of bad debts and the making of provision for doubtful debts and had satisfied themselves that there are no known bad debts to be written off and that adequate provision had been made for doubtful debts; and
 - (ii) to ensure that any current assets other than debts, which were unlikely to realise their book values in the ordinary course of business had been written down to their estimated realisable values.
- (b) In the opinion of the Directors, the results of the operations of the Group and of the Company during the financial year have not been substantially affected by any item, transaction or event of a material and unusual nature.

DIRECTORS' REPORT (CONT'D)

OTHER STATUTORY INFORMATION REGARDING THE GROUP AND THE COMPANY (Cont'd)

(II) FROM THE END OF THE FINANCIAL YEAR TO THE DATE OF THIS REPORT

- (c) The Directors are not aware of any circumstances:
 - (i) which would necessitate the writing off of bad debts or render the amount of the provision for doubtful debts in the financial statements of the Group and of the Company inadequate to any material extent;
 - (ii) which would render the values attributed to current assets in the financial statements of the Group and of the Company misleading; and
 - (iii) which have arisen which would render adherence to the existing method of valuation of assets or liabilities of the Group and of the Company misleading or inappropriate.
- (d) In the opinion of the Directors:
 - (i) there has not arisen any item, transaction or event of a material and unusual nature which is likely to affect substantially the results of operations of the Group and of the Company for the financial year in which this report is made; and
 - (ii) no contingent or other liability has become enforceable, or is likely to become enforceable, within the period of twelve (12) months after the end of the financial year which would or may affect the ability of the Group and of the Company to meet their obligations as and when they fall due.

(III) AS AT THE DATE OF THIS REPORT

- (e) There are no charges on the assets of the Group and of the Company which have arisen since the end of the financial year to secure the liabilities of any other person.
- (f) There are no contingent liabilities of the Group and of the Company which have arisen since the end of the financial year.
- (g) The Directors are not aware of any circumstances not otherwise dealt with in this report or the financial statements which would render any amount stated in the financial statements of the Group and of the Company misleading.

DIRECTORS' REPORT (CONT'D)

SUBSIDIARIES

The details of the subsidiaries are as follows:

Name of company	Country of incorporation/ Principal place of business	Effective interest in equity		Principal activities
		2025 %	2024 %	
Actimed Healthcare Sdn. Bhd.	Malaysia	100	100	Marketing and distribution of medical devices
Evo Medik Sdn. Bhd.	Malaysia	100	100	Marketing and distribution of medical devices as well as provision of after-sale service, healthcare and other related services and to operate nursing homes and healthcare centres as well as the provision of other related services
U Medihealth Sdn. Bhd.	Malaysia	100	100	Marketing and distribution of medical devices
UMediC Healthcare Sdn. Bhd.	Malaysia	100	100	Marketing and distribution of medical devices as well as provision of after-sale services, training, healthcare and other related services
UWHC Sdn. Bhd.	Malaysia	100	100	Holding of intellectual property rights
UWHM Sdn. Bhd.	Malaysia	100	100	Developing, manufacturing and marketing of medical devices
Patho Solutions (M) Sdn. Bhd.	Malaysia	70	70	Marketing and distribution of laboratory equipment and consumables
Akiteck (Malaysia) Sdn. Bhd.	Malaysia	70	70	Design, assembly and distribution of medical mounting solution products and related parts
Ateria Medika Sdn. Bhd.	Malaysia	90	90	Import, export, marketing and distribution of medical devices as well as the provision of after-sales service
Rescue Medic Sdn. Bhd.	Malaysia	85	0	Marketing and distribution of medical devices as well as the provision of after-sales service, healthcare and other related services

DIRECTORS' REPORT (CONT'D)

AUDITORS

The auditors, BDO PLT (201906000013 (LLP0018825-LCA) & AF 0206), have expressed their willingness to continue in office.

Auditors' remuneration of the Group and of the Company for the financial year ended 31 July 2025 were as follows:

	Group RM	Company RM
Statutory audit	93,500	31,100
Non-statutory audit	6,500	6,500
	<u>100,000</u>	<u>37,600</u>

Signed on behalf of the Board in accordance with a resolution of the Directors.

Dato' Seri Ng Chai Eng
Director

Lim Taw Seong
Director

Penang
7 November 2025

STATEMENT BY DIRECTORS

In the opinion of the Directors, the financial statements set out on pages 98 to 139 have been drawn up in accordance with Malaysian Financial Reporting Standards, IFRS Accounting Standards and the provisions of the Companies Act 2016 in Malaysia so as to give a true and fair view of the financial position of the Group and of the Company as at 31 July 2025 and of the financial performance and cash flows of the Group and of the Company for the financial year then ended.

On behalf of the Board,

Dato' Seri Ng Chai Eng
Director

Lim Taw Seong
Director

Penang
7 November 2025

STATUTORY DECLARATION

I, Lim Taw Seong (I/C No. 781014-07-5121), being the Director primarily responsible for the financial management of UMediC Group Berhad, do solemnly and sincerely declare that the financial statements set out on pages 98 to 139 are, to the best of my knowledge and belief, correct and I make this solemn declaration conscientiously believing the same to be true and by virtue of the provisions of the Statutory Declarations Act, 1960.

Subscribed and solemnly declared by the
abovenamed at Georgetown in the State of Penang
this 7 November 2025.

Lim Taw Seong

Before me,

Commissioner for Oaths

INDEPENDENT AUDITORS' REPORT

TO THE MEMBERS OF UMEDIC GROUP BERHAD

Report on the Audit of the Financial Statements

Opinion

We have audited the financial statements of UMediC Group Berhad, which comprise the statements of financial position as at 31 July 2025 of the Group and of the Company, and the statements of profit or loss and other comprehensive income, statements of changes in equity and statements of cash flows of the Group and of the Company for the financial year then ended, and notes to the financial statements, including material accounting policy information, as set out on pages 98 to 139.

In our opinion, the accompanying financial statements give a true and fair view of the financial position of the Group and of the Company as at 31 July 2025, and of their financial performance and their cash flows for the financial year then ended in accordance with Malaysian Financial Reporting Standards ('MFRSs'), IFRS Accounting Standards and the requirements of the Companies Act 2016 in Malaysia.

Basis for Opinion

We conducted our audit in accordance with approved standards on auditing in Malaysia and International Standards on Auditing ('ISAs'). Our responsibilities under those standards are further described in the *Auditors' Responsibilities for the Audit of the Financial Statements* section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence and Other Ethical Responsibilities

We are independent of the Group and of the Company in accordance with the *By-Laws (on Professional Ethics, Conduct and Practice)* of the Malaysian Institute of Accountants ('By-Laws') and the International Ethics Standards Board for Accountants' *International Code of Ethics for Professional Accountants (including International Independence Standards)* ('IESBA Code'), and we have fulfilled our other ethical responsibilities in accordance with the By-Laws and the IESBA Code.

Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial statements of the Group and of the Company for the current year. These matters were addressed in the context of our audit of the financial statements of the Group and of the Company as a whole, in forming our opinion thereon, and we do not provide a separate opinion on these matters.

Key Audit Matters of the Group

1. Impairment of trade receivables

Gross trade receivables of the Group as at 31 July 2025 were RM11,460,337 as disclosed in Note 9 to the financial statements.

We determined this to be key audit matter because it requires management to exercise significant judgement in determining the probability of default by trade receivables and appropriate forward-looking information.

Audit response

Our audit procedures included the following:

- (a) Recomputed the probability of default using historical data and forward-looking information adjustment applied by the Group;
- (b) Recomputed the correlation coefficient between the macroeconomic indicators used by the Group and historical credit losses to determine the appropriateness of the forward-looking information used by the Group; and
- (c) Inquired of management to assess the rationale underlying the relationship between the forward-looking information and expected credit losses.

We have determined that there are no key audit matters to communicate in our report in respect of the audit of the financial statements of the Company.

INDEPENDENT AUDITORS' REPORT (CONT'D)

TO THE MEMBERS OF UMEDIC GROUP BERHAD

Information Other than the Financial Statements and Auditors' Report Thereon

The Directors of the Company are responsible for the other information. The other information comprises the information included in the annual report, but does not include the financial statements of the Group and of the Company and our auditors' report thereon.

Our opinion on the financial statements of the Group and of the Company does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial statements of the Group and of the Company, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements of the Group and of the Company or our knowledge obtained in the audit or otherwise appears to be materially misstated.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

Responsibilities of the Directors for the Financial Statements

The Directors of the Company are responsible for the preparation of financial statements of the Group and of the Company that give a true and fair view in accordance with MFRSs, IFRS Accounting Standards, and the requirements of the Companies Act 2016 in Malaysia. The Directors are also responsible for such internal control as the Directors determine is necessary to enable the preparation of financial statements of the Group and of the Company that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements of the Group and of the Company, the Directors are responsible for assessing the ability of the Group and of the Company to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the Group or the Company or to cease operations, or have no realistic alternative but to do so.

Auditors' Responsibilities for the Audit of the Financial Statements

Our objectives are to obtain reasonable assurance about whether the financial statements of the Group and of the Company as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with approved standards on auditing in Malaysia and ISAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

As part of an audit in accordance with approved standards on auditing in Malaysia and ISAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- (a) Identify and assess the risks of material misstatement of the financial statements of the Group and of the Company, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- (b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the internal control of the Group and of the Company.
- (c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Directors.

INDEPENDENT AUDITORS' REPORT (CONT'D)

TO THE MEMBERS OF UMEDIC GROUP BERHAD

Auditors' Responsibilities for the Audit of the Financial Statements (Cont'd)

As part of an audit in accordance with approved standards on auditing in Malaysia and ISAs, we exercise professional judgement and maintain professional scepticism throughout the audit. We also: (Cont'd)

- (d) Conclude on the appropriateness of the Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the ability of the Group and of the Company to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditors' report to the related disclosures in the financial statements of the Group and of the Company or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditors' report. However, future events or conditions may cause the Group or the Company to cease to continue as a going concern.
- (e) Evaluate the overall presentation, structure and content of the financial statements of the Group and of the Company, including the disclosures, and whether the financial statements of the Group and of the Company represent the underlying transactions and events in a manner that achieves fair presentation.
- (f) Plan and perform the group audit to obtain sufficient appropriate audit evidence regarding the financial information of the entities or business units within the Group as a basis for forming an opinion on the financial statements of the Group. We are responsible for the direction, supervision and review of the audit work performed for purposes of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide the Directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the Directors, we determine those matters that were of most significance in the audit of the financial statements of the Group and of the Company for the current year and are therefore the key audit matters. We describe these matters in our auditors' report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

Other Matters

This report is made solely to the members of the Company, as a body, in accordance with Section 266 of the Companies Act 2016 in Malaysia and for no other purpose. We do not assume responsibility to any other person for the content of this report.

BDO PLT
201906000013 (LLP0018825-LCA) & AF 0206
Chartered Accountants

Penang
7 November 2025

Goh Chee Beng
03535/11/2026 J
Chartered Accountant

STATEMENTS OF FINANCIAL POSITION

AS AT 31 JULY 2025

		Group		Company	
	Note	2025 RM	2024 RM	2025 RM	2024 RM
ASSETS					
Non-current assets					
Property, plant and equipment	5	33,499,591	28,302,435	0	0
Right-of-use assets	6	4,637,691	4,689,277	0	0
Investments in subsidiaries	7	0	0	15,295,271	15,135,225
Goodwill on consolidation	8	287,237	287,237	0	0
Other receivables	9	0	0	14,265,025	12,647,034
Deferred tax assets	10	4,129	0	0	0
		38,428,648	33,278,949	29,560,296	27,782,259
Current assets					
Inventories	11	18,947,262	14,569,390	0	0
Trade and other receivables	9	15,024,995	20,131,390	2,983,770	2,898,747
Current tax assets		2,256,720	1,218,404	1,780	0
Short term funds	12	4,949,869	9,278,269	4,949,869	9,278,269
Cash and bank balances	13	11,616,715	4,231,579	37,518	77,663
		52,795,561	49,429,032	7,972,937	12,254,679
TOTAL ASSETS		91,224,209	82,707,981	37,533,233	40,036,938
EQUITY AND LIABILITIES					
Equity attributable to equity holders of the Company					
Share capital	14	44,348,333	44,348,333	44,348,333	44,348,333
Reserves	15	35,769,919	27,636,341	(6,875,778)	(6,531,919)
		80,118,252	71,984,674	37,472,555	37,816,414
Non-controlling interests	7(e)	1,234,159	788,678	0	0
TOTAL EQUITY		81,352,411	72,773,352	37,472,555	37,816,414
LIABILITIES					
Non-current liabilities					
Borrowings	16	0	256,221	0	0
Lease liabilities	6	7,841	0	0	0
Government grants	17	2,133,083	2,503,040	0	0
Deferred tax liabilities	10	1,948,188	1,150,617	0	0
		4,089,112	3,909,878	0	0
Current liabilities					
Trade and other payables	18	5,232,084	4,444,740	60,678	2,220,524
Borrowings	16	0	605,656	0	0
Lease liabilities	6	40,208	14,287	0	0
Government grants	17	496,598	430,519	0	0
Current tax liabilities		13,796	529,549	0	0
		5,782,686	6,024,751	60,678	2,220,524
TOTAL LIABILITIES		9,871,798	9,934,629	60,678	2,220,524
TOTAL EQUITY AND LIABILITIES		91,224,209	82,707,981	37,533,233	40,036,938

The accompanying notes form an integral part of the financial statements.

STATEMENTS OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

FOR THE FINANCIAL YEAR ENDED 31 JULY 2025

	Note	Group		Company	
		2025 RM	2024 RM	2025 RM	2024 RM
Revenue	21	48,564,379	54,570,002	140,000	0
Cost of sales		(26,201,263)	(31,898,890)	0	0
Gross profit		22,363,116	22,671,112	140,000	0
Other income		1,450,730	1,560,952	2,399,272	360,258
Net losses on impairment of financial assets	9	(201,076)	(25,835)	(695,715)	(2,493,390)
Marketing expenses		(1,308,483)	(1,145,221)	(7,776)	(8,582)
Administrative and other expenses		(11,386,358)	(10,284,668)	(2,178,889)	(1,794,226)
Finance costs	23	(67,160)	(135,820)	0	0
Profit/(Loss) before tax		10,850,769	12,640,520	(343,108)	(3,935,940)
Taxation	24	(2,586,580)	(3,343,610)	(751)	282
Profit/(Loss) for the financial year		<u>8,264,189</u>	<u>9,296,910</u>	<u>(343,859)</u>	<u>(3,935,658)</u>
Profit/(Loss) for the financial year attributable to:					
Equity holders of the Company		8,133,578	8,990,693	(343,859)	(3,935,658)
Non-controlling interests	7(e)	<u>130,611</u>	<u>306,217</u>	<u>0</u>	<u>0</u>
		<u>8,264,189</u>	<u>9,296,910</u>	<u>(343,859)</u>	<u>(3,935,658)</u>
Other comprehensive income, net of tax		<u>0</u>	<u>0</u>	<u>0</u>	<u>0</u>
Total comprehensive income/ (loss), attributable to:					
Equity holders of the Company		8,133,578	8,990,693	(343,859)	(3,935,658)
Non-controlling interests	7(e)	<u>130,611</u>	<u>306,217</u>	<u>0</u>	<u>0</u>
		<u>8,264,189</u>	<u>9,296,910</u>	<u>(343,859)</u>	<u>(3,935,658)</u>
Earnings per share attributable to equity holders of the Company:					
Basic and diluted (sen)	26	<u>2.18</u>	<u>2.40</u>		

The accompanying notes form an integral part of the financial statements.

CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

FOR THE FINANCIAL YEAR ENDED 31 JULY 2025

Group	Share capital RM	Reorganisation debit reserve RM	Retained earnings RM	Total attributable to equity holders of the Company RM	Non- controlling interests RM	Total equity RM
Balance as at 1 August 2023	44,348,333	(6,851,755)	25,497,403	62,993,981	482,331	63,476,312
Profit for the financial year	0	0	8,990,693	8,990,693	306,217	9,296,910
Other comprehensive income, net of tax	0	0	0	0	0	0
Total comprehensive income	0	0	8,990,693	8,990,693	306,217	9,296,910
<u>Transaction with owners</u>						
Issuance of subsidiaries' shares to non-controlling interest	0	0	0	0	130	130
Total transaction with owners	0	0	0	0	130	130
Balance as at 31 July 2024	44,348,333	(6,851,755)	34,488,096	71,984,674	788,678	72,773,352
Balance as at 1 August 2024	44,348,333	(6,851,755)	34,488,096	71,984,674	788,678	72,773,352
Profit for the financial year	0	0	8,133,578	8,133,578	130,611	8,264,189
Other comprehensive income, net of tax	0	0	0	0	0	0
Total comprehensive income	0	0	8,133,578	8,133,578	130,611	8,264,189
<u>Transactions with owners</u>						
Issuance of subsidiaries' shares to non-controlling interest	0	0	0	0	374,870	374,870
Dividend paid to non-controlling interest by subsidiary	0	0	0	0	(60,000)	(60,000)
Total transactions with owners	0	0	0	0	314,870	314,870
Balance as at 31 July 2025	44,348,333	(6,851,755)	42,621,674	80,118,252	1,234,159	81,352,411

The accompanying notes form an integral part of the financial statements.

STATEMENT OF CHANGES IN EQUITY

FOR THE FINANCIAL YEAR ENDED 31 JULY 2025

Company	Share capital RM	Accumulated losses RM	Total equity RM
Balance as at 1 August 2023	44,348,333	(2,596,261)	41,752,072
Loss for the financial year	0	(3,935,658)	(3,935,658)
Other comprehensive income, net of tax	0	0	0
Total comprehensive loss	0	(3,935,658)	(3,935,658)
Balance as at 31 July 2024	44,348,333	(6,531,919)	37,816,414
Balance as at 1 August 2024	44,348,333	(6,531,919)	37,816,414
Loss for the financial year	0	(343,859)	(343,859)
Other comprehensive income, net of tax	0	0	0
Total comprehensive loss	0	(343,859)	(343,859)
Balance as at 31 July 2025	44,348,333	(6,875,778)	37,472,555

The accompanying notes form an integral part of the financial statements.

STATEMENTS OF CASH FLOWS

FOR THE FINANCIAL YEAR ENDED 31 JULY 2025

	Note	Group		Company	
		2025 RM	2024 RM	2025 RM	2024 RM
CASH FLOWS FROM OPERATING ACTIVITIES					
Profit/(Loss) before tax		10,850,769	12,640,520	(343,108)	(3,935,940)
Adjustments for:					
Depreciation of:					
- property, plant and equipment	5	2,844,444	2,368,787	0	0
- right-of-use assets	6	123,773	129,027	0	0
Amortisation of government grants	17	(369,957)	(369,957)	0	0
Dividend income		0	0	(140,000)	0
Finance costs	23	67,160	135,820	0	0
Net losses on impairment of trade and other receivables		201,076	25,835	695,715	2,493,390
Interest income		(317,340)	(202,139)	(6,669)	(5,693)
Impairment losses on investments in subsidiaries	7(b)	0	0	1,670,564	0
Distribution income from short-term funds		(221,600)	(372,997)	(221,600)	(354,565)
Property, plant and equipment written off		0	4,825	0	0
Loss on fair value adjustment on derivative assets		0	5,625	0	0
Unrealised loss/(gain) on foreign exchange		133,877	(58,372)	0	0
Waiver of debt by subsidiaries		0	0	(2,171,000)	0
Operating profit/(loss) before changes in working capital		13,312,202	14,306,974	(516,098)	(1,802,808)
Increase in inventories		(4,377,872)	(2,055,181)	0	0
Decrease/(Increase) in trade and other receivables		4,767,893	(7,358,997)	371	(371)
Increase/(Decrease) in trade and other payables		763,787	1,875,581	11,154	(2,898)
Cash generated from/(used in) operations		14,466,010	6,768,377	(504,573)	(1,806,077)
Government grants received	17	66,079	60,562	0	0
Tax paid		(3,408,491)	(2,887,163)	(2,531)	0
Tax refunded		61,284	179,839	0	0
Net cash from/(used in) operating activities		11,184,882	4,121,615	(507,104)	(1,806,077)

STATEMENTS OF CASH FLOWS (CONT'D)

FOR THE FINANCIAL YEAR ENDED 31 JULY 2025

		Group		Company	
	Note	2025 RM	2024 RM	2025 RM	2024 RM
CASH FLOWS FROM INVESTING ACTIVITIES					
Subscription of shares in subsidiaries		0	0	(1,874,030)	(970)
Dividend received	21	0	0	140,000	0
Dividend paid to non-controlling interest	7(e)	(60,000)	0	0	0
Final distribution from subsidiaries		0	0	43,420	0
Interest received		317,340	202,139	6,669	5,693
Net advance to subsidiaries		0	0	(2,399,100)	(3,258,500)
Purchase of short-term funds		(4,500,000)	(5,150,000)	(4,500,000)	(3,850,000)
Purchase of property, plant and equipment	5	(8,041,600)	(6,305,673)	0	0
Proceeds from disposal of short-term funds		9,050,000	8,118,432	9,050,000	6,800,000
Net cash (used in)/from investing activities		(3,234,260)	(3,135,102)	466,959	(303,777)
Net advance from subsidiaries		0	0	0	2,171,000
Issuance of subsidiaries' shares to non-controlling interest		374,870	130	0	0
Repayment of term loans		(861,877)	(2,726,429)	0	0
Interest paid		(65,810)	(134,445)	0	0
Payment of lease liabilities	6	(39,775)	(45,830)	0	0
Net cash (used in)/from financing activities		(592,592)	(2,906,574)	0	2,171,000
Net increase/(decrease) in cash and cash equivalents		7,358,030	(1,920,061)	(40,145)	61,146
Effect of foreign exchange rates changes		27,106	45,012	0	0
Cash and cash equivalents at beginning of financial year		4,231,579	6,106,628	77,663	16,517
Cash and cash equivalents at end of financial year	13	11,616,715	4,231,579	37,518	77,663

STATEMENTS OF CASH FLOWS (CONT'D)

FOR THE FINANCIAL YEAR ENDED 31 JULY 2025

Reconciliation of liabilities arising from financing activities

Group	Lease liabilities (Note 6) RM	Term loans (Note 16) RM	Total RM
Balance as at 1 August 2024	14,287	861,877	876,164
Cash flows	(39,775)	(861,877)	(901,652)
Non-cash flows:			
- addition	72,187	0	72,187
- unwinding of interest	1,350	0	1,350
Balance as at 31 July 2025	48,049	0	48,049
Balance as at 1 August 2023	50,616	3,588,306	3,638,922
Cash flows	(45,830)	(2,726,429)	(2,772,259)
Non-cash flows:			
- addition	8,126	0	8,126
- unwinding of interest	1,375	0	1,375
Balance as at 31 July 2024	14,287	861,877	876,164

Amounts owing to subsidiaries (Note 18)

Company	2025 RM	2024 RM
Balance as at 1 August 2024/2023	2,171,000	0
Cash flows	0	2,171,000
Non-cash flow:		
- waiver of debt by subsidiaries	(2,171,000)	0
Balance as at 31 July	0	2,171,000

The accompanying notes form an integral part of the financial statements.

NOTES TO THE FINANCIAL STATEMENTS

31 JULY 2025

1. CORPORATE INFORMATION

The Company is a public limited liability company, incorporated and domiciled in Malaysia, and is listed on the Main Market of Bursa Malaysia Securities Berhad.

The registered office of the Company is located at 39, Irving Road, 10400 George Town, Pulau Pinang.

The principal place of business of the Company is located at PMT 790, Jalan Cassia Selatan 5/2, Taman Perindustrian Batu Kawan, 14110 Bandar Cassia, Pulau Pinang.

The consolidated financial statements for the financial year ended 31 July 2025 comprise the Company and its subsidiaries. These financial statements are presented in Ringgit Malaysia ('RM'), which is also the functional currency of the Company.

The financial statements were authorised for issue in accordance with a resolution by the Board of Directors on 7 November 2025.

2. PRINCIPAL ACTIVITIES

The Company is principally engaged as investment holding company. The principal activities of subsidiaries are mainly developing, manufacturing, marketing, design, assembly, import, export, distribution of medical devices and medical mounting solutions products as well as provision of after-sale services, and operating of nursing homes and healthcare centres. The details of the subsidiaries are set out in Note 7 to the financial statements.

There have been no significant changes in the nature of the activities of the Company and its subsidiaries during the financial year.

3. BASIS OF PREPARATION

The financial statements of the Group and of the Company have been prepared in accordance with Malaysian Financial Reporting Standards ('MFRSs'), IFRS Accounting Standards and the provisions of the Companies Act 2016 in Malaysia.

The accounting policies adopted are consistent with those of the previous financial year except for the effects of adoption of new MFRSs during the financial year. The Amendments to MFRSs adopted during the financial year are disclosed in Note 30.1 to the financial statements.

The financial statements of the Group and of the Company have been prepared under the historical cost convention except as otherwise stated in the financial statements.

4. OPERATING SEGMENTS

The Group is principally involved in investment holding. Through its subsidiaries, the Group is principally involved in manufacturing, marketing and distribution of various branded medical devices, consumables and mounting solutions products as well as the provision of after-sales service for all its products, and operating of nursing homes and healthcare centres.

For management purposes, the Group is organised into business units based on its products and services. The reportable segments of the Group are as follows:

- (a) Marketing and distribution - marketing and distribution of medical devices as well as the provision of after-sales service, operating of nursing homes and healthcare centres, and investment holding.
- (b) Manufacturing - developing, manufacturing and marketing of medical devices.

Management monitors the operating results of its business units separately for the purpose of making decisions about resource allocation and performance assessment.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

4. OPERATING SEGMENTS (Cont'd)

The accounting policies of operating segments are the same as those described in the respective notes to the financial statements.

Inter-segment revenue is priced along the same lines as sales to external customers and is eliminated in the financial statements. These policies have been applied consistently throughout the financial years.

Segment assets exclude short term funds, cash and bank balances, and tax assets. Segment liabilities exclude tax liabilities. Even though borrowings arose from financing activities rather than operating activities, they were allocated to the segments based on relevant factors (e.g. funding requirements).

31 July 2025	Manufacturing RM	Marketing and distribution RM	Eliminations RM	Consolidated RM
Revenue from external customers	16,365,586	32,198,793	0	48,564,379
Inter-segment revenue	3,134,355	0	(3,134,355)	0
Total revenue	19,499,941	32,198,793	(3,134,355)	48,564,379
Interest income and distribution income from short-term funds	216,088	322,852	0	538,940
Interest expense	(20,482)	(60,296)	13,618	(67,160)
Net interest expense	195,606	262,556	13,618	471,780
Segment profit before tax	5,015,289	5,815,849	19,631	10,850,769
Taxation	(887,432)	(1,699,148)	0	(2,586,580)
Other material non-cash items:				
- Depreciation of property, plant and equipment	(2,201,018)	(728,805)	85,379	(2,844,444)
- Depreciation of right-of-use assets	(508,382)	(73,730)	458,339	(123,773)
- Depreciation of investment properties	0	(135,422)	135,422	0
- Amortisation of government grants	(369,957)	0	0	(369,957)
- Impairment losses on trade receivables	(58,887)	(142,189)	0	(201,076)
Additions to non-current assets other than financial instruments	6,768,613	2,591,384	(1,246,210)	8,113,787
Assets				
Segment assets	25,551,517	71,526,559	(24,681,300)	72,396,776
Deferred tax assets	0	4,129	0	4,129
Short term funds	0	4,949,869	0	4,949,869
Cash and bank balances	8,402,851	3,213,864	0	11,616,715
Current tax assets	532,832	1,723,888	0	2,256,720
				91,224,209
Liabilities				
Segment liabilities	12,087,234	3,784,149	(7,961,569)	7,909,814
Deferred tax liabilities	1,471,000	477,188	0	1,948,188
Current tax liabilities	0	13,796	0	13,796
				9,871,798

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

4. OPERATING SEGMENTS (Cont'd)

31 July 2024	Manufacturing RM	Marketing and distribution RM	Eliminations RM	Consolidated RM
Revenue from external customers	18,378,823	36,191,179	0	54,570,002
Inter-segment revenue	1,617,296	0	(1,617,296)	0
Total revenue	19,996,119	36,191,179	(1,617,296)	54,570,002
Interest income and distribution income from short-term funds	138,294	436,842	0	575,136
Interest expense	(23,068)	(121,206)	8,454	(135,820)
Net interest expense	115,226	315,636	8,454	439,316
Segment profit before tax	5,491,540	7,218,862	(69,882)	12,640,520
Taxation	(1,673,734)	(1,669,876)	0	(3,343,610)
Other material non-cash items:				
-Depreciation of property, plant and equipment	(1,963,104)	(473,495)	67,812	(2,368,787)
-Depreciation of right-of-use assets	(347,104)	(78,984)	297,061	(129,027)
-Depreciation of investment properties	0	(117,855)	117,855	0
-Amortisation of government grants	(369,957)	0	0	(369,957)
-Impairment losses on trade receivables	0	(25,835)	0	(25,835)
Additions to non-current assets other than financial instruments	673,420	5,640,379	0	6,313,799
Assets				
Segment assets	22,854,713	63,191,269	(18,066,253)	67,979,729
Short term funds	0	9,278,269	0	9,278,269
Cash and bank balances	2,617,453	1,614,126	0	4,231,579
Current tax assets	6,292	1,212,112	0	1,218,404
				82,707,981
Liabilities				
Segment liabilities	7,476,904	3,935,060	(3,157,501)	8,254,463
Deferred tax liabilities	793,000	357,617	0	1,150,617
Current tax liabilities	407,445	122,104	0	529,549
				9,934,629

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

4. OPERATING SEGMENTS (Cont'd)

(a) Geographical information

In determining the geographical segment of the Group, revenue is based on the geographical location of customers. Segment assets are based on the geographical location of the assets.

	Group	
	2025	2024
	RM	RM
Revenue from external customers		
Malaysia	32,974,980	36,163,123
Asia Pacific (excluding Malaysia)	4,689,029	5,574,211
Americas	1,596,806	1,798,315
Europe	7,706,673	10,046,401
Middle East	544,238	252,452
Africa	110,655	330,234
Oceania	941,998	405,266
	<u>48,564,379</u>	<u>54,570,002</u>
Segment assets		
Malaysia	<u>72,396,776</u>	<u>67,979,729</u>

(b) Major customers

There are no major customers with revenue equal or more than ten percent (10%) of the revenue of the Group.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

5. PROPERTY, PLANT AND EQUIPMENT

Group	Freehold land RM	Buildings* RM	Solar PV systems RM	Plant and machinery RM	Tools & production equipment RM	Furniture, fittings, office equipment and computer system RM	Motor vehicles RM	Mould and simulator RM	Renovation RM	Capital work-in-progress RM	Total RM
At cost											
Balance as at 1 August 2024	460,000	9,352,472	525,000	15,141,442	1,793,215	1,580,420	269,589	909,165	1,146,487	4,664,006	35,841,796
Additions	0	9,650	0	3,622,000	1,211,873	544,780	0	254,000	1,229,375	1,169,922	8,041,600
Reclassification	0	5,339,036	0	0	0	0	0	0	0	(5,339,036)	0
Balance as at 31 July 2025	460,000	14,701,158	525,000	18,763,442	3,005,088	2,125,200	269,589	1,163,165	2,375,862	494,892	43,883,396
Accumulated depreciation											
Balance as at 1 August 2024	0	433,333	13,125	4,615,715	701,428	880,596	123,040	363,550	408,574	0	7,539,361
Current charge	0	222,427	52,500	1,715,926	272,179	222,527	52,367	97,454	209,064	0	2,844,444
Balance as at 31 July 2025	0	655,760	65,625	6,331,641	973,607	1,103,123	175,407	461,004	617,638	0	10,383,805
Carrying amount											
31 July 2025	460,000	14,045,398	459,375	12,431,801	2,031,481	1,022,077	94,182	702,161	1,758,224	494,892	33,499,591

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

5. PROPERTY, PLANT AND EQUIPMENT (CONT'D)

Group	Freehold land RM	Buildings* RM	Solar PV systems RM	Plant and machinery RM	Tools & production equipment RM	Furniture, fittings, office equipment and computer system RM	Motor vehicles RM	Mould and simulator RM	Renovation RM	Capital work-in-progress RM	Total RM
At cost											
Balance as at 1 August 2023	0	7,512,472	0	14,762,352	1,741,341	1,474,200	269,589	668,665	638,320	2,479,917	29,546,856
Additions	460,000	1,840,000	525,000	309,090	50,074	109,953	0	240,500	477,883	2,293,173	6,305,673
Written off	0	0	0	0	(7,000)	(3,733)	0	0	0	0	(10,733)
Reclassification	0	0	0	70,000	8,800	0	0	0	30,284	(109,084)	0
Balance as at 31 July 2024	460,000	9,352,472	525,000	15,141,442	1,793,215	1,580,420	269,589	909,165	1,146,487	4,664,006	35,841,796
Accumulated depreciation											
Balance as at 1 August 2023	0	298,503	0	3,120,755	469,562	673,001	69,122	286,180	259,359	0	5,176,482
Current charge	0	134,830	13,125	1,494,960	235,715	209,654	53,918	77,370	149,215	0	2,368,787
Written off	0	0	0	0	(3,849)	(2,059)	0	0	0	0	(5,908)
Balance as at 31 July 2024	0	433,333	13,125	4,615,715	701,428	880,596	123,040	363,550	408,574	0	7,539,361
Carrying amount											
31 July 2024	460,000	8,919,139	511,875	10,525,727	1,091,787	699,824	146,549	545,615	737,913	4,664,006	28,302,435

* Included in buildings are leasehold buildings and freehold building amounting to RM12,236,000 and RM1,809,398 (2024: RM7,082,206 and RM1,836,933) respectively.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

5. PROPERTY, PLANT AND EQUIPMENT (CONT'D)

- (a) All items of property, plant and equipment are initially measured at cost. Cost includes expenditure that is directly attributable to the acquisition of the asset. After initial recognition, property, plant and equipment are stated at cost less accumulated depreciation and any accumulated impairment losses.
- (b) Depreciation is calculated to write down the cost of the assets to their residual values on a straight line basis over their estimated useful lives. The principal depreciation periods and annual rates are as follows:

Buildings	2%
Solar PV systems	10%
Plant and machinery	10%
Tools & production equipment	10% to 20%
Furniture, fittings, office equipment and computer system	10% to 20%
Motor vehicles	20%
Mould and simulator	10% to 20%
Renovation	10% to 20%

- (c) Freehold land has unlimited useful life and is not depreciated. Capital work-in-progress represents machinery under installation and factory building under construction. Capital work-in-progress is not depreciated until such time when the asset is available for use.
- (d) The carrying amount of property, plant and equipment of the Group which have been pledged to licensed banks for banking facilities granted to the Group as referred to in Note 16 to the financial statements are as follows:

	Group	
	2025	2024
	RM	RM
Leasehold buildings	12,236,000	7,082,206

6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES

The Group as lessee

Right-of-use assets

	Balance as at	Addition	Depreciation	Balance as at
Carrying amount	1.8.2024	RM	charge for the	31.7.2025
	RM		financial	RM
			year	
			RM	
Leasehold land	4,675,318	0	(85,264)	4,590,054
Offices	6,965	10,862	(8,517)	9,310
Warehouse	6,994	61,325	(29,992)	38,327
	<u>4,689,277</u>	<u>72,187</u>	<u>(123,773)</u>	<u>4,637,691</u>

	Balance as at	Addition	Depreciation	Balance as at
Carrying amount	1.8.2023	RM	charge for the	31.7.2024
	RM		financial	RM
			year	
			RM	
Leasehold land	4,760,582	0	(85,264)	4,675,318
Offices	14,622	8,126	(15,783)	6,965
Warehouse	34,974	0	(27,980)	6,994
	<u>4,810,178</u>	<u>8,126</u>	<u>(129,027)</u>	<u>4,689,277</u>

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (CONT'D)

The Group as lessee (Cont'd)

Lease liabilities

	Balance as at 1.8.2024 RM	Addition RM	Lease payments RM	Interest expenses (Note 23) RM	Balance as at 31.7.2025 RM
Carrying amount					
Offices	6,996	10,862	(8,800)	291	9,349
Warehouse	7,291	61,325	(30,975)	1,059	38,700
	<u>14,287</u>	<u>72,187</u>	<u>(39,775)</u>	<u>1,350</u>	<u>48,049</u>

	Balance as at 1.8.2023 RM	Addition RM	Lease payments RM	Interest expenses (Note 23) RM	Balance as at 31.7.2024 RM
Carrying amount					
Offices	15,016	8,126	(16,430)	284	6,996
Warehouse	35,600	0	(29,400)	1,091	7,291
	<u>50,616</u>	<u>8,126</u>	<u>(45,830)</u>	<u>1,375</u>	<u>14,287</u>

	Group	
	2025 RM	2024 RM
Represented by:		
Current liabilities	40,208	14,287
Non-current liabilities	7,841	0
Lease liabilities owing to non-financial institutions	<u>48,049</u>	<u>14,287</u>

- (a) The Group leases offices, and warehouse in the location which it operates. The leases comprise only fixed payments over the lease terms.
- (b) Right-of-use assets are initially measured at cost, which comprise the initial amount of the lease liabilities adjusted for any lease payments made at or before the commencement date of the leases. After initial recognition, right-of-use assets are stated at cost less accumulated depreciation and any accumulated impairment losses, and adjusted for any remeasurement of the lease liabilities.
- (c) Right-of-use assets are depreciated on the straight-line basis over the earlier of the estimated useful lives of the right-of-use assets or the lease term. The lease terms of right-of-use assets are as follows:
- | | |
|----------------|----------------|
| Leasehold land | 60 years |
| Offices | 12 - 24 months |
| Warehouse | 24 months |
- (d) As at the end of the reporting period, leasehold land of the Group with a total carrying amounts of RM4,590,054 (2024: RM4,675,318) have been charged to licensed bank for credit facilities granted to the Group as disclosed in Note 16 to the financial statements.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (CONT'D)

The Group as lessee (Cont'd)

- (e) The Group has certain leases of offices and equipment with lease terms of twelve (12) months or less and low-value asset of RM20,000 and below. The Group applies the 'short term leases' and 'low-value asset' exemptions for those leases.

- (f) The following are the amounts recognised in profit or loss:

	Group	
	2025	2024
	RM	RM
Depreciation charge of right-of-use assets		
- included in administrative and other expenses	123,773	129,027
Interest expense on lease liabilities		
- included in finance costs	1,350	1,375
Expense relating to short-term leases		
- included in administrative and other expenses	54,573	37,509
Expense relating to leases of low-value assets		
- included in cost of sales	8,290	9,300
- included in administrative and other expenses	37,337	39,108
	<u>225,323</u>	<u>216,319</u>

- (g) The following are total cash outflows for leases as a lessee:

	Group	
	2025	2024
	RM	RM
Included in net cash from operating activities:		
Payment relating to low-value assets and short-term leases	100,200	85,917
Included in net cash from financing activities:		
Payment of lease liabilities	39,775	45,830
Total cash outflows for leases	<u>139,975</u>	<u>131,747</u>

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

6. RIGHT-OF-USE ASSETS AND LEASE LIABILITIES (Cont'd)

The Group as lessee (Cont'd)

- (h) The Group leases several lease contracts that include extension and termination options. These are used to maximise operational flexibility in terms of managing those assets used in the Group's operations. The following are the undiscounted potential future rental payments that are not included in the lease term:

	Group	
	2025	2024
	RM	RM
Extension options expected not to be exercised		
- within five (5) years	49,500	36,600

- (i) Information on maturities profile of the lease liabilities is disclosed in Note 29 to the financial statements.

7. INVESTMENTS IN SUBSIDIARIES

	Company	
	2025	2024
	RM	RM
Unquoted shares, at cost	16,965,835	15,135,225
Less: Impairment losses	(1,670,564)	0
	<u>15,295,271</u>	<u>15,135,225</u>

- (a) Investments in subsidiaries, which are eliminated on consolidation, are stated in the separate financial statements of the Company at cost less impairment losses, if any.

All components of non-controlling interests shall be initially measured at fair value on the acquisition date, unless another measurement basis is required by MFRS. The choice of the measurement basis is made on a combination-by-combination basis. Subsequent to initial recognition, the carrying amount of the non-controlling interests is the amount of those interests at initial recognition plus the non-controlling interests' share of subsequent changes in equity.

- (b) Management reviews the cost of investments in subsidiaries for impairment when there is an indication of impairment. Recoverable amounts of the cost of investments in subsidiaries are assessed by reference to the fair value less cost to sell ('FVLCTS') of the underlying assets or the value-in-use of the respective subsidiaries. Value-in-use is the net present value of the projected future cash flows derived from business operations of the respective subsidiaries discounted at an appropriate pre-tax discount rate. This discounted cash flows method involves the use of estimated future results and a set of assumptions to support their income and cash flows.

During the financial year, an impairment loss of RM1,670,564 (2024: Nil) was recognised to reduce the carrying amounts of certain subsidiaries to their recoverable amounts, arising from the commencement of members' voluntary winding up of two subsidiaries and the decline in operations of loss-making subsidiaries. The recoverable amounts were determined based on FVLCTS, using the subsidiaries' net assets as a proxy, and are categorised as Level 3 in the fair value hierarchy, except for the subsidiaries under winding up, which have no recoverable amounts and have been fully impaired.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

7. INVESTMENTS IN SUBSIDIARIES (CONT'D)

(c) Details of the subsidiaries are as follows:

Name of company	Country of incorporation/ Principal place of business	Effective interest in equity		Principal activities
		2025 %	2024 %	
Actimed Healthcare Sdn. Bhd.^	Malaysia	100	100	Marketing and distribution of medical devices
Evo Medik Sdn. Bhd.	Malaysia	100	100	Marketing and distribution of medical devices as well as provision of after-sale service, healthcare and other related services and to operate nursing homes and healthcare centres as well as the provision of other related services
U Medihealth Sdn. Bhd.^	Malaysia	100	100	Marketing and distribution of medical devices
UMediC Healthcare Sdn. Bhd.	Malaysia	100	100	Marketing and distribution of medical devices as well as provision of after-sale services, training, healthcare and other related services
UWHC Sdn. Bhd.	Malaysia	100	100	Holding of intellectual property rights
UWHM Sdn. Bhd.	Malaysia	100	100	Developing, manufacturing and marketing of medical devices
Patho Solutions (M) Sdn. Bhd.	Malaysia	70	70	Marketing and distribution of laboratory equipment and consumables
Akiteck (Malaysia) Sdn. Bhd.	Malaysia	70	70	Design, assembly and distribution of medical mounting solution products and related parts
Ateria Medika Sdn. Bhd.	Malaysia	90	90	Import, export, marketing and distribution of medical devices as well as the provision of after-sales service
Rescue Medic Sdn. Bhd.*	Malaysia	85	0	Marketing and distribution of medical devices as well as the provision of after-sales service, healthcare and other related services

^ In the process of members' voluntary winding up as of financial year end and completed on 20 August 2025. The results of these subsidiaries are consolidated based on the unaudited financial statements.

* Newly incorporated during the year.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

7. INVESTMENTS IN SUBSIDIARIES (CONT'D)

(d) Changes in investments in subsidiaries

(i) Rescue Medic Sdn. Bhd. ('Rescue Medic')

On 11 March 2025, the Company incorporated Rescue Medic with paid-up share capital RM1,000 comprising of 1,000 ordinary shares. The Company subscribed 850 ordinary shares for a total consideration of RM850. Pursuant to that, the Company holds 850 ordinary shares representing 85% equity interest in Rescue Medic.

On 30 May 2025, Rescue Medic issued additional 999,000 new ordinary shares at RM1 each for a total cash consideration of RM999,000, subscribed by the Company and non-controlling interest in proportion to their existing shareholdings. There were no changes to the percentage of shareholding of the Group on subsidiary arising from this additional investment of RM849,150.

(ii) Ateria Medika Sdn. Bhd. ('Ateria Medika')

On 30 July 2024, the Company incorporated Ateria with paid-up share capital RM1,000 comprising of 1,000 ordinary shares. The Company subscribed 900 ordinary shares for a total consideration of RM900. Pursuant to that, the Company holds 900 ordinary shares representing 90% equity interest in Ateria.

On 10 October 2024, Ateria Medika issued additional 749,000 new ordinary shares at RM1 each for a total cash consideration of RM749,000, subscribed by the Company and non-controlling interest in proportion to their existing shareholdings. There were no changes to the percentage of shareholding of the Group on subsidiary arising from this additional investment of RM674,100.

(iii) Akiteck (Malaysia) Sdn. Bhd. ('Akiteck')

On 20 May 2024, the Company incorporated Akiteck with paid-up share capital RM100 comprising of 100 ordinary shares. The Company subscribed 70 ordinary shares for a total consideration of RM70. Pursuant to that, the Company holds 70 ordinary shares representing 70% equity interest in Akiteck.

On 18 December 2024, Akiteck issued additional 499,900 new ordinary shares at RM1 each for a total cash consideration of RM499,900, subscribed by the Company and non-controlling interest in proportion to their existing shareholdings. There were no changes to the percentage of shareholding of the Group on subsidiary arising from this additional investment of RM349,930.

(iv) U Medihealth Sdn. Bhd. (U Medihealth) and Actimed Healthcare Sdn. Bhd. (Actimed)

During the year, final distribution amounting to RM43,420 were received from U Medihealth and Actimed during the process of members' voluntary winding up. Such distribution were off set against the cost of investment.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

7. INVESTMENTS IN SUBSIDIARIES (CONT'D)

(e) The subsidiaries of the Group that have non-controlling interests ('NCI') are as follows:

31 July 2025	Rescue Medic Sdn. Bhd.	Akiteck (Malaysia) Sdn. Bhd.	Ateria Medika Sdn. Bhd.	Patho Solutions (M) Sdn. Bhd.	Total
NCI percentage of ownership interest and voting interest	15%	30%	10%	30%	
Carrying amount of NCI (RM)	<u>153,263</u>	<u>147,652</u>	<u>71,811</u>	<u>861,433</u>	<u>1,234,159</u>
Profit/(Loss) allocated to NCI (RM)	<u>3,263</u>	<u>4,204</u>	<u>(3,189)</u>	<u>126,333</u>	<u>130,611</u>
Dividend paid to NCI (RM)	<u>0</u>	<u>0</u>	<u>0</u>	<u>60,000</u>	<u>60,000</u>
31 July 2024					
NCI percentage of ownership interest and voting interest		30%	10%	30%	
Carrying amount of NCI (RM)		<u>(6,522)</u>	<u>100</u>	<u>795,100</u>	<u>788,678</u>
(Loss)/Profit allocated to NCI (RM)		<u>(6,552)</u>	<u>0</u>	<u>312,769</u>	<u>306,217</u>

The summarised financial information before intra-group elimination of the subsidiaries are not disclosed as they are not material to the Group.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

8. GOODWILL ON CONSOLIDATION

	Group	
	2025	2024
	RM	RM
As at end of the financial year	<u>287,237</u>	<u>287,237</u>

- (a) Goodwill is initially measured at cost. Subsequent to initial recognition, goodwill is measured at cost less accumulated impairment losses, if any.
- (b) Goodwill has been allocated to Patho Solutions (M) Sdn. Bhd. ('Patho'), representing a separate cash-generating unit ('CGU'). For segment reporting purposes, the operation of Patho has been allocated into marketing and distribution segment.
- (c) Impairment tests for goodwill with indefinite useful live

Goodwill is tested for impairment by comparing the carrying amounts with the recoverable amounts of the CGUs. The recoverable amount of a CGU is determined based on value in use calculations using cash flow projections from the financial budgets and forecasts approved by management covering a period of five (5) years. Cash flows beyond the five (5) year period are extrapolated assuming zero growth rates.

Key assumptions used in the value in use calculations are as follows:

- (i) The growth rate of the revenue over the five-year forecast period based on the industry trend and management's expectations for the future;
- (ii) profit margin applied to the projections is the gross margin achieved in the preceding year before the budgeted year; and
- (iii) the pre-tax discount rates based on the weighted average cost of capital. The discount rates used is 9.70% (2024: 9.70%).

Based on the annual impairment testing undertaken by the Group, no impairment loss was required for the carrying amount of goodwill assessed as at 31 July 2025 as its recoverable amount was in excess of its carrying amount. Management believes that there is no reasonably possible change in the key assumptions on which management has based its determination of the CGU's recoverable amount, which would cause the CGU's carrying amount to materially exceed its recoverable amount.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

9. TRADE AND OTHER RECEIVABLES

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Non-current assets				
Other receivables				
Amounts owing by subsidiaries	0	0	16,936,900	14,916,900
Less: Impairment losses	0	0	(2,671,875)	(2,269,866)
	0	0	14,265,025	12,647,034
Current assets				
Trade receivables				
Third parties	11,460,337	17,503,062	0	0
Less: Impairment losses	(281,376)	(80,300)	0	0
	11,178,961	17,422,762	0	0
Other receivables				
Third parties	177,298	361,347	0	371
Amounts owing by subsidiaries	0	0	3,500,000	3,120,900
	177,298	361,347	3,500,000	3,121,271
Less: Impairment losses	0	0	(517,230)	(223,524)
	177,298	361,347	2,982,770	2,897,747
Deposits and prepayments				
Deposits	72,876	97,638	1,000	1,000
Prepayments	3,595,860	2,249,643	0	0
	3,668,736	2,347,281	1,000	1,000
Total current receivables	15,024,995	20,131,390	2,983,770	2,898,747
Total trade and other receivables	15,024,995	20,131,390	17,248,795	15,545,781

- (a) Trade and other receivables excluding prepayments are classified as financial assets measured at amortised cost.
- (b) Trade receivables are non-interest bearing and the normal trade credit terms granted by the Group range from 0 to 180 days (2024: 0 to 180 days). They are recognised at their original invoice amounts which represent their fair values on initial recognition.
- (c) Non-current amounts owing by subsidiaries are unsecured, interest-free, and not expected to be settled within the next twelve (12) months.
- Current amounts owing by subsidiaries are unsecured, interest-free and payable within next twelve (12) months or upon demand in cash and cash equivalents.
- (d) Included in the prepayments in was a total sum of RM3,230,572 (2024: RM1,864,828) paid in respect to the acquisition of plant and equipment.
- (e) The currency exposure profile of trade and other receivables excluding prepayment are as follows:

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Ringgit Malaysia ('RM')	9,243,503	12,540,961	17,248,795	15,545,781
United States Dollar ('USD')	2,174,161	5,253,827	0	0
Euro ('EURO')	11,471	0	0	0
Others	0	86,959	0	0
	11,429,135	17,881,747	17,248,795	15,545,781

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

9. TRADE AND OTHER RECEIVABLES (Cont'd)

- (f) Impairment for trade receivables that do not contain a significant financing component are recognised based on the simplified approach using the lifetime expected credit losses ('ECL').

The Group uses an allowance matrix to measure the ECL of trade receivables from their ageing. Expected loss rates are calculated using the roll rate method separately based on the common credit risk characteristic - by industry or allocation of customer base to a credit risk grade based on data that is determined to be predictive of the risk of loss and applying experience credit judgement. Credit risk grades are defined using qualitative and quantitative factors that are indicative of the risk of default.

During this process, the probability of non-payment by the trade receivables is adjusted by forward-looking information on macroeconomic factors, i.e. consumer price index and multiplied by the amount of the expected loss arising from default to determine the lifetime expected credit loss for the trade receivables. For trade receivables, which are reported net, such impairments are recorded in a separate impairment account with the loss being recognised in the statements of profit or loss and other comprehensive income. On confirmation that the trade receivable would not be collectable, the gross carrying amount of the asset would be written off against the associated impairment.

It requires management to exercise significant judgement in determining the probability of default by trade receivables and appropriate forward-looking information.

Lifetime expected loss provision for trade receivables of the Group are as follows:

Group	Trade receivables-days past due				Total
	Not past due	1-60 days past due	61-120 days past due	>120 days past due	
As at 31 July 2025					
Trade receivables, gross (RM)	7,213,083	3,283,186	237,509	726,559	11,460,337
Lifetime ECL allowance (RM)	(13,134)	(53,175)	(9,167)	(205,900)	(281,376)
Trade receivables, net (RM)	<u>7,199,949</u>	<u>3,230,011</u>	<u>228,342</u>	<u>520,659</u>	<u>11,178,961</u>
As at 31 July 2024					
Trade receivables, gross (RM)	13,252,650	2,391,032	1,160,476	698,904	17,503,062
Lifetime ECL allowance (RM)	(6,348)	(6,318)	(6,898)	(60,736)	(80,300)
Trade receivables, net (RM)	<u>13,246,302</u>	<u>2,384,714</u>	<u>1,153,578</u>	<u>638,168</u>	<u>17,422,762</u>

The Group did not renegotiate the terms of any trade receivables for the financial year ended 31 July 2025 and 31 July 2024 respectively.

- (g) Movements in the impairment allowance for trade receivables based on the simplified approach are as follows:

	Group Lifetime ECL RM
Balance as at 1 August 2024	80,300
Charge for the financial year	<u>201,076</u>
Balance as at 31 July 2025	<u>281,376</u>
Balance as at 1 August 2023	54,465
Charge for the financial year	<u>25,835</u>
Balance as at 31 July 2024	<u>80,300</u>

Trade receivables that are individually determined to be impaired at the financial year end relate to trade receivables who are in significant financial difficulties and have defaulted in payments. The Group considers trade receivables to be in default when the trade receivables are more than twelve (12) months past due.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

9. TRADE AND OTHER RECEIVABLES (CONT'D)

- (h) Impairment for other receivables and amounts owing by subsidiaries are recognised based on the three-stage general approach within MFRS 9 *Financial Instrument* using the forward-looking ECL model. The methodology used to determine the amount of the impairment is based on whether there has been a significant increase in credit risk since initial recognition of the financial asset. For those in which the credit risk has not increased significantly since initial recognition of the financial asset, twelve (12) months ECL along with gross interest income are recognised. For those in which credit risk has increased significantly, lifetime ECL along with the gross interest income are recognised. As at the end of the reporting period, the Group and the Company assess whether there has been a significant increase in credit risk for financial assets by comparing the risk for default occurring over the expected life with the risk of default since initial recognition. For those that are determined to be credit impaired, lifetime ECL along with interest income on a net basis are recognised.

The Group and the Company defined significant increase in credit risk based on payment trends and operational performance of other receivables and amounts owing by subsidiaries.

The probability of non-payment by other receivables and subsidiaries are adjusted by forward-looking information and multiplied by the amount of the expected loss arising from default to determine the twelve (12) months or lifetime expected credit loss for other receivables and subsidiaries. The Group and the Company have identified the consumer price index (2024: consumer price index and inflation index) as the key macroeconomic factor of the forward-looking information.

Movements in the impairment allowance for amounts owing by subsidiaries based on the general approach are as follows:

	12 months ECL RM	Company Lifetime ECL RM	Total RM
Balance as at 1 August 2023	0	0	0
Charge for the financial year	223,524	2,269,866	2,493,390
Balance as at 31 July 2024	223,524	2,269,866	2,493,390
Balance as at 1 August 2024	223,524	2,269,866	2,493,390
Charge for the financial year	293,706	402,009	695,715
Balance as at 31 July 2025	517,230	2,671,875	3,189,105

No ECL is recognised arising from other receivables as it is negligible.

- (i) Information on financial risks of trade and other receivables is disclosed in Note 29 to the financial statements.

10. DEFERRED TAX LIABILITIES/(ASSETS)

- (a) The deferred tax liabilities and (assets) are made up of the following:

	Group	
	2025 RM	2024 RM
Balance as at beginning of financial year	1,150,617	307,076
Relating to origination and reversal of temporary differences (Note 24)	571,871	761,976
Underprovision in prior years (Note 24)	221,571	81,565
Balance as at end of financial year	1,944,059	1,150,617
Presented after appropriate offsetting:		
Deferred tax assets	(4,129)	0
Deferred tax liabilities	1,948,188	1,150,617
	1,944,059	1,150,617

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

10. DEFERRED TAX LIABILITIES/(ASSETS) (CONT'D)

- (b) The components and movements of deferred tax liabilities and (assets) during the financial year are as follows:

Deferred tax assets of the Group

	Other temporary deductible differences RM	Unutilised reinvestment allowances RM	Total RM
Balance as at 1 August 2024	0	0	0
Recognised in profit or loss	(14,149)	(3,900)	(18,049)
Set off	13,920	0	13,920
Balance as at 31 July 2025	<u>(229)</u>	<u>(3,900)</u>	<u>(4,129)</u>
Balance as at 1 August 2023	0	(762,500)	(762,500)
Recognised in profit or loss	0	762,500	762,500
Balance as at 31 July 2024	<u>0</u>	<u>0</u>	<u>0</u>

Deferred tax liabilities of the Group

	Property, plant and equipment RM
Balance as at 1 August 2024	1,150,617
Recognised in profit or loss	811,491
Set off	(13,920)
Balance as at 31 July 2025	<u>1,948,188</u>
Balance as at 1 August 2023	1,069,576
Recognised in profit or loss	81,041
Balance as at 31 July 2024	<u>1,150,617</u>

11. INVENTORIES

	Group	
At cost	2025 RM	2024 RM
Raw materials	1,975,799	1,569,685
Work-in-progress	428,060	0
Finished goods	16,543,403	12,999,705
	<u>18,947,262</u>	<u>14,569,390</u>

- (a) Inventories are stated at the lower of cost and net realisable value.
- (b) Cost is determined using the first-in, first-out formula. Cost comprises all costs of purchase, costs of conversion and other costs incurred in bringing the inventories to their present location and condition. Cost of finished goods included the cost of raw materials, direct labour, other direct cost and a proportion of production overheads based on normal operating capacity of the production facilities.
- (c) During the financial year, inventories of the Group recognised as cost of sales amounted to RM18,732,866 (2024: RM24,297,720).

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

12. SHORT TERM FUNDS

	Group and Company	
	2025 RM	2024 RM
Financial assets at fair value through profit or loss		
In Malaysia		
Money market funds	4,949,869	9,278,269

- (a) Short term funds are denominated in Ringgit Malaysia.
- (b) The fair value of short term funds are determined by reference to the counter party quotes at the end of each reporting period.

Short term funds of the Company are categorised as Level 1 in the fair value hierarchy. There is no transfer between levels in the hierarchy during the financial year.

- (c) Information on financial risks of short term funds is disclosed in Note 29 to the financial statements.

13. CASH AND BANK BALANCES

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Cash and bank balances, representing cash and cash equivalent as reported in statements of cash flows	11,616,715	4,231,579	37,518	77,663

- (a) Cash and bank balances are classified as financial assets measured at amortised costs.
- (b) The currency exposure profile of cash and bank balances are as follows:

	Group		Company	
	2025 RM	2024 RM	2025 RM	2024 RM
Ringgit Malaysia ('RM')	3,390,874	1,703,930	37,518	77,663
United States Dollar ('USD')	8,192,343	2,495,261	0	0
Euro ('EURO')	33,498	32,388	0	0
	11,616,715	4,231,579	37,518	77,663

- (c) No expected credit loss is recognised arising from cash and bank balances because the probability of default of these financial institutions is negligible.
- (d) Information on financial risks of cash and bank balances is disclosed in Note 29 to the financial statements.

14. SHARE CAPITAL

	Group and Company			
	2025 Number of shares	Amount RM	2024 Number of shares	Amount RM
Issued and fully paid up with no par value				
Ordinary shares	373,910,000	44,348,333	373,910,000	44,348,333

The equity holders of the Company are entitled to receive dividends as and when declared by the Company and are entitled to one (1) vote per ordinary share at meetings of the Company. All ordinary shares rank pari passu with regard to the residual assets of the Company.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

15. RESERVES

	Group		Company	
	2025	2024	2025	2024
	RM	RM	RM	RM
Non-distributable:				
Reorganisation debit reserve	(6,851,755)	(6,851,755)	0	0
Accumulated losses	0	0	(6,875,778)	(6,531,919)
Distributable:				
Retained earnings	42,621,674	34,488,096	0	0
	<u>35,769,919</u>	<u>27,636,341</u>	<u>(6,875,778)</u>	<u>(6,531,919)</u>

Reorganisation debit reserve

The reorganisation debit reserve arose as a result of the difference between consideration paid over the share capital and reserves of Actimed Healthcare Sdn. Bhd., Evo Medik Sdn. Bhd., U Medihealth Sdn. Bhd., UMediC Healthcare Sdn. Bhd., UWHC Sdn. Bhd. and UWHM Sdn. Bhd. pursuant to business combinations under common control.

16. BORROWINGS

	Group	
	2025	2024
	RM	RM
Non-current liability		
Term loans	<u>0</u>	<u>256,221</u>
Current liabilities		
Term loans	<u>0</u>	<u>605,656</u>
Total borrowings	<u>0</u>	<u>861,877</u>
The term loans are repayable as follows:		
- not later than one (1) year	0	605,656
- later than one (1) year and not later than five (5) years	<u>0</u>	<u>256,221</u>
	<u>0</u>	<u>861,877</u>

(a) Borrowings were classified as financial liability measured at amortised cost.

(b) The banking facilities are secured by the following:

- (i) legal charge over property, plant and equipment and right-of-use assets of the Group as disclosed in Note 5 and Note 6 to the financial statements; and
- (ii) corporate guarantee by the Company.

(c) The carrying amounts of borrowings were reasonable approximation of the fair values, either due to the insignificant impact of discounting or they are floating rate instruments that are re-priced to market interest rates on or near the reporting date.

Fair value of the borrowings of the Group were categorised as Level 3 in the fair value hierarchy.

(d) Information on financial risks and remaining maturities of borrowings were disclosed in Note 29 to the financial statements.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

17. GOVERNMENT GRANTS

	Group	
	2025	2024
	RM	RM
At cost		
Balance as at beginning of financial year	2,933,559	3,242,954
Add: Grants received during the year	66,079	60,562
Less: Amortisation during the year	(369,957)	(369,957)
Balance as at end of financial year	<u>2,629,681</u>	<u>2,933,559</u>
 Represented by:		
Current	496,598	430,519
Non-current	<u>2,133,083</u>	<u>2,503,040</u>
	<u>2,629,681</u>	<u>2,933,559</u>

- (a) Government grants related to costs are recognised as income in profit or loss in the period in which the grants had been received to match them with the costs which they are intended to compensate.
- (b) Where the grants related to an asset, they are recognised as income and transferred to profit or loss on a systematic basis over the useful lives of the related asset.
- (c) The government grant with carrying amount of RM2,503,040 (2024: RM2,872,997) was obtained by UWHM Sdn. Bhd. from the Malaysian Investment Development Authority ('MIDA') for the purchase of certain item of property, plant and equipment. The subsidiary is not allowed to rent, sell or transfer the risk and rewards of the property, plant and equipment to third parties within five (5) years from the assets acquisition date.
- (d) Progress claims of government grant amounting to RM126,641 (2024: RM60,562) were received by UWHM Sdn. Bhd. from Northern Corridor Implementation Authority ('NCIA') for the participation in NCER Technology Innovation Centre ('NTIC') for technology and innovation program for the use of business.

18. TRADE AND OTHER PAYABLES

	Group		Company	
	2025	2024	2025	2024
	RM	RM	RM	RM
Trade payables				
Third parties	2,655,115	2,585,277	0	0
 Other payables				
Third parties	1,584,181	1,063,093	8,078	13,024
Amounts owing to subsidiaries	0	0	0	2,171,000
Accrued expenses	985,388	796,370	52,600	36,500
Deposit received	7,400	0	0	0
	<u>2,576,969</u>	<u>1,859,463</u>	<u>60,678</u>	<u>2,220,524</u>
Total trade and other payables	<u>5,232,084</u>	<u>4,444,740</u>	<u>60,678</u>	<u>2,220,524</u>

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

18. TRADE AND OTHER PAYABLES (Cont'd)

- (a) Trade payables are non-interest bearing and the normal trade credit terms granted to the Group range from 30 to 90 days (2024: 30 to 90 days).
- (b) The amounts owing to subsidiaries were unsecured, interest-free and payable within next twelve (12) months or upon demand in cash and cash equivalents.
- (c) The currency exposure profile of trade and other payables is as follows:

	Group		Company	
	2025	2024	2025	2024
	RM	RM	RM	RM
Ringgit Malaysia ('RM')	4,220,003	2,990,850	60,678	2,220,524
United States Dollar ('USD')	1,012,081	1,398,939	0	0
Euro ('EURO')	0	54,951	0	0
	<u>5,232,084</u>	<u>4,444,740</u>	<u>60,678</u>	<u>2,220,524</u>

- (d) Information on financial risks of trade and other payables is disclosed in Note 29 to the financial statements.

19. CAPITAL COMMITMENTS

	Group	
	2025	2024
	RM	RM
Capital expenditure in respect of purchase of property, plant and equipment:		
- Approved but not contracted for	0	6,843,041
- Contracted but not provided for	6,890,167	5,062,071
	<u>6,890,167</u>	<u>11,905,112</u>

20. FINANCIAL GUARANTEE CONTRACTS

	Company	
	2025	2024
	RM	RM
<u>Unsecured</u>		
Financial guarantee given to financial institutions for credit facilities		
- Limit of guarantee	14,255,000	18,474,833
- Amount utilised	<u>3,192,927</u>	<u>7,169,711</u>

- (a) The Company provides financial guarantees to financial institutions for credit facilities granted to certain subsidiaries.
- (b) The maximum exposure to credit risk in relation to financial guarantee contracts provided as credit enhancements to the secured loans of subsidiaries amounts to RM3,192,927 (2024: RM7,169,711) representing the outstanding banking facilities of the subsidiaries as at the end of the reporting period.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

20. FINANCIAL GUARANTEE CONTRACTS (CONT'D)

- (c) Financial guarantee contracts are initially measured at fair value and subsequently at the higher of the amount determined in accordance with the expected loss model under MFRS 9 and the amount initially recognised less amortisation, where appropriate.
- (d) Financial guarantees have not been recognised since the fair values was not material on initial recognition. As at the end of each reporting period, there was no indication that the subsidiaries would default on repayment.
- (e) Information on financial risks of financial guarantee contracts is disclosed in Note 29 to the financial statements.

21. REVENUE

	Group		Company	
	2025	2024	2025	2024
	RM	RM	RM	RM
Revenue from contracts with customers:				
Recognised at a point in time:				
Sale of goods and services	48,553,299	54,570,002	0	0
Recognised over time:				
Nursing services	11,080	0	0	0
Other revenue				
- Dividend income	0	0	140,000	0
	<u>48,564,379</u>	<u>54,570,002</u>	<u>140,000</u>	<u>0</u>

- (a) Sale of goods and services

Revenue from the sale of goods and services are recognised at a point in time when the Group satisfies a performance obligation by transferring a promised goods and services to a customer. An asset is transferred as and when the customer obtains control of that asset, which coincides with the delivery of goods and services and acceptance by customers.

There are no right of return and warranty provided to the customers on the sale of goods and services.

There are no significant financing component in the revenue arising from sale of goods and services as the sales are made on the normal credit terms not exceeding twelve (12) months.

- (b) Nursing services

Revenue from nursing services is recognised over time, as the performance obligations are generally satisfied throughout the patient's duration of stay, during which the patient simultaneously receives and consumes the benefits of the nursing care provided.

There are no right of return and warranty provided to the customers on the rendering of nursing services.

- (c) Revenue from contracts with customers is disaggregated by primary geographical market as disclosed in Note 4 to the financial statements.
- (d) Dividend income is recognised when the right to receive payment is established.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

22. EMPLOYEE BENEFITS

The details of the employee benefits are as follows:

	Group		Company	
	2025	2024	2025	2024
	RM	RM	RM	RM
Directors' fee	180,000	180,000	180,000	180,000
Directors' remuneration	1,401,021	841,087	3,000	3,000
Wages, salaries and bonuses	7,914,895	6,417,250	0	0
Contributions to defined contribution plan	646,031	557,638	0	0
Social security contributions	111,513	88,051	0	0
Other benefits	83,390	131,807	0	0
	<u>10,336,850</u>	<u>8,215,833</u>	<u>183,000</u>	<u>183,000</u>

Included in the employee benefits of the Group and of the Company are Directors' remunerations as below:

	Group		Company	
	2025	2024	2025	2024
	RM	RM	RM	RM
Directors of the Company				
Fee	180,000	180,000	180,000	180,000
Salaries and other emoluments	633,510	514,075	3,000	3,000
Contributions to defined contribution plan	51,744	42,216	0	0
Social security contributions	1,092	1,040	0	0
Other benefits	125	119	0	0
Total Directors' remuneration	<u>866,471</u>	<u>737,450</u>	<u>183,000</u>	<u>183,000</u>
Directors of the subsidiaries				
Salaries and other emoluments	652,000	228,000	0	0
Contributions to defined contribution plan	58,320	22,320	0	0
Social security contributions	3,797	2,080	0	0
Other benefits	433	31,237	0	0
Total Directors' remuneration	<u>714,550</u>	<u>283,637</u>	<u>0</u>	<u>0</u>
Total Directors' remuneration				
Fees	180,000	180,000	180,000	180,000
Other emoluments	1,401,021	841,087	3,000	3,000
	<u>1,581,021</u>	<u>1,021,087</u>	<u>183,000</u>	<u>183,000</u>

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

23. FINANCE COSTS

	Group	
	2025	2024
	RM	RM
Interest expenses on:		
- term loans	17,167	73,240
- lease interest	1,350	1,375
- letter of credit interest	8,607	24,462
- bank guarantee interest	40,036	36,743
	<u>67,160</u>	<u>135,820</u>

24. TAXATION

	Group		Company	
	2025	2024	2025	2024
	RM	RM	RM	RM
Current tax expense based on profit/(loss) for the financial year	1,869,023	2,461,270	221	0
(Over)/Underprovision of tax expenses in prior years	(75,885)	38,799	530	(282)
	<u>1,793,138</u>	<u>2,500,069</u>	<u>751</u>	<u>(282)</u>
Deferred tax (Note 10):				
Relating to origination and reversal of temporary differences	571,871	761,976	0	0
Underprovision in prior years	221,571	81,565	0	0
	<u>793,442</u>	<u>843,541</u>	<u>0</u>	<u>0</u>
Total taxation	<u>2,586,580</u>	<u>3,343,610</u>	<u>751</u>	<u>(282)</u>

- (a) The Malaysian income tax is calculated at the statutory tax rate of 24% (2024: 24%) of the estimated taxable profits for the fiscal year.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

24. TAXATION (CONT'D)

- (b) The numerical reconciliation between the taxation and the product of accounting profit/(loss) multiplied by the applicable tax rates of the Group and of the Company are as follows:

	Group		Company	
	2025	2024	2025	2024
	RM	RM	RM	RM
Profit/(Loss) before tax	10,850,769	12,640,520	(343,108)	(3,935,940)
Tax at Malaysian statutory tax rate of 24% (2024: 24%)	2,604,100	3,033,700	(82,300)	(944,600)
Tax effects in respect of:				
- Non-allowable expenses	406,407	846,544	82,521	944,600
- Income not subject to tax	(100,903)	(256,085)	0	0
Deferred tax assets not recognised during the financial year	62,858	0	0	0
Double deduction of expenses	(10,000)	(10,000)	0	0
Reinvestment allowance claimed during the year	(521,568)	(390,894)	0	0
Utilisation of previously unrecognised deferred tax assets	0	(19)	0	0
Underprovision of deferred tax in prior years	221,571	81,565	0	0
(Over)/Underprovision of tax expense in prior years	(75,885)	38,799	530	(282)
	<u>2,586,580</u>	<u>3,343,610</u>	<u>751</u>	<u>(282)</u>

- (c) The amounts of temporary differences for which no deferred tax assets have been recognised in the consolidated statement of financial position are as follows:

	Group	
	2025	2024
	RM	RM
Unabsorbed capital allowances	84,935	32,665
Unutilised tax losses		
- expires by 31 July 2035	209,639	0
	<u>294,574</u>	<u>32,665</u>

Deferred tax assets were not recognised in respect of these items as it was not probable that taxable profits would be available against which the deductible temporary differences could be utilised.

Any unused tax losses shall be deductible for a maximum period of ten (10) consecutive years of assessment immediately following that year of assessment. Any amount which is not deducted at the end of the period of ten (10) years of assessment shall be disregarded.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

25. STATUTORY DISCLOSURE

Pursuant to Section 249(4)(e) of Companies Act 2016, details of auditors' remuneration payable by the Group and the Company during the financial year were as follows:

	Group		Company	
	2025	2024	2025	2024
	RM	RM	RM	RM
BDO PLT				
- Statutory audit	93,500	75,100	31,100	25,500
- Non-statutory audit	6,500	99,000	6,500	96,000

26. EARNINGS PER SHARE

(a) Basic

Basic earnings per share for the financial year is calculated by dividing the profit for the financial year attributable to equity holders of the Company by the number of ordinary shares of the Company.

	Group	
	2025	2024
Profit attributable to equity holders of the Company (RM)	8,133,578	8,990,693
Weighted average number of ordinary shares in issue (units)	373,910,000	373,910,000
Basic earnings per share (sen)	2.18	2.40

(b) Diluted

Diluted earnings per share equals basic earnings per share because there are no potentially dilutive instruments in existence as at the end of each reporting period.

27. RELATED PARTY DISCLOSURES

(a) Identities of related parties

Parties are considered to be related to the Group if the Group has the ability, directly or indirectly, to control the party or exercise significant influence over the party in making financial and operating decisions, or vice versa, or where the Group and the party are subject to common control or common significant influence. Related parties could be individuals or other parties.

The Company has controlling related party relationship with its subsidiaries as disclosed in Note 7 to the financial statements.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

27. RELATED PARTY DISCLOSURES (CONT'D)

(b) Significant related parties transactions

In addition to the related parties information detailed elsewhere in the financial statements, the Company had the following significant transactions with a related party during the financial year:

	Company	
	2025	2024
	RM	RM
Dividend income from a subsidiary	<u>140,000</u>	<u>0</u>

The Group has not entered into any transactions with related parties during the financial year.

Balances with related parties at the end of the financial period are disclosed in Note 9 and Note 18 to the financial statements.

(c) Compensation of key management personnel

Key management personnel are those persons having the authority and responsibility for planning, directing and controlling the activities of the entity, directly and indirectly, including any Director (whether executive or otherwise) of the Group.

The remuneration of certain Directors and other members of key management during the year were as follows:

	Group	
	2025	2024
	RM	RM
Short term employee benefits	2,086,685	1,530,909
Contributions to defined contribution plan	<u>123,696</u>	<u>107,460</u>
	<u>2,210,381</u>	<u>1,638,369</u>

Included in the compensation of key management personnel are Directors' remuneration of the Group as disclosed in Note 22 to the financial statements.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

28. CAPITAL MANAGEMENT

The primary objective of the capital management of the Group is to ensure that the Group would be able to continue as a going concern whilst maximising return to shareholders through the optimisation of the debt and equity ratios. The overall strategy of the Group remains unchanged throughout the reporting periods.

The Group manages its capital structure and makes adjustments to it in response to changes in economic conditions. In order to maintain or adjust the capital structure, the Group may adjust the dividend payment to shareholders, return capital to shareholders or issue new shares. No changes were made in the objectives, policies or processes throughout the reporting periods.

The Group monitors capital utilisation on the basis of net debt-to-equity ratio, which is net debt divided by total capital. The Group includes within net debt, borrowings, lease liabilities and trade and other payables less cash and bank balances and short-term funds. Capital represents equity attributable to the equity holders of the Company. The net debt-to-equity ratios as at 31 July 2025 and 31 July 2024 are as follows:

		Group	
	Note	2025 RM	2024 RM
Borrowings	16	0	861,877
Lease liabilities	6	48,049	14,287
Trade and other payables	18	5,232,084	4,444,740
Total liabilities		5,280,133	5,320,904
Less: Short-term funds	12	(4,949,869)	(9,278,269)
Cash and bank balances	13	(11,616,715)	(4,231,579)
Net cash		(11,286,451)	(8,188,944)
Total equity		81,352,411	72,773,352
Net debt-to-equity ratio		*	*

* No net debt-to-equity ratio is presented as the Group are in net cash position.

Pursuant to the requirements of Practice Note No. 17/2005 of Bursa Malaysia Securities Berhad, the Group is required to maintain a consolidated shareholders' equity of more than twenty-five per centum (25%) of the issued and paid-up capital and such shareholders' equity is not less than RM40 million. The Group has complied with this requirement during the financial year ended 31 July 2025.

29. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES

The financial risk management objective of the Group is to optimise value creation for shareholders whilst minimising the potential adverse impact arising from fluctuations in foreign currency exchange and interest rates and the unpredictability of the financial markets.

The Group is exposed mainly to credit risk, liquidity and cash flow risk, foreign currency risk, interest rate risk and price risk. Information on the management of the related exposures is detailed below.

(a) Credit risk

Bank deposits with licensed banks and trade receivables could give rise to credit risk which requires the loss to be recognised if a counterparty fails to perform as contracted. The counterparties are the customers of the Group and licensed financial institutions. It is the policy of the Group to monitor the financial standing of these counterparties on an ongoing basis to ensure that the Group is exposed to minimal credit risk.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

29. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (CONT'D)

(a) Credit risk (Cont'd)

Credit risk is the risk that a counterparty will not meet its obligations under a financial instrument or customer contract leading to a financial loss.

The primary exposure of the Group to credit risk arises through its trade receivables. The trading terms of the Group with the customers are mainly on credit, except for new customers, where deposits in advance are normally required. The credit period is generally for a period of one (1) month, extending up to six (6) months for major customers. Nevertheless, the management of the Group may give longer credit terms by discretion. The Group consistently monitors its outstanding receivables to minimise credit risk.

The Group also invest cash assets safely and profitably with approved financial institutions in line with the policy of the Group. In respect of the bank balances placed with licensed banks, the Directors believe that the possibility of non-performance by these financial institutions is remote on the basis of their financial strength.

Exposure to credit risk

At the end of the reporting period, the maximum exposure of the Group to credit risk is substantially represented by the carrying amount of each class of financial assets recognised in the statements of financial position.

Credit risk concentration profile

The Group determines concentration of credit risk by monitoring the country and industry sector profiles of its trade receivables on an ongoing basis. The credit risk concentration profile of the trade receivables of the Group at the end of the reporting period are as follows:

By countries	2025	% of total	2024	% of total
	RM		RM	
Malaysia	9,253,003	83%	12,363,933	71%
South Korea	655,667	5%	762,873	4%
Italy	408,787	4%	1,182,400	7%
Spain	408,787	4%	1,025,243	6%
Chile	237,427	2%	114,350	*
Thailand	0	0%	652,544	4%
Czech Republic	0	0%	446,672	3%
Poland	0	0%	282,037	2%
Others	215,290	2%	592,710	3%
	<u>11,178,961</u>	<u>100%</u>	<u>17,422,762</u>	<u>100%</u>

* Amount less than 1%.

At the end of each reporting period, approximately 43% (2024: 61%) of the trade receivables of the Group were due from six (6) (2024: ten (10)) major customers.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

29. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (CONT'D)

(b) Liquidity and cash flow risks

Liquidity and cash flow risks are the risks that the Group will not be able to meet its financial obligations when they fall due. The exposure of the Group to liquidity risk arises principally from its trade and other payables and lease liabilities (2024: trade and other payables, borrowings and lease liabilities).

The Group actively manages its debt maturity profile, operating cash flows and availability of funding so as to ensure that all operating, investing and financing needs are met. In executing its liquidity risk management strategy, the Group measures and forecasts its cash commitments and maintain a level of cash and cash equivalents deemed adequate to finance the activities of the Group.

The Group also manages liquidity risk by minimising the mismatch of financial assets and financial liabilities whilst maintaining sufficient cash to meet working capital requirement.

The table below summarises the maturities profile of the liabilities of the Group and of the Company at the end of the reporting period based on contractual undiscounted repayment obligations.

	On demand or within one (1) year RM	One (1) to five (5) years RM	Total RM
Financial liabilities			
Group			
As at 31 July 2025			
Trade and other payables	5,232,084	0	5,232,084
Lease liabilities	41,100	7,875	48,975
Total undiscounted financial liabilities	<u>5,273,184</u>	<u>7,875</u>	<u>5,281,059</u>
As at 31 July 2024			
Trade and other payables	4,444,740	0	4,444,740
Borrowings	628,611	258,309	886,920
Lease liabilities	14,550	0	14,550
Total undiscounted financial liabilities	<u>5,087,901</u>	<u>258,309</u>	<u>5,346,210</u>
Company			
As at 31 July 2025			
Trade and other payables	60,678	0	60,678
Financial guarantee contracts	3,192,927	0	3,192,927
Total undiscounted financial liabilities	<u>3,253,605</u>	<u>0</u>	<u>3,253,605</u>
As at 31 July 2024			
Trade and other payables	2,220,524	0	2,220,524
Financial guarantee contracts	7,169,711	0	7,169,711
Total undiscounted financial liabilities	<u>9,390,235</u>	<u>0</u>	<u>9,390,235</u>

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

29. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (CONT'D)

(c) Interest rate risk

Interest rate risk is the risk that the fair value or future cash flows of the financial instruments of the Group would fluctuate because of changes in market interest rates.

The Group's interest rate risk arose primarily from interest-bearing borrowings. Borrowings at floating rates expose the Group to cash flow interest rate risk and fair value interest rate risk. Interest rates of bank borrowings are mainly subject to fluctuations in the banks' base lending rates. Short term borrowings which are on fixed rates are not significantly subject to interest rate risk.

Sensitivity analysis for interest rate risk

The following table demonstrates the sensitivity analysis of the Group's floating rate instrument if interest rates at the end of reporting period changed by fifty (50) basis points with all other variables held constant:

	Group	
	2025	2024
	RM	RM
Profit after tax		
- Increase by 0.5%	0	(753)
- Decrease by 0.5%	0	753

There was no interest rate risk exposure to the equity, hence the effect of change in the interest rate was not explained.

The Group did not account for any fixed rate financial instruments at fair value through profit or loss, and the carrying amount of fixed rate financial instruments of the Group is measured at amortised cost. Therefore, no sensitivity analysis for fixed rate instruments was prepared as the change in market interest rate at the end of the reporting period would not affect profit or loss.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

29. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (CONT'D)

(c) Interest rate risk (Cont'd)

The following table sets out the carrying amounts, the incremental borrowing rate ('IBR')/weighted average effective interest rates ('WAEIR') as at the end of each reporting period and the remaining maturities of the financial instruments of the Group that are exposed to interest rate risk, which included fixed rates financial instruments:

	IBR* / WAEIR per annum	Within 1 year RM	1-2 years RM	2-3 years RM	3-4 years RM	4-5 years RM	More than 5 years RM	Total RM
31 July 2025								
Fixed rate								
Lease liabilities	4.80% - 5.35%*	40,208	7,841	0	0	0	0	48,049
31 July 2024								
Fixed rate								
Term loans	3.50%	407,475	256,221	0	0	0	0	663,696
Lease liabilities	4.80% - 5.35%*	14,287	0	0	0	0	0	14,287
Floating rate								
Term loans	4.91%	198,181	0	0	0	0	0	198,181

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

29. FINANCIAL RISK MANAGEMENT OBJECTIVES AND POLICIES (CONT'D)

(d) Foreign currency risk

Foreign currency risk is the risk that the fair value or future cash flows of a financial instrument would fluctuate because of changes in foreign exchange rates.

The Group are exposed to foreign currency risk on sales and purchases that are denominated in a currency other than the respective functional currencies of the Group. The currencies giving rise to this risk are primarily in USD and EURO.

The Group also holds cash and bank balances denominated in foreign currencies for working capital purposes. At the end of each reporting period, such foreign currency balances in USD and EURO amounted to RM8,225,841 (2024: RM2,527,649).

The following table demonstrates the sensitivity analysis of the Group to a reasonably possible change in the USD and EURO exchange rate against the functional currency of the Group, with all other variables held constant:

	2025 RM	2024 RM
Profit after tax		
USD/RM		
- strengthen by 15%	1,066,404	723,917
- weaken by 15%	(1,066,404)	(723,917)
EURO/RM		
- strengthen by 15%	5,126	(2,572)
- weaken by 15%	(5,126)	2,572

Sensitivity analysis of other foreign currencies are not disclosed as they are not material to the Group.

The effect to the equity of the Group are not presented as they are not affected by the changes in the exchange rates.

(e) Price risk

Price risk is the risk that the fair value of future cash flows of the financial instruments of the Group and of the Company would fluctuate because of changes in market prices (other than interest or exchange rates).

The Group and the Company are exposed to changes in market quoted prices arising from short term funds held by the Group and the Company. The short term funds comprises mainly money market funds in Malaysia.

As the short term funds are mainly money market fund placement where the volatility of these fund's prices is considered low, the Directors were of the opinion that the Group and the Company were not subject to the significant exposure to price risk and accordingly, no sensitivity analysis was being presented at the end of each financial year.

NOTES TO THE FINANCIAL STATEMENTS (CONT'D)

31 JULY 2025

30. ADOPTION OF NEW MFRSs AND AMENDMENTS TO MFRSs

30.1 New MFRSs adopted during the financial year

The Group adopted the following Amendments to the Standards of the MFRS Framework that were issued by the Malaysian Accounting Standards Board ('MASB') during the financial year:

Title	Effective date
Amendments to MFRS 16 <i>Lease Liability in a Sale and Leaseback</i>	1 January 2024
Amendments to MFRS 101 <i>Classification of Liabilities as Current or Non-current</i>	1 January 2024
Amendments to MFRS 101 <i>Non-current Liabilities with Covenants</i>	1 January 2024
Amendments to MFRS 107 and MFRS 7 <i>Supplier Finance Arrangements</i>	1 January 2024

Adoption of the above Amendments to the Standards did not have any material effect on the financial performance or position of the Group and of the Company.

30.2 New MFRSs that have been issued, but only effective for annual periods beginning on or after 1 January 2025

The following are Standards and Amendments to Standards of the MFRS Framework that have been issued by the Malaysian Accounting Standards Board ('MASB') but have not been early adopted by the Group and the Company:

Title	Effective date
Amendments to MFRS 121 <i>Lack of Exchangeability</i>	1 January 2025
Amendments to MFRS 9 and MFRS 7 <i>Amendments to the Classification and Measurement of Financial Instruments</i>	1 January 2026
<i>Annual Improvements to MFRS Accounting Standards - Volume 11</i>	1 January 2026
Amendments to MFRS 9 and MFRS 7 <i>Contracts Referencing Nature-dependent Electricity</i>	1 January 2026
MFRS 18 <i>Presentation and Disclosure in Financial Statements</i>	1 January 2027
MFRS 19 <i>Subsidiaries without Public Accountability: Disclosures</i>	1 January 2027
Amendments to MFRS 10 and MFRS 128 <i>Sale or Contribution of Assets between an Investor and its Associate or Joint Venture</i>	Deferred

The Group and the Company are in the process of assessing the impact of implementing these Standards and Amendments to Standards, since the effects would only be observable for the future financial years.

LIST OF PROPERTIES

No.	Location	Description/ Existing use	Land Area/ Built-up area (sq. feet)	Tenure	Approximate age of building (years)	Carrying Amount as at 31 July 2025 (RM'000)	Date of Acquisition
1	UMediC Healthcare Sdn. Bhd. PMT 790, Jalan Cassia Selatan 5/2, Taman Perindustrian Batu Kawan, 14110 Bandar Cassia, Pulau Pinang	A double-storey office building annexed with a single-storey factory building	126,852.68/ 48,487.40	60 years' lease expiring on 20 September 2079	4	11,540	17 May 2019
		A single-storey factory building	-/21,728.86		1	5,286	20 Dec 2023
2.	Evo Medik Sdn Bhd No. 2, Jalan Perniagaan Vorteks 3, Pusat Perniagaan Vorteks, 14100 Simpang Ampat, Pulau Pinang.	A four-storey semi-detached corporate office	7,427.10/ 5,087.00	Freehold	2	2,260	11 July 2023

ANALYSIS OF SHAREHOLDINGS

TOTAL NUMBER OF ISSUED SHARES : 373,910,000
 CLASS OF SHARE : Ordinary shares
 VOTING RIGHTS : One vote per ordinary share

DISTRIBUTION OF SHAREHOLDINGS

Size of Shareholdings	No. of Holders	%	No. of Shares	%
1 - 99	4	0.15	150	0.00
100 - 1,000	362	13.15	195,000	0.05
1,001 - 10,000	1,244	45.20	7,603,800	2.04
10,001 - 100,000	941	34.19	32,801,150	8.77
100,001 - 18,695,499 (*)	198	7.20	120,895,889	32.33
18,695,500 AND ABOVE (**)	3	0.11	212,414,011	56.81
Total	2,752	100.00	373,910,000	100.00

* Less than 5% of issued shares

** 5% and above of issued shares

SUBSTANTIAL SHAREHOLDERS AS AT 31 OCTOBER 2025

No.	Name of Shareholder	Direct Interest		Indirect Interest	
		No. of Shares	% of Shares	No. of Shares	% of Shares
1	Dato' Seri Ng Chai Eng	90,953,419	24.32	10,405,935*	2.78
2	Dato' Lau Chee Kheong	69,036,260	18.46	-	-
3	Lim Taw Seong	62,424,332	16.70	-	-

* Deemed interest through Naluri Garuda (L) Foundation and the shares held by his daughter, Ng Sze Hui pursuant to Section 8 of the Companies Act 2016.

DIRECTORS' SHAREHOLDINGS AS AT 31 OCTOBER 2025

No.	Directors	Direct Interest	%	Indirect Interest	%
1	Dato' Seri Ng Chai Eng	90,953,419	24.32	10,405,935*	2.78
2	Lim Taw Seong	62,424,332	16.70	-	-
3	Pakirisamy Baskaran A/L P Thangavelu	300,000	0.08	-	-
4	Tan Chye Suan	300,000	0.08	-	-
5	Lee Yee Wooi	300,000	0.08	-	-
6	Dato' Dr. Teh Keng Hwang	-	-	-	-
7	Ng Sze Hui	300,000	0.08	-	-
Total		154,577,751	41.34		

* Deemed interest through Naluri Garuda (L) Foundation and the shares held by his daughter, Ng Sze Hui pursuant to Section 8 of the Companies Act 2016.

ANALYSIS OF SHAREHOLDINGS (CONT'D)

LIST OF 30 LARGEST SHAREHOLDERS

NO.	NAME	NO. OF SHARES HELD	PERCENTAGE (%)
1	NG CHAI ENG (DATO' SERI)	90,953,419	24.325
2	LIM TAW SEONG	62,424,332	16.695
3	LAU CHEE KHEONG	59,036,260	15.789
4	KONG YOEN HOO	15,606,387	4.174
5	LIM SUAT GIM	11,716,405	3.133
6	NALURI GARUDA (L) FOUNDATION	10,105,935	2.703
7	MAYBANK NOMINEES (TEMPATAN) SDN BHD MAYBANK PRIVATE WEALTH MANAGEMENT FOR LAU CHEE KHEONG (12023655) (447285)	10,000,000	2.674
8	CIMB GROUP NOMINEES (TEMPATAN) SDN BHD CIMB BANK BERHAD (EDP 2)	3,197,000	0.855
9	AMANAHRAYA TRUSTEES BERHAD PB ISLAMIC SMALLCAP FUND	3,041,900	0.814
10	AMANAHRAYA TRUSTEES BERHAD PB GROWTH SEQUEL FUND	2,256,400	0.603
11	CHAI MEI WAH	2,255,200	0.603
12	AMANAHRAYA TRUSTEES BERHAD PUBLIC E-ISLAMIC FLEXI ALLOCATION FUND	1,997,000	0.534
13	NG SZE LING	1,626,000	0.435
14	CIMB GROUP NOMINEES (TEMPATAN) SDN BHD CIMB ISLAMIC TRUSTEE BERHAD FOR PHILLIP DANA AMAN (3717 TRO1)	1,620,300	0.433
15	MAYBANK NOMINEES (TEMPATAN) SDN BHD PLEDGED SECURITIES ACCOUNT FOR SYED ABU HUSSIN BIN HAFIZ SYED ABDUL FASAL	1,462,500	0.391
16	KUAN MIN HUEY	1,312,300	0.351
17	CGS INTERNATIONAL NOMINEES MALAYSIA (TEMPATAN) SDN. BHD. PLEDGED SECURITIES ACCOUNT FOR MOHAMAD DAUD BIN MOHD YUSOFF (MF00667)	1,309,800	0.350
18	CIMB GROUP NOMINEES (TEMPATAN) SDN BHD CIMB COMMERCE TRUSTEE BERHAD FOR MAYBANK MALAYSIA SMALLCAP FUND	1,300,000	0.348
19	TAN AH NYAH	1,188,700	0.318
20	ALLIANCEGROUP NOMINEES (TEMPATAN) SDN BHD PLEDGED SECURITIES ACCOUNT FOR TEOH HUI PENG (8076778)	1,100,000	0.294
21	KONG YOEN HOO	1,025,552	0.274
22	MAYBANK NOMINEES (TEMPATAN) SDN BHD PLEDGED SECURITIES ACCOUNT FOR SYED ABU SALIM BIN HAFIS SYED ABD FASAL	1,010,000	0.270
23	CIMB GROUP NOMINEES (TEMPATAN) SDN BHD CIMB COMMERCE TRUSTEE BERHAD FOR PHILLIP RECOVERY FUND	897,400	0.240
24	LIM CHIN HON	850,000	0.227
25	TEOH MENG LEE	830,000	0.222
26	SEE HOCK CHUAN	746,200	0.200
27	MAYBANK SECURITIES NOMINEES (TEMPATAN) SDN BHD PLEDGED SECURITIES ACCOUNT FOR BOB STANDARD SDN. BHD.	699,000	0.187
28	MAYBANK SECURITIES NOMINEES (TEMPATAN) SDN BHD PLEDGED SECURITIES ACCOUNT FOR CHAN CHEE WOH (REM 646)	666,000	0.178
29	RHB NOMINEES (TEMPATAN) SDN BHD PLEDGED SECURITIES ACCOUNT FOR LEE BOON TIONG	650,000	0.174
30	PUBLIC NOMINEES (TEMPATAN) SDN BHD PLEDGED SECURITIES ACCOUNT FOR LEE BOON TIONG (E-BMM)	647,300	0.173

NOTICE OF FIFTH ANNUAL GENERAL MEETING

NOTICE IS HEREBY GIVEN THAT the Fifth Annual General Meeting (“5th AGM”) of UMediC Group Berhad (“UMC” or the “Company”) will be held at Sri Mas Ballroom, Level 4, Bayview Hotel Georgetown Penang, 25-A Farquhar Street, 10200 George Town, Pulau Pinang on Tuesday, 13 January 2026 at 10.30 a.m. for the transaction of the following business:

ORDINARY BUSINESS

1. To receive the Audited Financial Statements for the financial year ended 31 July 2025 together with the Reports of the Directors and Auditors thereon.
2. To approve the payment of Directors’ fees and benefits of up to an aggregate amount of RM200,000.00 to the Non-Executive Directors for the period from 14 January 2026 until the conclusion of the next annual general meeting (“AGM”) of the Company to be held in 2027.
3. To re-elect the following Directors who retire by rotation in accordance with Clause 165.1 of the Company’s Constitution and who, being eligible, offer themselves for re-election: -
 - (i) Dr. Pakirisamy Baskaran A/L P Thangavelu
 - (ii) Tan Chye Suan
4. To re-appoint Messrs. BDO PLT as Auditors of the Company and to authorise the Directors to determine their remuneration.

Ordinary Resolution 1

Ordinary Resolution 2
Ordinary Resolution 3

Ordinary Resolution 4

SPECIAL BUSINESS

To consider and, if thought fit, to pass the following resolution, with or without modification, as an Ordinary Resolution:

5. AUTHORITY PURSUANT TO SECTIONS 75 AND 76 OF THE COMPANIES ACT, 2016 FOR THE DIRECTORS TO ALLOT AND ISSUE SHARES

“THAT, subject always to the Companies Act, 2016 (“the Act”), the Constitution of the Company and the approvals of the relevant government and/or regulatory authorities, the Directors be and are hereby authorised, pursuant to Sections 75 and 76 of the Act, to allot and issue shares in the Company at any time until the conclusion of the next annual general meeting or the expiration of the period within which the next annual general meeting is required by law to be held or revoked/varied by resolution passed by the shareholders in general meeting whichever is the earlier and upon such terms and conditions and for such purposes as the Directors may, in their absolute discretion, deemed fit, provided that the aggregate of the shares to be issued does not exceed 10% of the total number of issued shares of the Company and that the Directors are also empowered to obtain the approval from Bursa Malaysia Securities Berhad for the listing of and quotation for the additional shares to be issued.

THAT the existing shareholders’ right of pre-emption under Clause 31 of the Company’s Constitution shall not apply to the allotment and issuance of new shares pursuant to this mandate.”

Ordinary Resolution 5

6. To transact any other business of which due notice shall have been given in accordance with the Company’s Constitution and the Companies Act, 2016.

BY ORDER OF THE BOARD

OOI YOONG YOONG (MAICSA 7020753/ SSM PC NO. 202008002042)

Company Secretary

Penang

28 November 2025

NOTICE OF FIFTH ANNUAL GENERAL MEETING (CONT'D)

Notes :-

Appointment of Proxy

1. A proxy need not be a member and a member may appoint any person to be his proxy without limitation save that the proxy must be of full age.
 2. A member of the Company entitled to attend, participate, speak and vote at the meeting is entitled to appoint one (1) or more proxies (who need not be members) to attend, participate, speak and vote at the same meeting.
 3. Where a member appoints more than one (1) proxy, the appointment shall be invalid unless he specifies the proportions of his shareholdings to be represented by each proxy.
 4. The instrument appointing a proxy shall be in writing under the hand of the appointor or of his attorney duly authorised in writing.
 5. Where a member of the Company is an authorised nominee as defined under the Securities Industry (Central Depositories) Act 1991 ("SICDA"), it may appoint at least one (1) proxy in respect of each securities account it holds with ordinary shares of the Company standing to the credit of the said securities account.
 6. Where a member is an exempt authorised nominee as defined under the SICDA which holds ordinary shares in the Company for multiple beneficial owners in one (1) securities account ("omnibus account"), there is no limit to the number of proxies which the exempt authorised nominee may appoint in respect of each omnibus account it holds.
 7. For a proxy to be valid, the instrument appointing a proxy must be made in a hard copy form or by electronic means in the following manner and must be received by the Company not less than forty-eight (48) hours before the time appointed for holding the meeting or adjourned meeting PROVIDED that in the event the member(s) duly execute(s) the Proxy Form but does/do not name any proxy, such member(s) shall be deemed to have appointed the Chairman of the meeting as his/their proxy, PROVIDED ALWAYS that the rest of the Proxy Form, other than the particulars of the proxy, have been duly completed by the member(s):
 - i. In hard copy form
The proxy form must be deposited at the office of the Share Registrar, Boardroom Share Registrars Sdn. Bhd. at 11th Floor, Menara Symphony, No. 5, Jalan Prof. Khoo Kay Kim, Seksyen 13, 46200 Petaling Jaya, Selangor.
 - ii. By electronic means via facsimile
The proxy form must be received via facsimile at +603-7890 4670.
 - iii. By electronic means via email
The proxy form must be received via email at bsr.helpdesk@boardroomlimited.com.
 - iv. By electronic means via Boardroom Smart Investor Portal, BSIP online (for individual shareholder only)
The Proxy Form can be lodged electronically via BSIP Online website at <https://investor.boardroomlimited.com>. Please refer to the Administrative Guide on the procedure for electronic lodgement of proxy form via Online.
- For option (ii) and (iii), the Company will require the member to deposit the original executed proxy form to the office of Share Registrar before or on the day of meeting for verification purpose.
8. Any authority pursuant to which an appointment is made by a power of attorney must be deposited at the office of the Share Registrar before the cut-off time for the lodgement of the proxy form.
 9. Please ensure that ALL particulars as required in the Proxy Form are completed and the said Proxy Form is duly signed and dated.
 10. Last date and time for lodging the Proxy Form is **Sunday, 11 January 2026 at 10.30 a.m.**
 11. For corporate member who has appointed an authorised representative instead of a proxy to attend this meeting, please bring the **original / duly certified** certificate of appointment executed in the following manner if the Proxy Form has not been lodged at the office of the Share Registrar earlier:
 - (a) If the corporate member has a common seal, the certificate of appointment should be executed under seal in accordance with the Constitution of the corporate member.
 - (b) If the corporate member does not have a common seal, the certificate of appointment should be affixed with the rubber stamp of the corporate member (if any) and executed by:
 - (i) at least two (2) authorised officers, of whom one shall be a director; or
 - (ii) any director and/or authorised officers in accordance with the laws of the country under which the corporate member is incorporated.

NOTICE OF FIFTH ANNUAL GENERAL MEETING (CONT'D)

General Meeting Record of Depositors

12. Only a depositor whose name appears on the Record of Depositors of the Company as at **31 December 2025** shall be entitled to attend this 5th AGM or appoint proxies to attend, participate, speak and/or vote on his/her behalf.

Ordinary Business

13. Audited Financial Statements for financial year ended 31 July 2025

The audited financial statements are laid in accordance with Section 340(1)(a) of the Companies Act 2016 for discussion only under Agenda 1. They do not require shareholders' approval and hence, will not be put for voting.

14. Ordinary Resolution 1 – To approve the payment of Directors' fees and benefits of up to an aggregate amount of RM200,000.00 to the Non-Executive Directors for the period from 14 January 2026 until the conclusion of the next AGM of the Company to be held in 2027

Pursuant to Section 230(1) of the Companies Act 2016, the fees of the directors and any benefits payable to the directors of the Company and its subsidiaries shall be approved at a general meeting.

The Ordinary Resolution 1 is to seek shareholders' approval on the payment of Directors' fees and benefits to the Non-Executive Directors. In determining the estimated total amount of fees and benefits, the Board considered various factors including the number of scheduled meetings as well as the number of Directors involved in these meetings for the period from 14 January 2026 until the next to be held in 2027. In the event that the proposed amount is insufficient (due to enlarged Board size and additional number of meetings), approval will be sought at the next AGM to meet the shortfall.

15. Ordinary Resolutions 2 and 3 – Re-election of Directors

Clause 165.1 of the Company's Constitution states that one-third (1/3) of the Directors shall retire from office and shall be eligible for re-election at each AGM. All the Directors shall retire from office at least once in each three (3) years but shall be eligible for re-election. A retiring Director shall retain office until the close of the meeting at which he retires.

Dr. Pakirisamy Baskaran and Tan Chye Suan retire in accordance with Clause 165.1 of the Company's Constitution and being eligible, have offered themselves for re-election.

In determining the eligibility of the Directors due for retirement to stand for re-election at the forthcoming 5th AGM, the Nomination Committee ("NC") has assessed the retiring Directors and recommended the re-election of retiring Directors based on the following consideration:

- (i) they met the criteria of character, experience, integrity, competence and time commitment in discharging their roles as directors of the Company;
- (ii) their active participation at the Board meetings showed that they were prepared and were effective in the discharge of their responsibilities; and
- (iii) Dr. Pakirisamy Baskaran A/L P Thangavelu and Tan Chye Suan are an Independent Non-Executive Director of the Company. They have fulfilled the requirements on independence as set out in the Main Market Listing Requirements of Bursa Malaysia Securities Berhad. No circumstances have arisen in the past year to impair the independent judgement of them on matters brought for Board discussion and they have always acted in the best interest of the Company as a whole.

Based on the above, the Board supports the re-election of the retiring Directors. The retiring Directors had abstained from deliberation and decision making on their own eligibility to stand for re-election at the relevant NC and Board meetings.

16. Ordinary Resolution 4 – Re-appointment of Messrs. BDO PLT as Auditors

The Audit and Risk Management Committee ("ARMC") and the Board have considered the re-appointment of Messrs. BDO PLT as Auditors of the Company, are satisfied with the performance, competency, audit approach and independence of Messrs. BDO PLT and collectively agreed that they have met the relevant criteria prescribed by Paragraph 15.21 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad. The Board endorsed ARMC's recommendation to seek for shareholders' approval to re-appoint Messrs. BDO PLT as external auditors of the Company and to authorise the Directors to fix their remuneration.

NOTICE OF FIFTH ANNUAL GENERAL MEETING (CONT'D)

Special Business

17. Ordinary Resolution 5 - Authority pursuant to Sections 75 and 76 of the Companies Act, 2016 for the Directors to allot and issue shares

The proposed Ordinary Resolution 5, if passed, will give authority to the Directors to allot and issue up to a maximum of ten per centum (10%) of the total number of issued shares of the Company at any time in their absolute discretion and that such authority shall continue in force until the conclusion of the next AGM of the Company or the expiration of the period within which the next AGM is required by law to be held or revoked/varied by resolution passed by the shareholders in general meeting whichever is the earlier.

This new general mandate will provide flexibility to the Company for any possible fund-raising activities, including but not limited to placing of shares, for purpose of funding future investment project(s), working capital and/or acquisitions.

At this juncture, there is no decision to issue new shares but the Directors consider it desirable to have the flexibility permitted to respond to market developments and to enable allotments to take place to finance business opportunities without making a pre-emptive offer to existing shareholders. If there should be a decision to issue new shares after the general mandate is obtained, the Company will make an announcement in respect thereof.

Voting at 5th AGM

18. Pursuant to Paragraph 8.29A of Bursa Malaysia Securities Berhad Main Market Listing Requirements, all resolutions set out in the Notice of 5th AGM will be put to vote by poll.

STATEMENT ACCOMPANYING NOTICE OF 5th AGM

(Pursuant to Paragraph 827 of Bursa Malaysia Securities Berhad Main Market Listing Requirements)

As at date of this notice, there are no individuals who are standing for election as Directors (excluding Directors who are standing for re-election as stated above) at this forthcoming 5th AGM.



UMediC Group Berhad
(Registration No. 202101015347) (1415647-D)

PROXY FORM

Number of shares held	
CDS account number	

I/We _____ NRIC/Passport/Company No _____
(Full name in block)
Tel no./ Email Address: _____ of _____
(Full Address)

being member(s) of UMEDIC GROUP BERHAD, hereby appoint: -

Full Name (in Block)	NRIC/Passport No.	Proportion of Shareholdings	
		No. of Shares	%
Email Address	Telephone No.		
Address			

* and/or failing him/her

Full Name (in Block)	NRIC/Passport No.	Proportion of Shareholdings	
		No. of Shares	%
Email Address	Telephone No.		
Address			

or failing *him/*her, the Chairman of the meeting, as *my/*our proxy/proxies to vote for *me/*us on *my/*our behalf at the Fifth Annual General Meeting ("5th AGM") of the Company to be held at Sri Mas Ballroom, Level 4, Bayview Hotel Georgetown Penang, 25-A Farquhar Street, 10200 George Town, Pulau Pinang on Tuesday, 13 January 2026 at 10.30 a.m. or and at any adjournment thereof, on the following resolutions referred to in the notice of 5th AGM. My/our proxy is to vote as indicated below:

No.	Ordinary Resolutions	For	Against
1.	To approve the payment of Directors' fees and benefits of up to an aggregate amount of RM200,000.00 to the Non-Executive Directors for the period from 14 January 2026 until the conclusion of the next AGM of the Company to be held in 2027.		
2.	To re-elect Dr. Pakirisamy Baskaran A/L P Thangavelu as Director of the Company.		
3.	To re-elect Tan Chye Suan as Director of the Company.		
4.	To re-appoint Messrs. BDO PLT as Auditors of the Company and to authorise the Directors to determine their remuneration.		
5.	Authority pursuant to Sections 75 and 76 of the Companies Act, 2016 for the Directors to allot and issue shares.		

Please indicate with an "X" in the appropriate space provided above on how you wish your vote to be cast. If no specific direction as to voting is given, the proxy will vote or abstain from voting at his/her discretion.

Dated this _____ day of _____ 20 _____

Signature of Member(s)/ Common Seal

* strike out whichever is not desired.

Appointment of Proxy

- A proxy need not be a member and a member may appoint any person to be his proxy without limitation save that the proxy must be of full age.
- A member of the Company entitled to attend, participate, speak and vote at the meeting is entitled to appoint one (1) or more proxies (who need not be members) to attend, participate, speak and vote at the same meeting.
- Where a member appoints more than one (1) proxy, the appointment shall be invalid unless he specifies the proportions of his shareholdings to be represented by each proxy.
- The instrument appointing a proxy shall be in writing under the hand of the appointor or of his attorney duly authorized in writing.
- Where a member of the Company is an authorised nominee as defined under the Securities Industry (Central Depositories) Act 1991 ("SICDA"), it may appoint at least one (1) proxy in respect of each securities account it holds with ordinary shares of the Company standing to the credit of the said securities account.
- Where a member is an exempt authorised nominee as defined under the SICDA which holds ordinary shares in the Company for multiple beneficial owners in one (1) securities account ("omnibus account"), there is no limit to the number of proxies which the exempt authorised nominee may appoint in respect of each omnibus account it holds.
- For a proxy to be valid, the instrument appointing a proxy must be made in a hard copy form or by electronic means in the following manner and must be received by the Company not less than forty-eight (48) hours before the time appointed for holding the meeting or adjourned meeting PROVIDED that in the event the member(s) duly execute(s) the Proxy Form but does/do not name any proxy, such member(s) shall be deemed to have appointed the Chairman of

the meeting as his/their proxy, PROVIDED ALWAYS that the rest of the Proxy Form, other than the particulars of the proxy, have been duly completed by the member(s):

- In hard copy form
The proxy form must be deposited at the office of the Share Registrar, Boardroom Share Registrars Sdn. Bhd. at 11th Floor, Menara Symphony, No. 5, Jalan Prof. Khoo Kay Kim, Seksyen 13, 46200 Petaling Jaya, Selangor.
- By electronic means via facsimile
The proxy form must be received via facsimile at +603-7890 4670.
- By electronic means via email
The proxy form must be received via email at bsr.helpdesk@boardroomlimited.com.
- By electronic means via Boardroom Smart Investor Portal, BSIP online (for individual shareholder only)
The Proxy Form can be lodged electronically via BSIP Online website at <https://investor.boardroomlimited.com>. Please refer to the Administrative Guide on the procedure for electronic lodgement of proxy form via Online.

For option (ii) and (iii), the Company will require the member to deposit the original executed proxy form to the office of Share Registrar before or on the day of meeting for verification purpose.

- Any authority pursuant to which an appointment is made by a power of attorney must be deposited at the office of the Share Registrar before the cut-off time for the lodgement of the proxy form.
- Please ensure that ALL particulars as required in the Proxy Form are completed and the said Proxy Form is duly signed and dated.

- Last date and time for lodging the Proxy Form is **Sunday, 11 January 2026 at 10.30 a.m.**

- For corporate member who has appointed an authorised representative instead of a proxy to attend this meeting, please bring the **original / duly certified** certificate of appointment executed in the following manner if the Proxy Form has not been lodged at the office of the Share Registrar earlier:

- If the corporate member has a common seal, the certificate of appointment should be executed under seal in accordance with the Constitution of the corporate member.
- If the corporate member does not have a common seal, the certificate of appointment should be affixed with the rubber stamp of the corporate member (if any) and executed by:
 - at least two (2) authorised officers, of whom one shall be a director; or
 - any director and/or authorised officers in accordance with the laws of the country under which the corporate member is incorporated.

General Meeting Record of Depositors

- Only a depositor whose name appears on the Record of Depositors of the Company as at **31 December 2025** shall be entitled to attend this 5th AGM or appoint proxies to attend, participate, speak and/or vote on his/her behalf.

Personal Data Privacy

By submitting the duly executed Proxy Form, the member and his/her proxy consent to the Company (and/or its agents/service providers) collecting, using and disclosing the personal data therein in accordance with the Personal Data Protection Act 2010, for the purpose of the 5th AGM, and any adjournment thereof.



First fold here

Affix
Stamp

The Share Registrar

UMEDIC GROUP BERHAD

Registration No. 202101015347 (1415647-D)

c/o Boardroom Share Registrars Sdn. Bhd.
11th Floor, Menara Symphony,
No. 5, Jalan Prof. Khoo Kay Kim, Seksyen 13,
46200 Petaling Jaya, Selangor.

Then fold here

ADMINISTRATIVE GUIDE

FOR THE FIFTH ANNUAL GENERAL MEETING ("5TH AGM")



UMedC Group Berhad
(Registration No. 202101015347) (1415647-D)

Dear Shareholders

Greeting from UMEDIC GROUP BERHAD

(A) Details of the 5th AGM

Date : Tuesday, 13 January 2026

Time : 10:30 a.m. or any adjournment thereof

Venue : Sri Mas Ballroom, Level 4, Bayview Hotel Georgetown Penang, 25-A Farquhar Street, 10200 George Town, Pulau Pinang

(B) Registration

1. Registration will start at 9.00 a.m. on Tuesday, 13 January 2026.
2. Kindly produce your original MyKad/Passport (for foreigners) to the registration staff at the registration counter for verification. Please ensure to collect your MyKad/Passport thereafter.
3. Upon verification, you are required to sign on the Attendance list prepared by the registration staff.
4. After registration, a polling slip will be issued to the respective shareholders and will only be given a wristband as identification in order to vote.
5. No person will be allowed to register on behalf of another person, even with the original MyKad/Passport of that person.
6. The registration counter will handle only the verification of identity and registration.
7. Please vacate the registration area immediately after registration and proceed to the meeting hall.
8. For any clarification or enquiry, please proceed to the Company's Helpdesk at the registration counter.
9. Poll Administrator's Helpdesk will handle the revocation of a proxy's appointment.

(C) Entitlement to Participate in the AGM

Only members whose names appear on the Record of Depositors as at 31 December 2025 shall be entitled to attend the AGM or appoint proxy(ies)/ Corporate representative (s)/ attorney to attend and to vote in his/her stead. A proxy must be 18 years and above and need not be a member of the Company.

(D) Proxy

1. A member entitled to attend and vote is entitled to appoint proxy/proxies, to attend and vote instead of him/her. If you are unable to attend the meeting and wish to appoint a proxy to vote on your behalf, please submit your proxy form in accordance with the notes and instructions printed therein.

ADMINISTRATIVE GUIDE (CONT'D)

FOR THE FIFTH ANNUAL GENERAL MEETING ("5TH AGM")

(D) Proxy (Cont'd)

2. You may submit your proxy form to the office of the Share Registrar of our Company, Boardroom Share Registrars Sdn. Bhd. at 11th Floor, Menara Symphony, No. 5, Jalan Prof. Khoo Kay Kim, Seksyen 13, 46200 Petaling Jaya, Selangor Darul Ehsan or by email to bsr.helpdesk@boardroomlimited.com or by fax +603-7890 4670 not less than forty-eight (48) hours before the time appointed for holding the meeting or adjourned meeting. We do not acknowledge receipt of the form(s) of proxy.
3. Alternatively proxy appointment may also be lodged electronically via Boardroom Smart Investor Portal ("BSIP") at <https://investor.boardroomlimited.com> not less than forty-eight (48) hours before the time appointed for holding the meeting or adjourned meeting which is free and available to shareholders. For further information, kindly refer to Table 1 below for proxy appointment via BSIP.

Table 1 – Proxy Appointment via Boardroom Smart Investor Portal

<p>Step 1 -</p> <p>Register Online with Boardroom Smart Investor Portal</p> <p>(For first time registration only)</p>	<p><i>Note: If you have already signed up with Boardroom Smart Investor Portal, you are not required to register again. You may proceed to Step 2.</i></p> <ul style="list-style-type: none"> • Access the website https://investor.boardroomlimited.com • Click "Register" to sign up as a user. • Complete registration with all the required information. Upload and attach a softcopy of your Identity Card (NRIC) (front and back) or Passport. Click "Register". • You will receive an email from BSIP Online for email address verification. Click on "Verify Email Address" from the email received to continue with the registration. • Once your email address is verified, you will be re-direct to BSIP Online for verification of mobile number. • Click on "Request OTP Code" and an OTP code will be sent to the registered mobile number. You will need to enter the OTP Code and click "Enter" to complete the process. • Once your mobile number is verified, registration of your new BSIP account will be pending for final verification. • An email will be sent to you to inform the approval of your BSIP account within one (1) business day. Subsequently, you can login at https://investor.boardroomlimited.com with the email address and password filled up by you during the registration to proceed.
<p>Step 2 -</p> <p>Appointment of Proxy</p>	<ul style="list-style-type: none"> • Login to https://investor.boardroomlimited.com using your user ID and password from Step 1 above. • Click "Meeting Event" and select from the list of companies "FIFTH (5TH) UMediC Group Berhad" and click "Enter". • Click "Submit eProxy Form". • Read and accept the General Terms and Conditions and enter your CDS account number. • Select your proxy — either the Chairman of the meeting or individual named proxy(ies) and enter the required particulars of your proxy(ies). • Indicate your voting instructions — FOR or AGAINST or ABSTAIN. If you wish to have your proxy(ies) to act upon his/her discretion, please indicate DISCRETIONARY. • Review and confirm your proxy appointment. Click "Apply". Download or print the eProxy Form as acknowledgement.

ADMINISTRATIVE GUIDE (CONT'D)

FOR THE FIFTH ANNUAL GENERAL MEETING ("5TH AGM")

(D) Proxy (Cont'd)

Table 1 – Proxy Appointment via Boardroom Smart Investor Portal

Step 2 – Appointment of Proxy (Cont'd)	Corporate Shareholders, Authorised Nominee and Exempt Authorised Nominee
	<p><u>Via BSIP</u></p> <ul style="list-style-type: none"> • Login to https://investor.boardroomlimited.com using your user ID and password from Step 1 above. • Select [FIFTH (5TH) UMEDIC GROUP BERHAD] from the list of Meeting Event and click "Enter". • Click on "Submit eProxy Form". • Select the company you would like to represent. • Proceed to download the file format for "Submission of Proxy Form" from the investor portal. • Prepare the file for the appointment of proxy(ies) by inserting the required data. • Proceed to upload the duly completed proxy(ies) appointment file. • Review and confirm your proxy(ies) appointment and click "Submit". • Download or print the eProxy Form as acknowledgement.

3. If you wish to attend the Meeting yourself, please do not submit any Proxy Form. You will not be allowed to attend the Meeting together with a proxy appointed by you.
4. If you have submitted your proxy form prior to the meeting and subsequently decided to attend the meeting yourself, please proceed to the Poll Administrator's Helpdesk to revoke the appointment of your proxy.

(E) Poll Voting

1. In accordance with Paragraph 8.27A of Main Market Listing Requirements of Bursa Malaysia Securities Berhad, the voting at the 5th AGM will be conducted by poll. Poll Administrator and Independent Scrutineers will be appointed to conduct the polling process and verify the results of the poll respectively.
2. The Poll Administrator will be available to brief and/or guide all 5th AGM Attendees before the commencement of and during the voting process.
3. Upon completion of the voting session for the 5th AGM, the Scrutineers will verify and announce the poll results followed by the Chairman's declaration of whether the resolutions are duly passed.

(F) Annual Report 2025

1. The Company's Annual Report 2025, Proxy Form, Corporate Governance Report and Administrative Guide are available on the following websites:
 - (a) <https://www.bursamalaysia.com>
 - (b) <https://www.umedic.com.my>
2. If you wish to request a printed copy of the Annual Report 2025, please complete and send the Requisition Form which can be downloaded from the Company's website at <https://www.umedic.com.my> and email the same to the Share Registrar or visit Boardroom Smart Investor Online Portal at <https://investor.boardroomlimited.com> by selecting "Request Annual Report" under "Investor service".
3. Kindly think of the environment before you decide to print the Annual Report 2025. We would appreciate your support by joining us to promote "Act Green" initiative to achieve environmentally responsible and paperless.

ADMINISTRATIVE GUIDE (CONT'D)

FOR THE FIFTH ANNUAL GENERAL MEETING ("5TH AGM")

(G) **Enquiry**

If you have any queries prior to the meeting, please contact the following officers during office hours:

Boardroom Share Registrars Sdn. Bhd. [199601006647 (378993-D)] 11th Floor, Menara Symphony No. 5, Jalan Professor Khoo Kay Kim Seksyen 13, 46200 Petaling Jaya Selangor Darul Ehsan, Malaysia	Tel No.	+603-7890 4700 / 4711
	Fax No.	+603-7890 4670
	Email Add	bsr.helpdesk@boardroomlimited.com
	Contact Person:	EN. MUHAMMAD FARHAN

The Company and its subsidiary companies, their officers and employees shall have no liability whatsoever to any and all shareholders, their proxies, corporate representatives and/or any other party arising out of or in connection of any infection or suspicion of any infection from Covid-19 and/or suffering any losses arising out of or in connection with attendance at the Company's AGM and/or measures are undertaken by the Company in the Company's sole discretion in response to the Covid-19 pandemic.



UMediC Group Berhad

(Registration No. 202101015347 (1415647-D))

PMT 790, Jalan Cassia Selatan 5/2,
Taman Perindustrian Batu Kawan,
14110 Bandar Cassia, Pulau Pinang.

☎ : +604-589 9676

📠 : +604-589 9677

info@umedichealthcare.com
www.umedic.com.my